Synthetic Approaches to Novel Pyridine and Indole

Derivatives as Potential Agents for the Treatment of

Neurodegenerative Disorders by Colgin, Neil
Colgin,   Neil   (2009)   Synthetic  Approaches   to   Novel   Pyridine   and   Indole 
Derivatives   as   Potential   Agents   for   the   Treatment   of   Neurodegenerative 
Disorders. Doctoral thesis, University of Sunderland.
Downloaded from: http://sure.sunderland.ac.uk/4064/
Usage guidelines
Please refer to the usage guidelines at http://sure.sunderland.ac.uk/policies.html or alternatively 
contact sure@sunderland.ac.uk. 
 
 
 
 
 
  
 
 
Synthetic Approaches to Novel Pyridine and Indole 
Derivatives as Potential Agents for the Treatment of 
Neurodegenerative Disorders 
 
 
Neil Colgin 
 
A thesis submitted in partial fulfilment of the 
requirements of the University of Sunderland 
for the degree of Doctor of Philosophy 
 
 
This research programme was carried out 
in collaboration with Institut de Recherches Servier 
 
 
May 2009i 
Acknowledgements 
 
I would like to express my gratitude to my supervisor Dr. Adrian Moore for 
his support and guidance. I am grateful to our collaborators at Institut de 
Recherches Servier for financial support and also Dr. Pierre Lestage and 
Dr. Denis Guedin at Servier for the pharmacological data. Thanks also to 
Dr. Yongxue Huang for helpful discussion and ChemiSPEC, University of 
Sunderland  for  NMR  and  elemental  data.
 ii 
Table of Contents  
 
Acknowledgements                    ..............i 
 
Table of Contents                 ...........   . .ii 
 
Abbreviations                        ........iii 
 
Abstract                          .........iv 
 
 
Chapter 1 
 
1.1 Dementia Related Disorders of the Central Nervous System...............1 
 
1.2.1 Current Treatments for Neurodegenerative Disorders.................3 
 
 1.2.2 Non steroidal Anti inflammatory Drugs........................................8 
 
 1.2.3 Cleavage of Amyloid Precurser Protein.......................................9 
  
 1.2.4 The Nicotinic Approach                ....11 
 
1.3 Structure and Subtypes of Nicotinic Acetylcholine Receptors  .....12 
 
1.4 Nicotine and its Analogues in the Treatment of Dementia    ....16 
 
1.4.1 Nicotinic Acetylcholine Receptor Agonists         18 
 
1.4.2 Lobeline and Sedamine                ...23 
 
1.5 Reported Synthetic Strategies for the Synthesis of Lobeline and 
 
Sedamine Analogues   ................................................................29 
 
1.6 Preamble to Synthetic Work................................................................34 
 
 
Chapter 2 
 
2.1 Reported Methodology for the Metallation of 3 Methylpyridine...........40 
 
2.2 Synthetic Approaches to Target Compounds 75 and 78....................48 
 
2.3 Metallation of 3,5 Dimethylpyridine.....................................................63 
 
2.4 Synthesis of Optically Pure Alcohols...................................................68 
 
2.5 Conclusion...........................................................................................77 ii 
Chapter 3 
 
3.1. Reactions of 3 Bromopyridine 
 
3.1.1. Halogen Lithium Exchange of 3 Bromopyridine 
 
3.1.1.1. Introduction.....................................................................80 
 
3.1.1.2. Results and Discussion...................................................83 
 
3.1.1.3. Summary.........................................................................86 
 
3.1.2. Metal Mediated Reactions of 3 Bromopyridine 
   
3.1.2.1. Sonogashira Cross coupling Reactions 
 
3.1.2.1.1. Preamble..............................................................88 
 
3.1.2.1.2. Introduction..........................................................89 
 
3.1.2.1.3. Results and Discussion........................................92 
 
3.1.2.1.4. Summary..............................................................96 
 
3.1.2.2. Heck Coupling Reactions of 3 Bromopyridine 
 
3.1.2.2.1. Introduction..........................................................97 
 
3.1.2.2.2. Results and Discussion........................................99 
 
3.1.2.2.3. Summary............................................................102 
 
3.2.  Reactions  of  3 Bromo 1methyl 1H indole,  3 Iodo 1 methyl 1H indole   
or 3 Iodo 5 methoxy 1 methyl 1H indole 
 
3.2.1. Sonogashira Reactions..........................................................103 
 
3.2.2. Halogen Lithium Exchange of 1 Methyl 3 bromo 1H indole..107 
 
3.2.3. Summary................................................................................109 
 
 
Chapter 4  
 
4.1. Halogen Lithium Exchange of 3,5 Dibromopyridine 
 
4.1.1. Introduction.............................................................................110 
 
4.1.2. Results and Discussion..........................................................111 
 
4.2. Sonogashira Reactions of 3,5 Dibromopyridine 
 
4.2.1. Introduction.............................................................................113 
 ii 
4.2.2. Results and Discussion..........................................................115 
 
4.3. Summary..........................................................................................124 
 
 
Chapter 5  
 
5.1. Pharmacological Testing 
 
5.1.1. Binding and Functional Assays..............................................126 
  
5.2. Discussion of Biological Data 
 
5.2.1. α7 Neuronal Nicotinic Receptor Binding Affinities..................131 
 
5.2.2. Further Testing 
 
5.2.2.1. hERG Affinity................................................................135 
   
5.2.2.2. Permeability Profiling in vitro.........................................136 
 
5.2.2.3. Ames Testing................................................................137 
 
5.2.2.4. Metabolic Stability.........................................................138 
 
5.3. Summary of Pharmacological Testing..............................................139 
 
Chapter 6 
 
6.1. Experimental.....................................................................................141 
 
References                       .......238 
 iii 
Abbreviations 
ACh    Acetylcholine 
AChE   Acetylcholine esterase 
AD     Alzheimer’s Disease 
n BuLi   n Butyllithium 
t BuLi   t Butyllithium 
CBS    Corey Bakshi Shibata catalyst 
CNS    Central nervous system 
DCM    Dichloromethane 
DMF    N,N dimethylformamide 
DMPU    1,3 dimethyl 3,4,5 tetrahydro 2(1H) pyrimidione 
DMSO  Dimethyl sulphoxide 
HMPA   Hexamethylphosphoramide 
HMPT   Hexamethylphosphorus triamide 
HPLC     High performance liquid chromatography 
IPA    Isopropyl alcohol 
IR    Infrared 
LBD    Lewy Body Disease 
LDA    Lithium diisopropylamide 
MS    Mass spectrometry 
nAChR  Nicotinic acetylcholine receptor 
NADPH  Nicotinamide adenine dinucleotide phosphate 
NAM    Negative allosteric modulator 
NICE    National Institute for Clinical Excellence 
NMDA    N methyl D aspartate iii 
NMR    Nuclear magnetic resonance 
NSAID  Non steroidal anti inflammatory drug 
PAM    Positive allosteric modulator 
PCC    Pyridinium chlorochromate 
PD    Parkinson’s Disease 
THF    Tetrahydrofuran 
TLC    Thin layer chromatography 
 iv 
Abstract 
Alzheimer’s  Disease  (AD),  Parkinson’s  Disease  (PD)  and  Lewy  Body 
Disease  (LBD)  are  some  of  the  many  neurodegenerative  disorders 
associated with dementia, for which there is no ultimate cure. It is widely 
accepted  that  central  nervous  system  (CNS)  nicotinic  acetylcholine 
receptors (nAChRs) may be strongly implicated in the pathology of these 
devastating  disorders,  and  that  stimulation  of  nAChRs  can  enhance 
cognitive behaviour in animals and humans. Nicotine and other nicotinic 
receptor  binding  compounds  have,  over  many  years,  been  explored  as 
potential therapies for disorders such as AD and PD. This thesis describes 
the  preparation  and  pharmacological  investigation  of  a  series  of  3 
substituted and 3,5 disubstitued pyridine derivatives as potential novel and 
selective nictotinic receptor agonists. 
 
Chapter  Two  details  the  synthesis  of  targeted  compounds  using  the 
generation  of  [(pyridin 3 yl)methyl]lithium  and  [(5 methylpyridin 3 
yl)methyl]lithium,  respectively  and  subsequent  reaction  with  various 
electrophiles. Unsuccessful attempts at the synthesis of enantiomerically 
pure 4 substituted arylpyridin 3 yl ethanol derivatives by reduction of pro 
chiral 4 substituted arylpyridin 3 yl ethanone derivatives were made using 
both  catalytic  and  enzymatic  approaches;  however,  a  pair  of 
enantiomerically  pure  alcohols  were  isolated  via  the  resolution  of 
diastereomeric  esters  (prepared  by  reaction  with  (S) O acetyl  mandelic 
acid) and subsequent hydrolysis. iv 
 
Chapter  Three  explores  the  synthesis  of  targeted  compounds  using 
halogen lithium exchange reactions of 3 bromopyridine using n BuLi and 
ring opening  by  the  resultant  pyridin 3 yllithium  of  4 substituted  aryl 
epoxides.  As  an  extension,  Sonogashira  cross coupling  of  3 
bromopyridine and 4 substituted arylacetylenes and subsequent hydration 
as  an  approach  to  4 substituted  pyridin 3 yl ethanone  derivatives  is 
described. A series of indole derivatives were synthesised using identical 
approaches. 
 
Using  methodology  developed  in  previous  Chapters,  Chapter  Four 
describes  approaches  to  symmetrical  and  asymmetrical  3,5 
bis(arylethynyl)pyridine  derivatives,  the  corresponding  bis(ketones), 
alcohols and 3,5 disubstituted keto alcohol products. 
 
Chapter  Five  details  preliminary  pharmacological  data  (binding  and 
functional  assays)  performed  by  our  collaborators  at  Institut  de 
Recherches Servier. 
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Chapter 1 
 
1.1 Dementia Related Disorders of the Central Nervous System 
 
Dementia can be defined as a syndrome which features the deterioration 
of  previously  acquired  intellectual  abilities,  sufficiently  severe  to  hinder 
social or occupational functioning. The most common forms of dementia 
related  disorders  of  the  central  nervous  system  include  Alzheimer’s 
Disease, Parkinson’s Disease, Huntingdon’s Disease and Dementia with 
Lewy Bodies. 
 
Dementia is currently estimated to affect seven hundred thousand people 
in the UK and this figure is estimated to rise to over one million by 2025.
1 
Alzheimer’s  Disease  (AD)  is  the  most  common  form  of  dementia 
diagnosed and is becoming even more prevalent in developed countries 
as  a  result  of  increasing  life  expectancies.  AD  is  a  progressive  brain 
disorder  that  gradually  destroys  memory  and  the  ability  to  learn; 
eventually, communication becomes almost impossible and a sufferer will, 
in time, be unable to complete simple day to day tasks and will, almost 
certainly, require full time care. 
 
The primary cause of AD dementia appears to be the disruption of the 
regulation, expression or scavenging of abnormal proteins present in the 
neuronal  cell membrane.
2  This  is  thought  to  be  due  to  a  defect  on 
chromosome  21;  this  defect  affects  amyloid  precursor  protein  (APP) 
resulting in fibrillary aggregates of β amyloid protein, which are toxic to Page | 2  
 
neurons.
3  The  neurotoxicity  of  β amyloid    protein  leads  to  the 
degeneration of a large number of neurotransmitter systems responsible 
for cognitive expression.
4 Perry et al.
5 demonstrated that the entorhinal 
cortex, which has a high concentration of nicotinic receptors, is vulnerable 
to amyloid plaque induced loss of receptors. Patients suffering from AD 
show a marked reduction in nicotinic cholinergic receptor binding relative 
to  age  matched  healthy  subjects.
2,6  AD  is  also  characterised 
neuropathologically by the presence of neurofibrillary tangles formed by 
aggregates of hyperphosphorylated tau protein inside the neurons. In AD, 
tau proteins bind to each other and grow to form Paired Helical Filaments 
(PHF). PHF do not degrade normally and grow to such an extent that they 
fill the cytoplasm, eventually causing the death of a cell.
7  
 
Nicotinic receptor loss also appears to be linked to the primary pathology 
of  Parkinson’s  Disease  (PD).
6  A  loss  of  cholinergic  cells  in  the  basal 
forebrain  similar  to  that  seen  in  AD  has  also  been  witnessed  in  PD.
8 
Parkinson’s Disease patients suffer from muscular rigidity, tremors, poor 
balance  and  bradykinesia  (difficulty  in  the  initiation  of  movement),  but 
usually show no signs of the mental deterioration seen in AD. It is believed 
that PD results from the degeneration of dopamine producing nerve cells 
in the substantia nigra region of the brain. Dopamine is a neurotransmitter 
that  stimulates  the  motor  neurones  which  control  muscle  movement    
depletion of dopamine, therefore, causes impairment of motor function.  
 
In rare PD cases where dementia exists, Lewy bodies (spherical protein 
deposits found inside neurons) are often found in the cerebral cortex and Page | 3  
 
substantia  nigra  and  this  is  commonly  known  as  Lewy  Body  Disease 
(LBD).  LBD  was  often  misdiagnosed  as  either  AD  or  PD,  but  is  now 
recognised  as  a  disease  in  its  own  right.  Sufferers  of  LBD  display 
symptoms of both AD, e.g. language disturbances, and the tremors and 
rigidity which are classic symptoms of PD. 
 
1.2.1 Current Treatments for Neurodegenerative Disorders 
 
No cures currently exist for neurodegenerative disorders such as AD and 
PD, and current therapies only serve to alleviate some of the life affecting 
symptoms of the disorders. 
 
Several pharmaceuticals have been licenced for the short term relief of the 
symptoms  of  AD.  These  include,  tacrine  (Cognex
®,  Sciele  Pharma)  1, 
donepezil  (Aricept
®,  Pfizer)  2,  rivastigmine  (Exelon
®,  Novartis)  3, 
galantamine (Reminyl
®, Shire Pharmaceuticals) 4 and memantine (Ebixa
®, 
Lundbeck) 5.  
 
Donepezil, galantamine and rivastigmine are all broadly termed ‘Second 
Generation’  Acetylcholine  Esterase  Inhibitors  (AChEIs),  however,  their 
structure, pharmacokinetics and pharmacology differ significantly. With the 
exception of memantine, these pharmaceuticals act via inhibition of the 
enzyme acetylcholine esterase (AChE). 
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AChE  is  found  in  the  brain,  muscles  and  cholinergic  neurons, where  it 
hydrolyses  acetylcholine  (ACh)  6  upon  its release  at  the  synaptic  cleft, 
thereby reducing cholinergic function. The inhibition of AChE prevents the 
breakdown  of  acetylcholine,  increasing  cerebral  acetylcholine 
concentrations  and  producing  some  improvement  in  cognitive 
performance. 
 
 
In 1993, Tacrine 1 was the first of the AChEIs approved for treatment of 
AD.
9  Tacrine  has  been  shown  to  be  useful  in  the  stabilisation  and 
improvement  of  symptoms  in  AD.
10 12  Initial  trials  of  tacrine  with  LBD 
sufferers
13 and PD patients
14,15 have, thus far, proven promising. However, 
in  recent  years  the  clinical  use  of  tacrine  has  become  uncommon  in 
response  to  findings  that  therapeutic  concentrations  can  cause 
hepatoxicity.
16,17  
 
Donepezil 2, a piperidine based compound, selectively inhibits AChE. It is 
metabolised in the liver by cytochrome P 450 isoenzymes. Donepezil has 
been proven to have beneficial effects on cognitive function and aspects of Page | 5  
 
daily living of AD patients.
18,19 Aarsland et al.
20 have demonstrated that 
donepezil  also  has  the  ability  to  improve  cognition  in  PD  patients; 
however, more recent studies contradict this work and report a worsening 
in  Parkinsonism.
21  Similar  contradictory  evidence  exists  for  the  use  of 
donepezil on patients suffering from LBD; several studies have shown that 
LBD  responds  well  to  AChEIs  such  as  donepezil,
22,23  whereas  some 
groups  have  reported  observable  improvement  in  overall  function,  but 
some worsening of symptoms (primarily motor function).
24,25  
 
Rivastigmine 3 is a slowly reversible AChEI and butyrylcholine esterase 
inhibitor  (BChEI).
26  Rivastigmine  is  not  metabolised  in  the  liver  but  is 
hydrolysed during the process of inhibition of AChE; unlike other AChEIs it 
is, therefore, not involved in a hepatic cyctochrome P 450 cycle, reducing 
unwanted  drug  interactions.
27  Recently,  Bullock  et  al.
28  performed  a 
clinical comparison of rivastigmine and donepezil and, although both are 
similarly  effective  AChEIs  with  similar  cognitive  efficacy,  the  authors 
concluded  that  rivastigmine  gave  better  results  with  respect  to 
improvements  in  the activities  of  daily  living.  In common with the other 
AChEIs described here, rivastigmine has also shown some promise for the 
treatment of LBD
29 31 and PD.
32  
 
Galantamine  4  posseses  selective  AChE  inhibitive,  as  well  as  nicotinic 
allosteric  agonist  properties.
33  Allosterically  potentiating  ligands  (APLs) 
have a distinct advantage over agonist or antagonists in that they interact 
with different binding sites to agonist or antagonists and are, therefore, not Page | 6  
 
involved in processes such as receptor desensitisation.
34 Galantamine has 
been used successfully for the treatment of mild to moderate AD and is 
well tolerated by most patients.
35,36 Galantamine has also been suggested 
as a potential agent in the cholinergic approach to PD therapy and may be 
a  useful  strategy  in  the  alleviation  of  cognitive  and  psychiatric 
symptoms.
37,38  The  efficacy  of  galantamine  has  also  been  assessed 
against  LBD  with  some  success.  Initial  trials  suggest  that  galantamine 
improves  a  patient’s  independence  and  allows  them  to  continue  their 
activities  of  daily  living;  for  these  reasons  galantamine  may  also  be  a 
suitable candidate for clinical use in LBD.
39,40  
 
Memantine 5 is a partial antagonist at the N methyl D aspartate (NMDA) 
receptor. NMDA receptor activation causes a net flow of Ca
2+ into neurons 
and this intracellular influx of Ca
2+ leads to death of the affected neurons.
41 
Memantine  is  also  a  moderate  affinity  NMDA  antagonist  at  the  central 
phenylcyclidine  binding  ion  channel  of  NMDA;  administration  of 
memantine  has  proven  effective  for  neuroprotection  from  glutamate 
mediated  excitotoxicity,  whilst  not  activating  the  NMDA  receptor.
42 
Memantine has also been shown to slow  neurodegeneration in PD.
43,44 
Mixed  results  have,  however,  been  reported  when  memantine  was 
administered to LBD sufferers, suggesting that the efficacy of memantine 
for the treatment of LBD is variable at best. For example, Marwan et al. 
reported  that  seven  out  of  eleven  patients  showed  improvement  (or 
stability)  of  symptoms  upon  administration  of  memantine.
45  In  contrast, 
Menendez Gonzalez et al.
 described a worsening of motor and cognitive Page | 7  
 
function which subsided when the drug was withdrawn;
46 moreover, Ridha 
et al. reported delusions and hallucinations in some patients administered 
with memantine.
47  
 
In  summary,  studies  have  shown  that  the  AChEIs  1 4  and  the  NMDA 
antagonist memantine 5 have some proven benefit for patients suffering 
from differing forms of dementia. Both short term cognitive and long term 
neuroprotective  effects  have  been  described.  However,  some 
contradictory  evidence  is  also  reported  along  with  side effects  such  as 
hepatoxicity,
16,17 dizziness, nausea and malaise.
48 
 
In recent years, the cost effectiveness and efficacy of AChEI and NMDA 
drugs has been questioned. A recent appraisal of donepezil, rivastigmine, 
galantamine and memantine for the treatment of Alzheimer’s disease was 
conducted  by  the  National  Institute  for  Health  and  Clinical  Excellence 
(NICE) and it was concluded, based on cost effectiveness, that donepezil, 
rivastigmine and galantamine should only be prescribed for patients with 
moderate  AD  and  that  memantine  should  not  be  recommended  for 
patients with moderate to severe AD.
49 Contradictory to the NICE survey, 
a  number  of  international  studies  have  concluded  that  treatment  with 
AChEIs can be cost effective.
50 52 Nevertheless, further clinical trials and 
cost effectiveness studies of AChEIs remains to be undertaken in order to 
establish their overall efficacy and their realistic long term clinical use for 
the treatment of dementia patients.  
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1.2.2 Non Steroidal Anti Inflammatory Drugs  
 
 
Senile  plaques  and  neurofibrillary  tangles  are  classic  neuropathological 
hallmarks of AD. Senile plaques are composed of extracellular aggregates 
of  β amyloid  protein  (Aβ)  and  neurofibrillary  tangles  of  intracellular 
aggregates of tau protein. Inflammation develops around these β amyloid 
deposits and it has been suggested that this inflammation may play a role 
in inducing neuronal damage in AD.
53  
 
Several studies
54 59 have shown that the incidence of AD was reduced with 
long term use of non steroidal anti inflammatory drugs (NSAIDs), such as 
indomethacin  and  ibuprofen,  suggesting  that  NSAIDs  may  have  some 
neuroprotective effect against AD. For example, Lim et al., reported that 
chronic administration of oral ibuprofen over six months decreased plaque 
inflammation  and  β amyloid  concentration  in  mice.
58  Similar 
neuroprotective  effects  have  been  described  when  NSAIDs  were 
administered to PD patients.
59  
 
Unfortunately, NSAIDs are associated with a number of adverse effects, 
such as gastrointestinal ulceration and bleeding
60 which may compromise 
their  long term  use  in  patients.  Research  into  NSAID  therapy  for 
neurodegenerative  disorders  is  still  at  a  relatively  early  stage; 
nevertheless,  the  NSAID  approach  appears  promising  and  controlled 
clinical trials are required to fully establish the benefits of NSAIDs.  
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1.2.3 Cleavage of Amyloid Precursor Protein  
 
β Amyloid  (Aβ)  protein  is  known  to  play  an  important  role  in  the 
pathogenesis  of  AD.  Approaches  for  the  treatment  of  AD  that  aim  to 
prevent the build up of Aβ through cleavage of amyloid precursor protein 
(APP) is an emerging area. 
 
Aβ peptides are generated by processing of APP (encoded by a gene on 
chromosome 21). Two metabolic pathways are thought to be involved in 
the  metabolism  of  APP  (Figure  1).  The  first  is  a  non amyloidogenic 
pathway  (i.e.  preventing  Aβ  formation)  involving  the  activation  of  α 
secretase; α secretase cleaves APP within the Aβ domain and prevents 
the generation of Aβ peptide.
61 The second is an amyloidogenic pathway 
(i.e. leading to the generation of Aβ) involving both β   and γ secretases. 
APP  is  initially  cleaved  by  β secretase  (BACE1;  β site  APP cleaving 
enzyme)  at  the  N terminus,  generating  a  99  amino  acid  C terminal 
fragment; this fragment is subsequently cleaved by γ secretase (consisting 
of  presenilin,  nicastrin,  PEN 2  and  APH 1)  within  the  transmembrane 
domain of APP to release Aβ.
62  
 
In particular, the β and γ secretases are thought to be plausible molecular 
targets  for  AD  treatment  with  a  number  of  pharmaceutical  companies 
reporting a range of structurally diverse and potent secretase inhibitors. 
Much of this work has focussed on γ secretase as this is the last biological 
step in Aβ production and determines its length. 
 Page | 10  
 
 
 
Figure 1.  Illustration of APP cleavage (adapted from Lichtenthaler et al.)
 61  
 
 
γ Secretase  inhibitors  have  been  shown  to  reduce  Aβ  in  animal
63  and 
human models.
  Notably,  LY411575 7  and  its  derivatives  (e.g.  8 and 9)
 
have been shown to possess good inhibitory activities in humans.
64  
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Perhaps  the  most  promising  γ secretase  inhibitor  to  emerge  in  recent 
years is LY450139 10, which has been demonstrated to reduce Aβ in AD 
patient’s blood by up to 38%.
65 LY450139, currently in phase II clinical 
trials, is well tolerated by patients and produces a good dose dependent Page | 11  
 
response in Aβ. Chen et al.
66 have very recently reported the synthesis of 
highly  potent  γ secretase  inhibitors  incorporating  similar  ‘bis(amide)’ 
functionality of LY450139 into a series of thiazole based compounds e.g. 
11 (IC50 0.22 nM).
  
 
 
 
The synthesis of novel γ secretase inhibitors is fast becoming an important 
area of research and appears to be a promising approach to the treatment 
of  AD  and  other  neurodegenerative  diseases  which  possess  similar 
neuropathology. 
 
 
 
1.2.4 The Nicotinic Approach 
 
Acetylcholine 6 is an endogenous neurotransmitter that acts upon various 
types  of  receptors  found  in  the  body.  It  is  a  simple  quaternary  amine 
biosynthesised  from  choline  and  acetylcoenzyme  A  and  subsequently 
released by neurons at synapses. Acetylcholine receptors are classified as 
either Muscarinic or Nicotinic and are named for their preferential affinity 
for either nicotine 12 or muscarine 13 respectively. For example, receptors Page | 12  
 
that are activated by acetylcholine and the tobacco alkaloid nicotine are 
referred to as nicotinic receptors. 
 
 
 
Nicotinic acetylcholine receptors (nAChRs) have a long history of study 
and were one of the first receptors to be cloned. nAChRs present in the 
autonomic  system,  and  especially  those  present  in  muscle,  have  been 
studied  extensively.  However,  only  in  recent  years  have  the  central 
nervous system (CNS) nAChRs become the subject of intensive research 
with  the  improving  knowledge  of  how  neuronal nAChRs  can mediate a 
wide  variety  of  behavioural  and  neurochemical  functions.  Although  it  is 
widely recognised that CNS nAChRs may be implicated in the pathology 
of  a  wide  range  of  debilitating  disorders,
67  the  binding  mechanisms, 
regulation  and  subunit  composition  are  not,  as  yet,  fully  understood. 
Progress  made  in  the  understanding  of  the  distribution,  function  and 
structure of CNS nAChRs will no doubt, in time, lead to nicotinic agents 
with therapeutic potential. 
 
 
1.3 Structure and Subtypes of Nicotinic Acetylcholine Receptors 
 
Nicotinic  acetylcholine  receptors  (nAChRs)  are  pentameric  integral 
membrane  proteins  belonging  to  a  ‘superfamily’  of  ligand gated  ion Page | 13  
 
channel receptors
69 that include γ  aminobutyric acid A (GABAA), glycine, 
glutamate and serotonin 3 (5 HT3) receptors.
69,70 nAChRs are found in a 
variety of tissue types including those of the autonomic nervous system, 
the neuromuscular junction and in brain tissue of vertebrates.  
 
Early elucidation of the nicotinic receptor structure was performed in the 
1970s  and  was  facilitated  by  the  natural  abundance  of  nAChRs  in  the 
electric  ray  Torpedo  californica  and  in  the  eel  Electrophorus  electricus. 
Extraction  and  solubilisation  of  the  receptor  using  anionic  surfactants, 
followed  by  passage  through  an  affinity  column  containing  the  snake 
neurotoxin,  α bungarotoxin,  allowed  the  efficient  isolation  of  the  pure 
receptor
71  (α Bungarotoxin  binds  irreversibly  and  competitively  at 
acetylcholine  receptors  and  is  also  able  to  act  as  a  highly  selective 
antagonist at α7 nAChRs). More recently, molecular biological techniques 
and  research  with  cDNA  and  monoclonal  antibodies  has  allowed  the 
subunits  to  be  cloned  and  sequenced,  yielding  further  structural 
information.
72 
 
The nAChRs consist of five subunits labelled α, β, γ and δ (ε in adults) with 
a  stoichiometry  of  two  α  to  each  of  the  other  two  subunits.  When  the 
endogenous neurotransmitter acetylcholine 6 binds to the two α subunits, 
it produces a conformational change in the ion channel allowing cations 
(such as Ca
2+, Na
+ and K
+) to pass across the cell membrane. The five 
subunits  are  arranged  around  the  central  ion  channel  in  a  ‘barrel like’ 
formation (Figure 2). Each subunit consists of a protein approximately 500 Page | 14  
 
amino  acids  in  length,  which  crosses  back  and  forth  across  the  cell 
membrane giving four transmembrane spanning segments (Figure 3). 
 
 
Figure 2.  3 D representation of a pentameric nAChR 
 
 
 
 
Figure 3.  Four transmembrane segments of the nAChR 
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The nicotinic receptors found in the autonomic nervous system and in the 
brain have more diversity than those of the neuromuscular junction, due to 
the greater number of α and β subunits present. To date, eleven neuronal 
nAChR subunits have been identified in mammals (α2 α7, α9, α10 and β2 
β4).
73  The  various  combinations  of  these  different  subtypes  into  a 
pentameric  form  results  in  a  large  variety  of  nAChRs  with  differing 
pharmacological,  electrophysical  and  behavioural  properties.
74  The 
receptors that are formed may be either heteromeric in αβ combination 
(e.g.  α4β2)  or  homomeric  (e.g.  α7)  (Figure  4).
75  The  α4β2  and  α7 
subtypes are the two most common subtypes present in the mammalian 
brain  to  be  affected  by  the  normal  aging  processes  and  also  by 
neurodegenerative diseases, such as AD and LBD. 
 
 
 
 
Figure 4.  Receptor subtypes showing (i) heteromeric α4β2 and (ii) homomeric 
α7 combinations 
 
Homomeric  subunits  such  as  α7  or  α9  display  little,  or  no,  affinity  for 
nicotine  and  are  inhibited  by  the  antagonist  α bungarotoxin,
76  whereas Page | 16  
 
heteromeric nAChRs are characterised as having a very high affinity for 
nicotine but do not bind to α bungarotoxin.
69 
 
Such diverse possibilities for receptor combination gives rise to a multitude 
of functions in the CNS, making these receptors prime targets for a wide 
variety  of  therapeutic  agents.  Figure  5  illustrates  some  of  the  possible 
binding sites and function of the pentameric nAChRs suggested to date.
77 
 
 
 
Figure 5.    Possible  functions  of  the  various  pentameric  nAChR  subtypes 
(adapted from Lloyd et al.)
 77 
 
1.4 Nicotine and its Analogues in the Treatment of Dementia 
 
It is widely recognised that central nervous system nAChRs play a major 
role in a wide range of cognitive, motor and behavioural systems. Nicotine 
has been investigated extensively for its usefulness in increasing cognitive Page | 17  
 
function  and  improving  memory  function  and  learning.
78  Nicotinic 
mechanisms are thought to be heavily involved in the pathology of disease 
states, such as PD, AD, LBD and even Attention Deficit Disorder.
77 
 
Nicotine is one of around four thousand compounds identified from the 
tobacco  plant,  Nicotiana  tabacum,  and  is  the  major  psychoactive 
compound present. Other constituents of tobacco, such as cyanide, heavy 
metals and carcinogenic compounds (e.g. benzopyrene) are responsible 
for  the  negative  health  effects  associated  with  smoking  such  as  heart 
disease, emphysema and cancer. 
 
The usefulness of tobacco products can, therefore, only be very limited for 
the treatment of dementia unless delivered by other, safer, routes (e.g. 
transdermal  patches  are  common  in  the  treatment  of  nicotine 
dependency); this approach to nicotine administration in the treatment of 
dementia may yet prove useful. 
  
A  number  of  studies  have  shown  that  the  incidence  of  Alzheimer’s 
Disease  and  Parkinson’s  Disease
79  is  decreased  amongst  smokers. 
Furthermore, it has been demonstrated that smoking not only provides a 
long term neuroprotective effect, but can also provide short term effects 
on patients, such as improved attention and arousal.
80 Nicotine was first 
examined for the treatment of PD as long ago as the 1920’s.
81 A variety of 
studies with both animals
82 and humans
83 have shown that nicotine can 
improve cognitive performance.
 Some studies are however, contradictory, Page | 18  
 
suggesting  that  this  improvement  in  cognition  is  restricted  to  smokers 
suffering from withdrawal   re administration serving only to either restore 
performance  lost  during  deprivation
84  or  even  failing  to  have  any 
discernable effect on memory or cognition. The reason for these disparate 
opinions may be due, in part, to the inability of nicotine to bind selectively 
to  nAChR  subtypes,  leading  to  effects  which  may  nullify  some  of  its 
positive  therapeutic  benefits.  Additionally,  side effects  such  as 
gastrointestinal and cardiovascular toxicity have been observed. 
 
 
 
1.4.1 Nicotinic Acetylcholine Receptor Agonists 
 
Nicotinic  agonists  interact  with  the  AChR  agonist  site  to  produce  a 
conformational change in the receptor, leading to the opening of the cation 
conducting  pore  in  much  the  same  way  as  acetylcholine.
85,86  This  so 
called cholinergic approach is currently of great interest to pharmaceutical 
companies and a concerted effort is being made to discover agonists  that 
possess the potency of nicotine but exhibit none of its toxicity or other 
undesired  properties.  If  nicotinic  stimulation  is  to  provide  an  effective 
treatment for neurodegenerative diseases such as AD, it is important that 
novel  and  highly  subtype  selective  nAChR  agonists  are  discovered  so 
their neuroprotective and cognitive efficacy can be determined. 
 
Until  recent  years,  selective  nAChR  ligands  for  the  study  of  receptor 
function were scarce. However, as it has become increasingly clear that a 
relationship exists between neuronal nicotinic receptors and increasingly Page | 19  
 
prevalent  disease  states  such  as  Alzheimer’s  disease,  many  new 
compounds have been synthesised over the past two decades, some of 
which  have  subsequently  progressed  to  clinical  trials.
  A  selection  of 
reported nAChR agonists 14 27 investigated recently are shown in Figure 
6 emphasising the structural diversity of compounds considered 
 
Like  nicotine,  many  of  the  compounds  that  have  shown  promise  as 
nicotinic  acetylcholine  receptor  (nAChR)  selective  agonists  contain  a 
substituted pyridine ring. RJR 2403 14 is formed by the ring opening of 
nicotine  and  is  naturally  present  in  tobacco.  RJR 2403  has  a  similar 
potency to nicotine at α4β2 receptors and exhibits very similar cognitive 
enhancement properties. It is, however, much less potent in its effect on 
cardiovascular function and locomotor activity
93 which are significant side 
effects  of  nicotine.  SIB 1508Y  15  is  more  potent  and  selective  than 
nicotine at α4β2 sites and also appears to improve cognitive and motor 
function deficits in certain models of PD.
91,92  
 
Epibatidine 16 is a potent nAChR agonist isolated from the skin of the 
Ecuadorian frog E. tricoloris and is a potent natural nAChR agonist,
87,88 
epibatidine  is,  however,  not  useful  therapeutically  as  it  shows  poor 
selectivity  for  the  various  nAChRs.
89  Interestingly  epibatidine  also 
possesses potent analgesic effects (~ 100   200 times more potent than 
morphine). 
 
One of the most promising non aromatic heterocycles studied is ABT 418 
21. ABT 418 is a full agonist at α4β2 sites and shows improved receptor P
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selectivity  when  compared  to  nicotine.  Notably,  ABT 418  has  shown 
cognitive  enhancing  properties  in  animals  and  also  appears  to  have 
separate cardiovascular and CNS function.
90 
 
Lobeline  23  is  the  most  biologically  active  compound  produced  by  the 
plant Lobelia inflata. Lobeline has a very high affinity for α4β2 nAChRs 
and  is  now  believed  to  possess  both  agonist  and  antagonist 
properties.
94,95 Lobeline has been studied extensively as a potential agent 
for treatment of CNS disorders; this will be further discussed in Section 
1.4.2. 
 
To  date,  a  number  of  nAChR  selective  agonists  possessing  an  indole 
framework  have  been  reported.
96,97  Tropisetron  27  possesses  5HT3  
antagonist properties, however, recent studies have also shown 27 to be a 
potent and selective α7 nAChR partial agonist.
98 Although not known to be 
an nAChR agonist, indole propanoic acid (IPA) (Oxigon
TM) 28 is a naturally 
occurring anti oxidant and has undergone clinical trials for the treatment of 
Alzheimer’s Disease. 
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Alongside having significant beneficial neuroprotective effects, IPA 28 is 
believed to be a powerful inhibitor of β amyloid fibril formation.
99 Similarly, 
melatonin 29 has also shown good efficacy in the inhibition of β amyloid 
fibril formation.
100 Interestingly, Carter et al. have demonstrated that the 
neuroprotective effect of melatonin 29 is dependent on the presence of the 
5 methoxy  group     when  this  group  is  absent,  as  in  N acetyl  serotonin 
(NAS) 30, the compound possesses no neuroprotective properties.
101 
 
The nicotinic agonists shown in Figure 6 display a marked difference in 
structure, functional group types and spatial arrangements of the potential 
binding sites into the pharmacological receptor, whilst often having very 
similar activities or selectivities at nAChRs. As the precise geometry of the 
nicotinic receptor sites have not yet been elucidated, potential molecules 
must be modelled around compounds that are known to be biologically 
active.  This  involves  the  mimicking  of  promising  inter atomic  distances, 
functional group interactions and other structural likenesses with the aim 
of designing selective nAChR agonists with equivalent or better potency 
than nicotine, yet without its toxicity. This approach has been explored by 
Institut de  Reserches  Servier  for  several  years,  but,  as  yet,  no reliable 
structure activity relationship has been revealed 
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1.4.2 Lobeline and Sedamine 
 
Lobelia inflata is native to North America and is an annual or bi annual 
plant that thrives in dry soils. It grows up to two feet tall and produces 
white or pale blue flowers (Figure 7). The plant is named in honour of the 
botanist Matthias De Lobel (1570 1616) and after its inflated seed pods. 
Sometimes known as Indian Tobacco or Wild Tobacco, Lobelia inflata is 
thought to have been smoked by North American Indian tribes, such as 
the Penobscot. The Lobelia family consists of over 50 species that include 
Lobelia kalamis, Lobelia spitaca and Lobelia erinus. Of the 47 compounds 
extracted from Lobelias, 29 are piperidines (see Figure 7 for structures) 
with the greatest concentration being found in Lobelia inflata; of these, ( ) 
lobeline is the most abundant and most biologically active compound.
103  
 
Sedum  is  a  large  genus  of  crassulaceae  which  contains  around  400 
species.  These  include  Sedum  adolphii,  Sedum  aizoon,  Sedum 
albomarginatum  and  perhaps  the  most  interesting,  Sedum  acre 
(sometimes known as biting stonecrop). Sedum acre (Figure 8) was often 
used  in  ancient  Greece  to  treat  skin  disorders  and  epilepsy.  Figure  8 
shows the piperidine based structures isolated from sedum acre. 
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Lobeline 23 possess a variety of useful pharmacological properties. In the 
late 1960s lobeline was used as a respiratory stimulant.
107 In small doses, 
lobeline  activates  carotid  and  aortic  body  chemoreceptors,  whilst  larger 
doses have been shown to induce coughing.
108 
 
Perhaps the most promising biological aspect of lobeline is its potential for 
use  in  the  therapy  of  various  CNS  conditions  including  PD,  LBD, 
Tourette’s syndrome and schizophrenia. Lobeline possesses a number of 
properties in common with nicotine; these include the ability to stimulate 
autonomic  ganglia
109  and  to  improve  memory.
110  Lobeline  does  not, 
however, up regulate nicotinic receptors with chronic use
111 or desensitise 
central nicotinic receptors (a significant drawback of nicotine). 
 
Although  the  active  site  of  the  nAChR  is  not  yet  fully  mapped,  some 
essential properties of the potential nAChR agonist have been suggested 
from binding data. Beers and Reich
112 initially suggested that compounds 
which display nAChR binding activity possess a quaternised nitrogen and 
a hydrogen bond acceptor (e.g. a carbonyl group) which is able to form a 
hydrogen bond with a donor group in the receptor. Subsequent modelling 
studies of known nicotinic agonists structures by Sheridan et al. suggested 
these two binding elements should be separated by between 4.6 and 6.3 
Å.
113 Barlow and Johnson
114 claimed that lobeline 23 is able to assume a 
conformation which agrees with this model.
 It is thought that lobeline has 
mixed agonist and antagonist activity and this has been attributed to site 
selective  binding  in  the  nAChR  through  either  the  ketone  or  hydroxyl Page | 27  
 
functionality, respectively
115 (see section 5.2.1 for a further discussion of 
the pharmacophore). 
 
The biosynthesis of lobeline has been extensively studied since the 1960s 
and is not yet fully determined. Indeed, certain enzymes involved in the 
final stages of the biosynthesis still remain unknown. As early as 1917, 
Robinson
116 proposed  that  lysine  31  was  the  common  precursor  of  the 
piperidinic alkaloids, such as lobeline and sedamine.  
 
The currently accepted biosynthesis of lobeline and sedamine is shown in 
Scheme  1.  It  is  suggested  that  2,3,4,5 tetrahydropyridine  34  is  formed 
from lysine 31 via 5 aminopentanal 33. A route via cadaverine 32 has also 
been proposed but tracer studies suggested that this route is less likely.
117 
Condensation  of  34  with  benzoylacetic  acid  35  gives  the  ketone  36.  
Oxidation  of  36  to  37  and  subsequent  condensation  with  a  further 
molecule  of  benzoylacetic  acid,  furnishes  the  bis(ketone)  38.  38  Then 
undergoes  N methylation  and  stereoselective  reduction  of  one  ketonic 
group  to  give  ( ) lobeline  23.  Feeding  studies  with  radiolabelled 
phenylalanine 40, cinnamic acid 41 and 3 hydroxy 3 phenyl propionic acid 
42 have shown their intermediacy in the biosynthesis of benzoylacetic acid 
35 and that they are also precursors for lobeline biosynthesis (Scheme 
2).
118 In addition, feeding studies
119 have shown that lobeline 23 can be 
biosynthesised in good yield by administration of radiolabelled lobelanine 
39, providing further evidence for the proposed biosynthetic pathway.
120  
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Scheme 1.   Proposed biosynthesis of ( ) lobeline 23 
 
  
Scheme 2.   Precursors in the biosynthesis of ( ) lobeline 23 
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1.5 Reported Synthetic Strategies for the Synthesis of Lobeline and 
Sedamine Analogues 
 
The synthesis of lobeline was first reported in 1929 by Wieland et al.
121 
(Scheme 3), who utilised a double Claisen condensation between diethyl 
pentanedioate 43 and acetophenone followed by addition of NH3 to give 
the  piperidine based  ring  structure  44.  In  the  next  steps,  the  carbonyl 
groups were reduced using H2 / PtO2 and the diastereoisomers separated 
by crystallisation; treatment with Al/Hg gave norlobelanidine 46. 46 was 
subsequently  N methylated  with  methyl  p toluenesulphonate  to  give  47 
and oxidised using KMnO4 to give racemic lobeline 23; ( ) lobeline 23 was 
finally resolved using D tartaric acid.  
 
O
O OEt
EtO
i, NaNH2
iii, NH3
O
N
H
O
H2, PtO2
OH
N
H
OH
Al/Hg
OH
N
H
OH
p TolSO3Me
OH
N
OH
D tartaric acid
O
N
OH
ii,
yield not given 29 %
yield not given
27 %
yield not given
O
CH3
CH3
CH3
O
N
OH
CH3
KMnO4
yield not given
43 44 45
46
( ) 23
47
23
 
Scheme 3.   Wieland synthesis of ( ) lobeline 23 (1929) Page | 30  
 
Also  in  1929,  a  full  synthesis  of  (±) lobeline  from  2,6 lutidine  48  was 
described  by  Scheung  and  Winterhalder  (Scheme  4).
122  Initially,  2,6 
bis(phenylethynyl)pyridine 49 was synthesised using a method described 
by Shaw in 1924.
123 Hydration of the alkyne 49 with concentrated H2SO4 
produced the bis(ketone) 50, which was N methylated and subsequently 
reduced using H2 / Pt / BaSO4 to give 47. Oxidation using KMnO4 furnished 
racemic lobeline 23, which was not subjected to optical resolution. 
 
 
Scheme 4.   Synthesis  of  racemic  (±) lobeline  23  by  Scheung  and 
Winterhalder (1929) 
 
In 1935, Schopf and Lehmann
124 described a remarkable high yielding, 
one pot synthesis of lobelanine 39, the bis(ketone) derivative of lobeline 
(Scheme 5). In their synthesis, a mixture of benzoyl acetic acid 51, glutaric 
dialdehyde 52 and methylamine hydrochloride was simply stirred at room Page | 31  
 
temperature for eight days in pH 4 buffered solution to give lobelanine 39 
in 90% yield. 
 
Scheme 5.   The Schopf and Lehhmann one pot synthesis of lobelanine 39 (1935) 
 
Few  other  syntheses  of  racemic  lobeline  have  been  reported  in  recent 
years.  However,  several  multi step,  highly  enantioselective  syntheses 
have  recently  been  reported  by  Compère  et  al.
125  and  Felpin  et  al.
103 
These,  along  with  a  number  of  other  approaches,  are  discussed 
comprehensively in a recent review of Lobelia inflata alkaloids.
103 
 
A number of strategies have been employed for the synthesis of sedamine 
and  its  related  alkaloids.  The  simplest  of  those  described  involves 
attachment of an aromatic component to a pyridine derivative followed by 
reduction.  The  first  synthesis  of  sedamine  was  reported  in  1956  by 
Beyerman  et  al.
126  using  the  addition  of  (pyridin 2 ylmethyl)lithium  54 
(generated from 2 methylpyridine 53 and n BuLi) to benzaldehyde to give, 
after work up, the alcohol 55 (Scheme 6). Subsequent N methylation and 
hydrogenation over Pt gave (±) sedamine 57 and its diastereoisomer (±) 
allosedamine  58  (also  present  in  Lobelia  inflata).  An  analogous 
preparation  has  also  been  reported  by  Beyerman  using  [(1 
methylpyridinium 2 yl)methyl]lithium  iodide  59  as  the  starting  reagent 
(Scheme 6).
127 Page | 32  
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Scheme 6.   Approaches of Beyerman to the synthesis of (±) sedamine 57 
 
Meth Cohn  et  al.
128  and  Chu Yu  et  al.
129  synthesised  ketone  65  by 
displacement  of  the  halogen  from  2 fluoro 1 methylpyridinium  salt  61 
using  pyrrolidinoenamine  62  (Scheme  7).  The  resulting  adduct  63  was 
easily hydrolysed under acidic conditions to give the corresponding ketone 
64 which was subsequently hydrogenated using PtO2 to give the ketone 
species 65. Reduction of 63 using NaBH4 gave the tetrahydropyridine 66.  Page | 33  
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Scheme 7.   Chu Yu et al. synthesis of sedamine based ketone derivatives 
 
Meth Cohn  and  co workers  also  tackled  the  problem  of  obtaining 
enantiomerically pure sedamine analogues by investigating the reduction 
of  the  ketone  67  using  both  R,R  and  S,S  Jacobsen’s  catalyst.
130  For 
example,  reduction  of  ketone  67  with  modified  NaBH4  and  (S,S) 
Jacobsen’s  catalyst  gave  the  (R) alcohol  55  in  both  good  yield  and 
enantiomeric excess (76 %, 86 % ee) (Scheme 8). Subsequent reduction 
and  separation  of  diastereoisomers  gave  68  and  69;  methylation  of  69 
gave sedamine 57. Page | 34  
 
 
Scheme 8.   Meth Cohn & Chu Yu synthesis of enantiomerically pure sedamine 57 
 
A comprehensive review by Bates and Kanicha covering the synthesis of 
sedamine  and  related  compounds  was  published  recently.
106 Unlike  the 
approaches  described  above,  many  of  the  strategies  described  are 
piperidine based, and are often complex involving syntheses consisting of 
ten steps (or more).  
 
 
1.6 Preamble to Synthetic Work 
 
The work reported in this thesis forms part of a wide ranging collaborative 
project between the University of Sunderland and Institut de Recherches 
Servier. This research programme began in 1996 (originally instigated by 
Prof. Otto Meth Cohn) with the aim of developing heterocyclic derivatives 
as  potential  agents  for  treatment  of  neurodegenerative  diseases.  The Page | 35  
 
project  arose  from  the  reported  observations  of  neuroprotective  effects 
seen in lobeline and sedamine administration and has targeted a broad 
spectrum of compounds that can be loosely represented by the schematic 
illustration  in  Figure  9.  A  representative  selection  of  compounds 
synthesised and investigated pharmacologically to date is shown in Figure 
10.
131 
 
 
Figure 9.  Schematic representation of the target compounds in the University 
of Sunderland –Institut de Recherches Servier research collaboration 
 
Of  the many  compounds  prepared  at  the University  of  Sunderland  and 
investigated  pharmacologically  by  Institut  de  Recherches  Servier, 
compounds 70 and 71 (Figure 11) have been of particular interest.
132 Both 
70 (S24795 1) and 71 (S24806 1) were shown to be negative allosteric 
modulators  at  nicotinic  receptors  with  wide spectrum  pro cognitive  and 
pro psychobehavioural  activity.  Notably,  both  70  and  71  have  excellent 
membrane  permeability,  borderline acceptable  metabolic  stability  and 
good  binding  at  nicotinic  receptors  (Figure  11).P
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Compound 70 completed Phase I Clinical Studies during the course of this 
project,  notably  with  no  negative  interactions  at  the  eighty  alternative 
physiological binding sites investigated; unfortunately however, 70 has not 
progressed into Phase II Clinical Studies due to metabolite related in vitro 
clastogenotoxicity.  Compound  71  has  been  studied  intensively  in  pre 
clinical trials but has recently been shown to have unacceptable blocking 
at  the  human  ether à go go  related  gene  potassium  ion  (hERG  K
+) 
channel, precluding further investigation. Blocking at the hERG K
+ channel 
has been shown to cause acquired long QT syndrome (acquired LQTS) 
that  can,  under  certain  circumstances,  lead  to  potentially  fatal  cardiac 
arrhythmias. 
 
 
 
Figure 11.  Pharmacological data for S 24795 1 and S 24806 1  
 
Through structure activity relationships developed from studying the many 
compounds  previously  synthesised  in  the  research  programme,  the  4 
substituted  3 pyridin yl  ketone  and  alcohol  compounds  (and  their 
S 24795 1 70 
Electrophysiology   α7 = 42   2; α4β2 = 230   16  M 
Binding   α7, α3β2 and α4β2 > 10000 nM 
S 24806 1 71 
Electrophysiology    α7 = 43   12; α4β2 = 79   7;  
α3β2 = 116   23  M 
Binding   α7, α3β2  and α4β2 > 10000 nM Page | 38  
 
respective  N methylated  derivatives)  depicted  in  Figure  12a  were  the 
primary targets for investigation in this project. Chapters 2, 3 and 4 detail 
our  endeavours  to  synthesise  bis ketone,  bis   alcohol  and  keto alcohol 
compounds (Figure 12b). Chapter 3 also details the synthesis of indole 
derivatives (Figure 12c). 
 
 
 
Figure 12.   Primary targets of investigation in this project 
 
The  compounds  synthesised  in  this  project  have  been  sent  to  our 
collaborators  at  Institut  de  Recherches  Servier  for  pharmacological 
evaluation.  Chapter  5  details  some  of  the  pre clinical  pharmacological 
investigations  performed,  giving  a  brief  summary  of  the  initial  results Page | 39  
 
obtained  to  date.  Pharmacological  data  obtained  from  compounds 
synthesised in this project will be of great value to aid further refinement of 
the  structure activity  database  and  provide  great  insight  for  designing 
future targets for the research programme. Naturally, it was hoped that the 
compounds prepared in this project could provide candidates for detailed 
pre clinical pharmacological investigation and, ultimately perhaps, agents 
for treatment of neurodegenerative disease. 
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Chapter 2 
 
This  chapter  details  our  approach  to  3 pyridin yl  ketone  and  alcohol 
compounds using synthetic approaches that involve metallation reactions 
of 3 methylpyridine. 
 
2.1 Reported Methodology for the Metallation of 3 Methylpyridine 
 
The reaction of 3 methylpyridine 72 with strong bases has been known 
since  the  early  1950s.  The first  report  by  Brown  and  Murphy  (1951)
133 
used sodium amide / liq. ammonia to generate 73a; subsequent trapping 
with methylchloride afforded 3 ethylpyridine 74 (Scheme 9). 
 
N
CH3
N
CH2CH3 NaNH2 / NH3
25 oC
N
CH2Na
CH3Cl
72 73a 74
yield not given
 
Scheme 9.   Brown and Murphy metal amide metallation procedure 
 
In a later report, Miller and Levine (1959)
134 used benzaldehyde and 2 
methylpropanal to trap 73b generated by treating 72 with potassium amide 
/ liq. ammonia to give the corresponding secondary alcohols 75a and 76 
(17 % and 6 % respectively); it is noteworthy that the structural motif of 
compound 75a is of interest in this study. In an analogous reaction, tertiary 
alcohol 77 was isolated when 73b was intercepted when benzophenone 
was employed as electrophile (27 % yield) (Scheme 10). The use of these 
metal amide / ammonia systems is, however, inconvenient with poor yields Page | 41  
 
seen (typically < 20 %); no suggestions have been offered to account for 
the  poor  isolated  yields  and  no  significant  optimisation  of  reaction 
conditions have been reported. 
 
 
Scheme 10. 
 
An improved lithiation procedure was reported by Kaiser et al. in 1975,
135 
who were able to generate (pyridin 3 ylmethyl)lithium 73c in THF at 0 
oC 
using  lithium  diisopropylamide  (LDA)  and  hexamethylphosphoric  acid 
triamide  (HMPT)  as  a  chelating  co solvent  (Scheme  11);  subsequent 
trapping of 73c with either benzophenone or methyl benzoate gave the 
respective alcohol 77 (75 %) and ketone 78a (90 % yield). Comparatively, 
for reactions of benzophenone as electrophile this methodology appears Page | 42  
 
to show a marked improvement in yield to the approach reported by Miller 
and Levine for synthesis of the same compound (75 versus 27 % from 3 
methylpyridine).
134  
N
CH3
N
CH2Li
N
N
O
LDA, HMPA, THF
0 oC, 1.25 h
1 h, 25 oC
75 %
1 h, 25 oC
90 %
HO
72 73c
77
78a
OCH3
O
O
 
Scheme 11. 
 
More recently, Davis et al.
136 have successfully synthesised a number of 
pyrrolopyridines (79a c) by deprotonation of 3 methylpyridine using LDA in 
the  absence  of  any  stabilising  co solvent  (Scheme  12)  (see  later  for  a 
more detailed discussion). 
 
N
CH3
N N
R
79a R = H, 90 %
79b R = OCH3, 72 %
79c R = Cl, 3 %
i, LDA, THF, 0 oC
ii,
iii, LDA, 25 oC, 17 h
72
R
NC
 
 
Scheme 12. 
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Koller  et  al.
137  investigated  the  use  of  LDA  in  the  presence  of 
hexamethylphosphoramide  (HMPA)  in  THF  at  0 
oC  to  metallate  3 
methylpyridine  (Scheme  13);  reported  yields  for  trapping  reactions  with 
aromatic aldehydes as electrophile were in the range 3 45 %. A significant 
drawback of methods employing phosphoramide co solvents is that HMPA 
and  HMPT,  like  many  other  phosphoramides,  are  known  to  be  highly 
carcinogenic compounds
138 and their use is obviously undesirable. 
 
 
Scheme 13. 
 
Baldwin  and  co workers
139a d  demonstrated  that  3 methylpyridine  was 
efficiently lithiated using LDA in THF in the presence of 1,3 dimethyl 3,4,5 
tetrahydro 2(1H) pyrimidione (DMPU). DMPU is a dipolar, aprotic solvent 
which, in recent years, has been used to some success as a replacement 
for phosphoramide solvents.
140 The Baldwin group reported that reactions 
of 73c (from 72) with various primary alkyl halides proceeded smoothly, 
with yields of between 55 and 70 %.
139d This approach was employed as a 
key  step  in  the  synthesis  of  a  number  of  marine  sponge  alkaloids,  for 
example,  hachijodines  F  and  G  and  pyrinodemin  A.  The  synthesis  of 
hachijodine F is outlined in Scheme 14. Page | 44  
 
 
Scheme 14. 
 
Since the inception of this project Miwatashi et al.
141 have reported the 
synthesis of a series of 2, 3 and 4  substituted pyridylketones via trapping 
reactions  of  (pyridin 3 ylmethyl)lithium  with  substituted  tertiary  amides 
(e.g. Scheme 15).  
 
 
 
Scheme 15. 
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Metallated  3 methylpyridine  has  been  trapped  with  aldehydes, 
ketones,
134,135,137,142 arylnitriles,
136 acylhalides / esters
135,141,143 145 and alkyl 
halides.
133,139d,146 150  The  specific  method  of  metallation  and  subsequent 
reaction with electrophiles differs significantly in each of these examples. 
For  example,  Davis  et  al.,
136  Kaiser  et  al.
135  and  Koller  et  al.
137  have 
reported the generation of the organometallic by maintaining the mixture of 
3 methylpyridine and base at 0 
°C, followed by addition of the electrophile, 
also  at  0 
°C.  In  contrast,  Davies Coleman  et  al.
151  performed  reactions 
entirely at  78 
°C, whereas, Baldwin et al.
139d described a hybrid reaction, 
first generating the organometallic at 0 
°C, then cooling the solution to  78 
°C before addition of the electrophile. 
 
Organometallic generation times also appear to vary widely. For example, 
Miller and Levine
134 Kaiser et al.
135 Baldwin et al.
139d and Davis et al.
136 all 
report  stirring  for  30  min.  at  0 
°C.  However,  organometallic  generation 
required just 20 min. at  78 
°C in the hands of Morimoto et al.
152 who report 
comparable yields for similar reactions. 
 
Although several authors have reported achieving moderate yields through 
reaction of metallated 3 methylpyridines 73a c with various electrophiles, it 
is clear that the methodology for the generation of these organometallics is 
not  well  defined  or  consistent  and  reported  organometallic  generation 
times and reaction temperatures often vary without explanation. The range 
of  electrophiles  explored  thus  far  could  be  extended  to  provide  further Page | 46  
 
insight  into  the  metallation  of  3 methylpyridine  and  establish  a  clearer 
general metallation method. 
 
In  contrast  to  the  apparent  problems  with  deprotonation  of  3 
methylpyridine,  it  should  be noted  that deprotonation of  both 2   and 4 
methylpyridine  is  possible  both  by  using  either  weak  bases  (e.g. 
hydroxides, alkoxides and amines) in protic media or strong bases (e.g. 
alkali  metal  amides,  organolithium  compounds)  in  aprotic  media; 
subsequent  reaction  with  a  wide variety  of  electrophiles  generally 
proceeds cleanly, often occuring in high yield (typically > 70%).
153 155 For 
example,  in  an  analogous  reaction  to  those  reported  by  Miller  and 
Levine
134  and  subsequently  Kaiser  et  al.  using  3 methylpyridine,
135 
benzophenone reacted smoothly with (pyridin 2 ylmethyl)lithium 54 to give 
alcohol 84 in 94 % yield (Scheme 16).
156 
 
 
Scheme 16. 
 
Similarly, good yields have been reported  for compounds synthesised via 
the metallation of 4 methylpyridine.
141,157 For example, Jiang et al.
158 were 
able to able to carry out the deprotonation and subsequent alkylation of 4 
methylpyridine 85 using n BuLi to give 86 in excellent yield 92 % (Scheme 
17). Page | 47  
 
 
Scheme 17. 
 
The  improved  ease  of  formation  of  2   and  4 metallomethylpyridines 
compared to 3 metallomethylpyridines may be attributed to the favourable 
resonance stabilisation (with participation of the ring nitrogen) afforded to 
anions derived from both 2  and 4 methylpyridine (Scheme 18). H / D 
exchange  experiments  of  2 ,  3 ,  and  4 methylpyridine  with  a  relative 
exchange rate of 130: 1 : 1810 (MeOD / MeONa at 20 °C, c.f. toluene ~10
 
5) demonstrate this point.
 159 
 
 
Scheme 18.  Resonance structures for carbanions derived from deprotonation of 
(a) 2 methylpyridine, (b) 3 methylpyridine and (c) 4 methylpyridine. 
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2.2 Synthetic Approaches to Target Compounds 75 and 78 
 
As  part  of  our  synthetic  strategy,  approaches  via  lithiation  of  3 
methylpyridine were appealing, offering a potentially simple one step entry 
into  the  target  compounds  1 phenyl 2 (pyridin 3 yl)ethanol  75  and  1 
phenyl 2 (pyridin 3 yl)ethanone 78. To begin our investigation we sought 
to  establish  reliable  reaction  conditions  for  efficient  metallation  of  3 
methylpyridine. 
 
Our  initial  investigations  focused  on  reproducing  the  methodology  of 
Kaiser and Petty
135 who synthesised the alcohol 77 and ketone 78a, by 
trapping  (pyridin 3 ylmethyl)lithium  73c  with  benzophenone  and  methyl 
benzoate, respectively (Scheme 11) (compound 78a has been identified 
as a compound of pharmacological interest in this study). In our work, the 
co solvent  HMPT  employed  by  Kaiser  and  Petty
135  was  replaced  with 
DMPU, successfully utilised by Baldwin et al. (Scheme 14) for the reasons 
described previously. 
 
In  our  hands,  the  formation  of  (pyridin 3 ylmethyl)lithium  using  LDA  / 
DMPU and its subsequent reaction with benzaldehyde proved testing. A 
maximum  isolated  yield  of  only  11  %  was  achieved  despite  extensive 
alteration of the reaction stoichiometry (i.e. the ratio of 3 methylpyridine : 
LDA : chelating agent : electrophile, e.g. 1:2:2:1.2 or 1:3:3:1.2) in attempts 
to  improve  the  reaction  yield.  As  a  varying  range  of  organometallic 
generation times and reaction temperatures have been described in the Page | 49  
 
literature, these variations were also explored; (pyridin 3 ylmethyl)lithium 
generation times of 15, 30 and 45 min were investigated with reactions 
being  carried  out  at  both   78  and  0 
°C.  However,  no  improvement  in 
isolated  yield  was  achieved.  The  maximum  yields  obtained  using  our 
methodology are given in Scheme 19. Comparatively, the modest yield of 
75a (11%) is consistent with that reported by Miller and Levine
134 utilising 
the metal amide / ammonia procedure (17 %), but somewhat lower than 
that detailed by Kaiser and Petty, who used LDA and HMPT (40 %).
135 
 
 
Scheme 19. 
 
The reaction of (pyridin 3 ylmethyl)lithium (Scheme 19) generated using 
LDA  in  the  presence  of  DMPU  with  methyl  benzoate  appeared  more 
promising with, a maximum isolated yield obtained in our hands of 43 %. 
However, Kaiser et al.
135 reported a yield of 90 % for the synthesis of the 
same compound using HMPT (and not DMPU) as co solvent, suggesting 
that DMPU may not be as efficient as a chelating agent when compared 
with HMPT. This was illustrated under our conditions by an improved yield 
(67 %)  when DMPU was replaced by HMPT as the co solvent. It was, Page | 50  
 
however,  noted  that  reactions  with,  for  example,  Weinreb  amides, 
arylnitriles  and  alkyl  halides  did  not  proceed  in  our  hands  using  this 
methodology. Nevertheless, it was encouraging that in all trial reactions of 
(pyridin 3 ylmethyl)lithium  using  either  HMPT  or  DMPU,  no  evidence  of 
side reactions was observed, with only products and / or starting materials 
ever recovered.  
  
As  our  initial  attempts  to  improve  upon  reported  methods  for  the 
generation  and  trapping  of  the  (pyridin 3 ylmethyl)lithium  using  LDA  / 
DMPU  under  various  reaction  conditions  had  proven  difficult,  we  next 
turned our attention to the work reported by Davis et al.
136 in an attempt to 
identify an alternative method for efficient metallation of 3 methylpyridine. 
In  a  reaction  of  interest  to  us,  this  group  used  1  equiv.  of  LDA  to 
deprotonate 3 methylpyridine at 0 
°C in THF, followed by the addition of 4 
methoxybenzonitrile, to give the intermediate 87 (Scheme 20). A further 
equivalent  of  LDA  and  warming  to  room  temperature
  effected 
deprotonation  at  the  α position  and  induced  cyclisation  to  the 
pyrrolopyridine  79b  (72  %  yield).  Davis  et  al.
136  suggested  that  good 
evidence for this mechanistic rationale is provided by the isolation of 88 
and  89  on  trapping  with  methyliodide  (their  yields  or  respective  ratios 
were, however, not reported).  
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N
O
OCH3
H3C CH3
N
O
OCH3
H CH3
N
CH3
N
N
OCH3
Li
N N
H
OCH3
i, 1 equiv. LDA
THF, 0 oC
30 min
ii,
1 equiv. LDA
THF, 25 oC, 17 h
72 87 79b
88 89
i, 1 equiv. LDA
THF, 0 oC
ii, 4 equiv. MeI
iii, H3O
72 %
OCH3
NC
 
Scheme 20. 
 
From the work of Davis et al. it is apparent that initial deprotonation of 3 
methylpyridine with LDA in THF at 0 
°C to afford intermediate imine 87 
must be reasonably efficient. It was expected that (acidic) hydrolysis of 87 
could readily furnish the target ketone 78f (Scheme 21). Interestingly, in 
the work by Davis et al. the ketone 78f was never isolated. Thus, following 
the procedure detailed by Davis et al.,
136 treating 3 methylpyridine in THF 
at  0 
°C  with  1.2  equivalents  of  LDA  with  subsequent  addition  of  4 
methoxybenzonitrile  and  aqueous  work up,  the  desired  ketone  78f  was 
obtained in an isolated yield of 66 %. Procedurally, once the benzonitrile 
had been added, stirring was continued at 0 
°C for 1 h prior to reaction 
work up (however in our experience, from monitoring of the reaction by 
TLC, the reaction appeared to be complete in approximately 30 min). 
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N
CH3
N
N
OCH3
Li
i, 1.2 equiv. LDA
THF, 0 oC
30 min
ii,
0 oC, 1 h
72 87
72 %
OCH3
NC
N
O
OCH3
N
NH
OCH3
N
OCH3
NH2
H2O
90
78f
91
H2O
 
Scheme 21. 
 
On  reaction  work up,  hydrolysis  of  the  intermediate  imine  87  occurred 
rapidly by simply quenching the reaction with water. In comparison, it is 
interesting to note that analogous reaction with 2 methylpyridine afforded, 
on  aqueous  work up,  the  stable  enamine  94  with  no  evidence  for 
hydrolysis  to  ketone  67f  found.  In  this  case,  only  acidic  hydrolysis  of 
intermediate 92 or enamine 94 afforded ketone 67f (in solution (DMSO) 
this exists as a mixture of keto / enol tautomers, with a ratio of 3 keto to 1 
enol, Scheme 22, Figure 13).
160 Carey et al. have studied the keto enol 
equlibria  for  a  range  of  1 (4 substituted  phenyl) 2 (pyridin 2 
yl)ethanone
161a and 1 phenyl 2 (quinolin 2 yl)ethanone derivatives.
161b Page | 53  
 
 
Scheme 22. 
 
In contrast, 
1H (Figure 14) and 
13C NMR showed that compound 78f does 
not  exist  with  a  contribution  from  the  enol  form  in  the  solution  state  in 
either CDCl3 or DMSO d6. P
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As a methodological improvement, we were able to obtain compound 78f 
using  a  greater  excess  of  LDA  (2  equiv.)  and  a  reduced  (pyridin 3 
ylmethyl)lithium generation time (5 min.) at 0 
°C without witnessing any 
loss  in  yield;  all  other  parameters  remained  true  to  the  methodology 
described above. Interestingly, using an organometallic generation time of 
5 min. at 0 °C and the original 1.2 equiv. of LDA, the isolated yield of 78f 
was  approximately  halved  (35  %).  In  all  attempts,  no  products  of 
cyclisation (cf. Davis et al.
136), or other side products, were ever witnessed 
in these reactions. 
 
For  completeness,  the  above  methodology  was  also  attempted  in  the 
presence  of  varying  concentrations  of  the  chelating  agent  DMPU.  On 
these occasions, no improvement in yield was noted with yields of ketone 
78f  being  similar  to  those  obtained  in  the  absence  of  DMPU.  In  these 
reactions, the DMPU presented problems in the purification of the reaction 
product; DMPU has a similar polarity to compound 78f and was, therefore, 
often difficult to remove by column chromatography or re crystallisation.  
 
Having developed a reliable, reproducible methodology for the formation 
of  (pyridin 3 ylmethyl)lithium  and  subsequent  reaction  with  4 
methoxybenzonitrile to give the ketone 78f, we investigated application of 
this  approach  to  reactions  of  (pyridin 3 ylmethyl)lithium  with  a  range  of 
commercially  available  electrophiles;  these  results  are  summarised  in 
Table 1. Page | 57  
 
_________________________________________________________________
Entry Electrophile Product Yield (%)
_________________________________________________________________
I
N
1. 58
2.
Br
N
37
3.
O
H
N
OH
11
4.
O
H N
OH
32
5.
O
H3C
N
HO
CH3
28
_________________________________________________________________
96a
96b
75a
96c
96d
6.
O
7.
O
H3CO
N
OH
59
43
N
O
8.
N
O O
Cl 26
9.
OCH3
NC
N
O
OCH3
66
96e
78a
78a
78f
 
Table 1.  Reactions of (pyridin 3 ylmethyl)lithium with various electrophiles 
Reagents and Conditions: i, 3 methylpyridine 72, 2 equiv. LDA, THF, 
0 
°C, 5 min; ii, electrophile, 0 
°C, 1h; iii, H2O or NH4Cl. Yields are 
quoted after work up and purification by column chromatography and 
/ or recrystallisation. Page | 58  
 
Alkylation of 73c with iodopropane (entry 1) or benzyl bromide (entry 2) 
gave the expected products 96a (58 %) and 96b (37 %). The isolated yield 
of 96a was consistent with that reported by Baldwin et al.
139d who reported 
reactions of (pyridin 3 ylmethyl)lithium 73c with a range of alkyl halides 
that  proceeded  in  yields  of  55 70  %,  (although  these  were  largely  the 
somewhat  less  reactive  bromoalkanes).  To  our  knowledge,  reaction  of 
(pyridin 3 ylmethyl)lithium with a benzylic halide has not been reported to 
date; however, Alunni et al. have recently reported the reaction of (pyridin 
2 ylmethyl)lithium 54 with benzyl bromide using similar methodology.
162 
 
Regioselective ring opening of an aliphatic epoxide (entry 6) with (pyridin 
3 ylmethyl)lithium  was  also  demonstrated,  giving  the  corresponding 
alcohol  96e  (59  %  yield).  To  our  knowledge,  no  examples  of  the  ring 
opening  of  epoxides  by  (pyridin 3 ylmethyl)lithium  have  been  reported 
previously. 
 
Given the lack of reactivity of 4 substituted benzaldehydes with 73c it was 
perhaps surprising that alcohol 96d could be obtained from reaction of 73c 
with acetophenone (28 %) (entry 5). Reaction of (pyridin 3 ylmethyl)lithium 
73c  with  phenylacetaldehyde  gave  the  secondary  alcohol  96c  (32  %) 
(entry 4). Unfortunately, in our hands, reaction of 73c with benzaldehyde 
was unsuccessful (even after stir out at room temperature for up to 4 h) 
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lack of reactivity was noted with other 4 substituted benzaldehydes (e.g. 4 
fluoro, 4 bromo and 4 nitro).  
 
Acylation of (pyridin 3 ylmethyl)lithium using either benzoyl chloride (entry 
8) or methyl benzoate (entry 7) as electophile to give ketone 78a in 26 and 
43  %  yields,  respectively,  was  also  possible.  In  the  reactions  of 
acetophenone,  phenyacetaldehyde  and  benzoyl  chloride  with  73c, 
products  other  than  the  expected  target  compounds  were  always 
witnessed by TLC (perhaps accounting for reduced isolated yields). The 
more reactive benzoyl chloride, in particular, gave a complex mixture of 
highly polar compounds making purification of the desired reaction product 
78a extremely difficult (the side products were, however, never isolated or 
identified).  
 
The  above  investigation  into  the  general  reactions  of  (pyridin 3 
ylmethyl)lithium, although brief, provided evidence that a methodology had 
been developed that could be widely applicable and reasonably efficient, 
with potential for optimisation. We rapidly demonstrated that a compound 
of interest, 78f, could be synthesised in reasonable yield, from the reaction 
of 73c with 4 methoxybenzonitrile by employing a modified version of a 
procedure  originally  reported  by  Davis  et  al.
136  This  significant  result 
indicated that this methodology could be a useful approach towards the 
synthesis of compounds of interest in this study. 
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Target  ketones  78a,c f  (Scheme  23),  were  readily  prepared,  with  most 
isolated  in  good  yield  (40     81%).  It  is  noteworthy  that,  although  these 
reactions have been performed many times, the yields reported here are 
unoptimised and with further work, greater yields could be achievable. 
 
 
Scheme 23. 
 
With  the  target  ketones  in  hand,  N methylation  of  78a,c f  with  excess 
methyl iodide in refluxing THF smoothly afforded pyridinium salts 98a,c f 
in excellent yield (Scheme 24). 
 
 
Scheme 24. 
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Ketones 78a,c f could be easily reduced using NaBH4 in ethanol at room 
temperature to give target alcohols 75a,c f (57   92 %) (in our experience, 
this  two step  approach  to  75a,c f  via  78a,c f  offers  better  yields  than 
reaction of 73c with 4 substituted benzaldehydes). As with ketones 78a,c 
f, the alcohol derivatives 75a,c f could be readily N alkylated with methyl 
iodide to furnish salts 99a,c f (80   94 %) (Scheme 25).  
 
 
Scheme 25. 
 
 
To act as a direct comparison with alcohols 75a,c f for pharmacological 
assessment, a series of novel propane based secondary alcohols were Page | 62  
 
prepared via the ring opening of commercially available aromatic epoxides 
100a d with (pyridin 3 ylmethyl)lithium (Scheme 26). Interestingly, in the 
reaction of 73c with 100a, the desired product 101a (63 %) was isolated 
along with the more polar primary alcohol 102a (17 %). TLC of the crude 
reaction  mixtures  from  reactions  of  73c  with  100b d  also  indicated 
competition by this side reaction; however, in these cases isolation and 
purification  of  102b d  was  never  accomplished  due  to  other  interfering 
impurities. The formation of product 102a can be rationalised through ring 
opening of the corresponding epoxide by (pyridin 3 ylmethyl)lithium 73c at 
the more sterically hindered carbon; there was no evidence for this ring 
opening  in  the  reaction  of  73c  with  with  an  aliphatic  epoxide  (entry  6, 
Table 1).  
 
 
Scheme 26. 
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2.3 Metallation of 3, 5 Dimethylpyridine 
 
Our work on the lithiation of 3 methylpyridine was further extended to the 
metallation  and  subsequent  trapping  of  3,5 dimethylpyridine  with 
arylnitriles.  In  this  instance,  we  were  particularly  interested  in  the 
possibility of deprotonation of the second pyridyl methyl group. It has been 
demonstrated  that  2,6 dimethylpyridine  48  is  able  to  undergo  both 
single
163 and double deprotonation
164,165 followed by trapping with various 
electrophiles (Scheme 27). 
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Scheme 27. 
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Additionally,  efficient  sequential  deprotonation  followed  by  sequential 
trapping with a range of benzaldehydes and / or benzonitriles to furnish 
2,2' (pyridine 2,6 diyl)bis(1 phenylethanone),  2,2' (pyridine 2,6 diyl)bis(1 
phenylethanone)  or  2 (6 (2 hydroxy 2 phenylethyl)pyridin 2 yl) 1 
phenylethanone derivatives (e.g. Scheme 28) has been demonstrated in 
both a ‘one pot’
166 and ‘two pot’
166 manner (a literature example is given in 
Scheme 29).
156 A similar sequence of reactions using 3,5 dimethylpyridine 
as substrate could provide a versatile methodology for the synthesis of a 
large variety of 3,5 disubstitutedpyridine analogues. 
 
 
Scheme 28. 
 
 
Scheme 29. 
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Using our general procedure established for preparation and reactions of 
(pyridin 3 ylmethyl)lithium 73c, treatment of 3,5 dimethylpyridine 108 with 
2 equiv. of LDA followed by addition of substituted benzonitriles 95a,c f 
gave  the  expected  compounds  110a,c f  arising  from  mono metallation. 
Derivatives 110a,c f were obtained in good excellent unoptimised yields 
(90 %, 85 % and 65 %, respectively), whereas halogenated benzonitriles 
97c d, gave products 110c and 110d in somewhat disappointing yields 
(49 % and 22 %, respectively) (Scheme 30). This pattern of reactivity is 
similar to reactions between (pyridin 3 ylmethyl)lithium and benzonitriles 
described earlier in this Chapter. Indeed, as for 3 methylpyridine, reactions 
of 108 with LDA followed by addition of benzaldehydes gave no detectable 
reaction  in  our  hands,  with  only  starting  materials  ever  recovered 
(essentially quantitatively).  
 
 
Scheme 30. 
 
Compounds 110c f have, to our knowledge, not been reported to date and 
provide a further series of novel compounds for pharmacological testing. 
Unsubstituted  derivative  110a  has  been  synthesised  previously  by 
Baradarani et al.
167 In this case, 3,5 dimethylpyridine  was deprotonated Page | 66  
 
using LDA in the presence of HMPT and the resultant ((5 methylpyridin 3 
yl)methyl)lithium trapped with methylbenzoate (Scheme 31). 
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Scheme 31. 
 
Compounds  110a,c f  were  easily  converted  to  their  N methylated  salts 
111a,c f on refluxing with excess iodomethane in THF (68 – 94 % yields) 
(Scheme  32).  Reduction  of  ketones  110a,c f  with  NaBH4  at  room 
temperature proceeded smoothly and the alcohols 112a,c f were obtained 
in  good  yields  (72  –  95  %).  Subsequent  N alkylation  of  112a e  with 
methyliodide furnished the expected pyridinum alcohols salts 113a,c f (69 
– 99 %). 
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Scheme 32. 
 
Attempts to effect a double deprotonation in a one step procedure using 
up to 4 equiv. LDA followed by addition of benzonitrile yielded only 2 (5 
methylpyridin 3 yl) 1 phenylethanone 110a.  
 
Attempts to deprotonate both alcohol 112a and ketone 110a using excess 
LDA or t BuLi in THF at both 0 
°C and  78 
°C with subsequent addition of 
either benzaldehyde, benzonitrile or methyl iodide were all unsuccessful; 
on each occasion only unreacted starting materials were ever recovered 
suggesting  that  deprotonation  had  not  occurred  under  the  reaction 
conditions employed or that the generated lithiospecies were unreactive 
towards the electrophile employed. Similarly, Baradarani et al.
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no  evidence  for  a  second  proton  abstraction  in  their  investigation  of 
lithiation  reactions  of  3,5 dimethylpyridine;  no  other  literature  exists  to 
suggest that it has been achieved to date for 3,5 dimethylpyridine. With 
this  in  mind,  we  did  not  further  explore  metallation  reactions  of  3,5 
dimethylpyridine  as  an  approach  to  the  bis substituted  derivatives 
targetted at the outset of this project. However, future work in this area 
could explore further the necessary reaction conditions to effect a one 
step or sequential double lithiation successfully. 
 
 
2.4 Synthesis of Optically Pure Alcohols 
 
As a reliable synthetic method had been developed for the synthesis of the 
target ketones 78a,c f and their reduced products 75a,c f (isolated in a 
racemic  mixture  from  NaBH4  reduction),  we  became  interested  in  the 
possibility  of  an  asymmetric  reduction  of  ketones  78  to  afford 
enantiomerically pure alcohols 75. 
 
First to be investigated was the stereoselective reduction of ketone 78f 
using baker’s yeast (Saccharomyces cerevisiae) and glucose in tap water 
as described by Fantin et al. (Scheme 33)
168 – after the mixture had been 
stirred at 30 
°C for 8 days, no reduction of ketone 78f had occurred and no 
other products were visible by TLC. Page | 69  
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Scheme 33. 
 
Asymmetric reduction was next attempted using 115, commonly referred 
to  as  the  CBS  reagent.  CBS  115  is  a  borane  complex,  based  on  (S) 
proline,  developed  by  Corey  et  al.
169  and  is  a  highly  efficient 
enantioselective reducing agent, particularly useful for prochiral ketones. 
The unstable ‘inactive’ reducing agent 114 is available commercially. The 
active  reducing  agent  was  prepared  following  a  literature  procedure  by 
treating 114 with borane dimethyl sulphide complex (BMS) in dry toluene 
at room temperature for 30 min.; addition of dry heptane precipitated 115 
as  a  white  crystalline  solid  (86%  yield)  (Scheme  34).  115  is  the  more 
stable form and is preferred to 114 for long term storage.
170  
 
Scheme 34. 
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Reduction  of  ketone  78f  was,  subsequently,  attempted  using  CBS  115 
following  the  method  of  Mathre  et  al.
170  Ketone  78f  was  added  to  a 
catalytic amount of 115 in dry DCM at  20 
°C and the mixture stirred for 3h 
at this temperature.
170 Unfortunately, after work up, no reduced product 
was  evident  by  TLC,  with  only  the  unchanged  starting  material  being 
observed. This result was, perhaps, surprising as Mathre et al.
170 achieved 
both an excellent yield (95 %) and ee (98.6 %) for the reduction of the 
structurally similar compound 116 to 117 when using both a stoichiometric 
and catalytic amount of 115 (Scheme 35). This group did not, however, 
attempt  reduction  of  ketones  possessing  substituted  aromatic  rings  or 
heterocycles. The reason for our result, reproduced on several occasions, 
is unclear. It is known that good complexation is important for effective 
hydride  transfer  by  CBS  as  it  is  a  relatively  weak  hydride  source;  the 
presence  of  the  pyridine  ring,  or  the  electron  donating  effects  of  the 
methoxy group, may affect the outcome of the reaction  investigated in this 
work. 
 
 
Scheme 35. 
 
The work by Mathre et al. does, however, suggest that the two groups 
adjacent to the prochiral carbonyl in 78f are sufficiently different sterically Page | 71  
 
for hydride delivery to occur preferentially from one face. Clearly, further 
work  for  the  asymmetric  reduction  of  ketones  78a,c f  using  this 
methodology is worthwhile as Mathre et al.
170 have shown that structurally 
similar compounds can be reduced with excellent yield and enantiomeric 
excess. 
 
Paralleling  our  results,  Chu Yi  et  al.
130  reported  that  baker’s  yeast  and 
CBS did not affect the stereoselective reduction of the 1 phenyl 2 (pyridin 
2 yl)ethanone 67a. Excellent yields and ee were, however, achieved by 
this group using (S,S) or (R,R) ( ) Jacobsen’s MnCl with modified NaBH4 
(NaBH4 / ethanol / tetrahydrofurfuryl alcohol)
170 in chloroform (Scheme 36). 
 
 
Scheme 36. 
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Subsequently Ohtsuka et al.
172 reported an analogous reduction using the 
(S,S) Jacobsen’s Co (III) complex with modified NaBH4 to obtain the (S) 
alcohol 55 in 94 % yield (92 % ee) (Scheme 37). Interestingly, the (R) 
product was obtained when the (S,S) Manganese complex modified with 
NaBH4 was employed by Chu Yi et al.
130 
 
 
Scheme 37. 
 
Given  these  excellent  reported  results,  an  enantioselective  reduction  of 
ketone  78c  was  attempted,  using  (S,S) Jacobsen’s  MnCl  complex 
modified with NaBH4. Initial reactions following the procedure by Chu Yi et 
al.
130 did not produce a selective reduction and only the racemic alcohol 
75e was ever obtained (typically ~ 65 % yield) as determined by chiral 
HPLC or polarimetry. Initially it was believed that this may be due to poor 
modification of the NaBH4 as a solid had precipitated from the modified 
NaBH4  solution  at   20 
°C;  performing  the  reaction  at  0 
°C  prevented 
precipitation, but again gave only racemic alcohol in similar yield.  
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Scheme 38. 
 
Similarly,  (R,R) Jacobsen’s  Cobalt  complex  modified  with  NaBH4  gave 
only  racemic  75e  (following  the  procedure  by  Ohtsuka  et  al.).
172  The 
reason for the lack of enantioselectivity in the reduction of 78e is unclear. 
However,  assuming  that  the  NaBH4  complex  had  been  adequately 
modified, and that free NaBH4 had not been introduced, the problem may 
lie  in  the  poor  formation  of  the  pyridyl Jacobsen’s  complex,  precluding 
preferential face selective hydride delivery. 
 
The  catalytic  mechanism  for  the  enantioselective  reduction  using 
Jacobsen’s  catalyst  modified  with  NaBH4  is  not  yet  fully  understood. 
However, Chu Yi et al.
130 speculated that in their work 1 phenyl 2 (pyridin 
2 yl)ethanone 67a in its enol form may complex with Jacobsen’s catalyst. 
This may explain a lack of complexation of the 3 position analogue 78e, as 
we  have  shown  that  these  derivatives  exist  only  in  the  keto  form  in 
solution.  
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Figure 15a.   Molecular  model  of  the  octahedral  complex  formed  by 
coordination of 2 pyridin 2 yl 1 (4 methylphenyl) ethanone 67e [minimised energy 
in Chem3D
®]. 
 
 
 
Figure 15b.   Molecular  model  of  the  octahedral  complex  formed  by 
coordination  of  2 pyridin 3 yl 1 (4 methylphenyl) ethanone  78e  with  Jacobsen’s 
catalyst [minimised energy in Chem3D
®]. 
 
An  alternative  explanation  may  lie  in  the  molecular  geometry  of  78e. 
Molecular  modelling  suggests  that  coordination  of  2 pyridin 2 yl 1 (4 
methylphenyl) ethanone  67e through  the pyridine  nitrogen  and  carbonyl 
oxygen  to  the  manganese  (III) salen  Schiff  base  complex  produces  a 
favourable octahedral complex with minimum distortion to the substrate Page | 75  
 
geometry (it remains effectively planar) (Figure 15a) [calculations suggests 
the optimum bond length between the α carbon and pyridine carbon to be 
1.50 Å and the actual to be 1.54 Å; the internal angle between the two 
pyridine carbons was found to be 122.32° compared to an optimum angle 
of  120.0°].  However,  to  adopt  a  similar  conformation  in  an  octahedral 
complex with the manganese (III) salen Schiff base complex, the pyridine 
ring  of  1 phenyl 2 (pyridin 3 yl)ethanone  78e  would  be  required  to  twist 
unfavourably  about  C 3  of  the  pyridine  ring  (Figure  15b).  Modelling 
suggests  the  bond  length  between  α carbon  and pyridine  carbon  to  be 
1.94  Å  and  the  internal  angle  between  pyridine  carbons  to  be  95.18°, 
indicating  significant  deformation  of  the  molecule,  and  in  particular,  the 
pyridine ring.  
 
As catalytic asymmetric reduction to obtain enantiomerically pure alcohol 
derivatives  75a,c f  had  proven  unsuccessful  in  our  hands,  we  next 
attempted  the  formation  and  subsequent  resolution  of  diastereoisomers 
prepared from the racemic alcohol 75e (Scheme 39). Thus, using (S) O 
acetylmandelic  acid  it  was  possible  to  prepare  a  mixture  of  a  pair  of 
diastereomeric esters 118 (Scheme 39) in excellent yield (85 %) using a 
procedure described by Hutchison et al.
173 [who used the more expensive 
(R)  and  (S) Mosher’s  acids].  Recrystallisation  of  118  afforded  one 
diastereoisomer as a colourless oil (99 % de, Figure 16b) and the second 
as a white crystalline solid (99 % de, Figure 16c). Hydrolysis of each ester 
occurred  readily  under  basic  conditions
174  and  furnished  the 
enantiomerically pure alcohols (S) 75e and (R) 75e (Figures 16e and 16f) Page | 76  
 
also  in  excellent  yield  ([α]D  =  +/   16.2).  Unfortunately,  the  absolute 
stereochemistry of each enantiomer / diastereoisomer has not yet been 
determined. 
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Scheme 39. 
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Figure  16.  Chromatograms  of  (a)  mixture  of  diastereoisomers  118;  (b)  separated 
diastereoisomer  (oil);  (c)  separated  diastereoisomer  (solid);  (d)  racemic  alcohol 
75e;  (e)  (R)  or  (S)   alcohol  75e  (oil);  (f)  (R)  or  (S)   alcohol  75e  (solid);  HPLC 
Conditions: mobile phase: 90 / 10, Hexane / IPA; samples: 1 mg mL
 1 in mobile 
phase;  flow  rate:  1  mL  /  min;  detection:  UV  254  nM;  Loop:  10   L.
(a)  (d) 
(b)  (e) 
(c) 
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2.5 Conclusion 
 
In summary, the ability to generate (pyridin 3 yl)methyl)lithium 73c and ((5 
methylpyridin 3 yl)methyl)lithium  109  by  the  addition  of  3   or  3,5 
dimethylpyridine,  respectively,  to  LDA  in  THF  at  0 
°C  has  been 
demonstrated.  Subsequent  reaction  of  73c  and  109  with  various 
electrophiles afforded compounds of sufficient purity for pharmacological 
testing;  preliminary  pharmacological  data  for  these  compounds  are 
presented in Chapter 5. The synthetic protocol developed in this Chapter 
was  a  modification  of  published  literature  procedures,  and  the 
methodology still has scope for further optimisation. Compared to current 
literature  procedures  for  the  lithiation  of  3   or  3,5 dimethylpyridine,  the 
method  described  in  this  Chapter  has  the  advantages  of  (i)  a  simpler 
reaction procedure, (ii) a shorter reaction time, and (iii) no requirement for 
a chelating co solvent (e.g. DMPU or HMPT). 
 
A number of methods to enable the preparation of enantiomerically pure 
alcohols by asymmetric reduction of prochiral ketone derivatives 78a,c f 
were  assessed.  However,  the  various  methodologies  investigated 
(enzymatic  and  catalytic)  proved  to  be  unsuitable.  Despite  this, 
enantiomerically pure alcohols (S) 75e and (R) 75e could be prepared via 
the resolution of the diastereomeric esters 118 [prepared by reaction of 
(±) 75e with (S) O acetyl mandelic acid] and subsequent hydrolysis. This 
strategy should be equally applicable to all the alcohol derivatives 75a,c f Page | 79  
 
described in this Chapter, allowing access to single enantiomers of each 
for pharmacological testing, if required.  
 
With an established  synthetic  methodology  in  place, future  work  in  this 
area  could  focus  around  the  synthesis  of  derivatives  which  possess 
alternate  substitution  patterns  around  the  aromatic  ring  for 
pharmacological  comparison.  Additionally,  an  extension  to  the  work 
described  in  this  Chapter  could  investigate  the  synthesis  of  novel, 
enantiomerically pure piperidine derivatives 119 (piperidin 3 yl analogues 
of sedamine) (e.g. using the methodology shown in Scheme 40). 
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Chapter 3 
 
This chapter details our approaches to target compounds 75a d, 78a d, 
144a,c e and 159a e employing 3 bromopyridine 120 as starting reagent 
using either halogen lithium exchange reactions (Section 3.1.1) or metal 
mediated  cross coupling  reactions  (Sonogashira,  Section  3.2.1.1;  Heck, 
Section  3.2.1.2)  as  the  key  synthetic  step.  These  approaches  were 
successfully extended to prepare compounds 170 171a e from either 3 
bromo 1 methyl 1H indole  169a,  3 iodo 1 methyl 1H indole  169b  or  3 
iodo 5 methoxy 1 methyl 1H indole 169c (Section 3.3). 
   
3.1 Reactions of 3 Bromopyridine 
 
3.1.1 Halogen Lithium Exchange Reactions of 3 Bromopyridine 
 
3.1.1.1 Introduction 
 
 
As an alternative to the synthetic approach to alcohols 75a,c f described 
in Chapter 2, a single step synthesis of racemic alcohol derivatives 75a d 
was explored via halogen lithium exchange reactions of 3 bromopyridine. 
 
The exchanges of lithium
175 and magnesium
176 for halogens on pyridine 
have  been  reported  extensively.  Several  authors  have  reported  that 
(pyridin 3 yl)lithium  121  may  be  generated  easily  from  3 bromopyridine 
120 using n BuLi in either THF
180 or toluene
180 at low temperatures. Cai et 
al.
175  in  particular,  have  reported  the efficient  bromine lithium exchange Page | 81  
 
reaction of 120 using n BuLi in toluene at  60 
oC to give 121 (which was 
relatively  stable  at  this  temperature);  subsequent  trapping  of  121  using 
various  electrophiles  gave  the  expected  products  in  good to excellent 
yields (Scheme 41). 
 
 
Scheme 41. 
 
 
Trecourt et al.
 have reported an efficient bromine–magnesium exchange 
reaction on 3 bromopyridine using i PrMgCl in THF at room temperature to 
give pyridin 3 ylmagnesium chloride 125; 125 subsequently reacted with a 
range  of  electrophiles  to  give  various  3 substituted  pyridines  126a i  in 
moderate to high yields (Scheme 42).
176 Page | 82  
 
 
 
 
Scheme 42. 
 
 
It is also worthwhile noting that metallation of 3 bromopyridine with LDA at 
temperatures above  78 °C has been shown to promote halogen migration 
to  afford  4 bromo 3 substituted  pyridines  as  the  major  products  after 
addition of an electrophile.
177 At temperatures below  78 °C no bromine 
migration  was  observed  and  either  3 bromo 4 substituted  pyridines 
(Scheme 43)
178a c or 3 bromo 2,4 disubstituted pyridines were obtained.
179 
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Scheme 43. 
 
 
3.1.1.2 Results and Discussion 
 
 
To  our  knowledge,  reactions  involving  the  ring opening  of  aromatic 
epoxides using pyridin 3 yllithium 121 have not, to date, been reported. 
Our successful investigation of the synthesis of 1 (4 substituted phenyl) 2 
pyridin 3 yl ethanol  derivatives  75  via  the  halogen lithium  exchange 
reaction  of  3 bromopyridine  120  using  n BuLi  and  subsequent  reaction 
with aromatic epoxides 100a d (Scheme 44) is discussed below. 
 
An initial test reaction using 3 bromopyridine 120 as substrate was carried 
out based on the halogen lithium exchange methodology reported by Cai 
et  al.
175  with  subsequent  reaction  using  phenylacetaldehyde  as  the 
electrophile  (Scheme  44).  In  our  hands,  the  addition  of Page | 84  
 
phenylacetaldehyde  to  pyridin 3 yllithium  121,  generated  from  120  in 
toluene by slow addition of n BuLi at  60 
°C, furnished the alcohol 123 in 
moderate  yield  after  work up  and  purification  (47  %);  the  only  other 
constituents of the reaction mixture were identified as starting materials 
(the presence of unchanged 3 bromopyridine was indicative of incomplete 
halogen lithium  exchange  under  the  reaction  conditions  employed).  
Similarly, application of this methodology using 2 phenyloxirane 100a as 
the electrophile afforded the desired alcohol 75a in 48 % yield with only 
unreacted  starting  materials  and  product  again  isolated  after 
chromatography. 
 
 
Scheme 44. 
 
 
Scheme 45. 
 
In  order  to  optimise  the  isolated  yield  of  75a,  variation  of  the  reaction 
conditions was, investigated. Specifically, (i) the addition time of n BuLi to 
the cooled solution ( 60 °C) of 3 bromopyridine in toluene (10 – 60 min); Page | 85  
 
(ii)  the  (pyridin 3 yl)lithium  generation  time  (15  –  60  min);  and,  (iii)  the 
addition time of the electrophile (5   30 min) were varied, whilst the final 
stir out time (1 h), reaction temperature and work up procedure remained 
the  same  as  the  reported  methodology  of  Cai  et  al.  Additionally,  the 
reaction mixture was allowed to warm to room temperature immediately 
after the addition of the epoxide. In all cases, no detectable improvement 
in the isolated yield of 75a was found. It was noted that all these reactions 
suffered from solubility problems and the addition of THF to the reaction 
mixture was often required. Repeating reactions at  60 °C in either THF or 
diethyl  ether  as  the  sole  solvent  improved  solubility,  but  offered  no 
improvement in isolated yield of 75a. However, reactions carried out in 
diethyl ether at  100 
°C gave an improved isolated yield (61 %) with no 
solubility issues noted. Thus, reaction of 3 bromopyridine with n BuLi in 
ether at  100 °C followed by addition of 2 (4 substitutedphenyl)oxiranes 
75a d afforded, after work up and purification, alcohols 75a,d f (31   61 % 
yield) (Scheme 46). 
 
 
Scheme 46. 
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Interestingly, employing the methodology of Trecourt et al.,
176 we did not 
observe  a  reaction  between  pyridin 3 ylmagnesium  chloride  and  2 
phenyloxirane, despite extensive modification of the reaction conditions. 
Oxidation of alcohols 75a d to ketones 78a d was readily achieved using 
pyridinium chlorochromate (PCC) in DCM (70 83 % yield) (Scheme 47).
181 
 
 
 
Scheme 47. 
 
 
3.1.1.3 Summary 
 
 
To  our  knowledge,  this  work  describes  the  first  example  of  the  ring 
opening  of  an  epoxide  with  the  organolithium  derived  from  3 
bromopyridine  and  n BuLi.  Indeed,  no  examples  could  be  found  in  the 
literature  of  the  analogous  reactions  with  either  2 bromopyridine  or  4 
bromopyridine and only one relevant example using 2,6 dibromopyridine 
132. In this latter case, (S) alcohol 134 was obtained as the major product 
with retention of configuration (> 98 % ee, 48 % yield) by boron trifluoride 
assisted  ring opening  of  (S) epoxide  133  by  (6 bromopyridin 2 yl)lithium 
(Scheme 48).
182 Alongside (S) alcohol 134, (S,S) bis alcohol 135 (10 %) 
was  also  isolated  arising  from  formation  and  reaction  of  pyridin 2,6 
diyllithium.  Ring opening  of  the  enantiomeric  (R) epoxide  similarly  gave 
the (R) alcohol (> 98 % ee). 
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Scheme 48. 
 
The ring opening of epoxides 100a d with pyridin 3 yllithium allowed the 
direct entry to target alcohol derivatives 75a d; this methodology has the 
potential  to  be  extended  to  prepare  a  wide  range  of  derivatives  by 
variation of the electrophile   this may prove valuable in the future if the 
compounds  studied  in  this  work  are  shown  to  exhibit  interesting 
pharmacological activity. Perhaps the most interesting application of this 
methodology lies in the potential one step synthesis of enantiomerically 
pure  alcohol  derivatives  75  by  reaction  of  pyridin 3 yllithium  with 
enantiomerically pure epoxides following the strategy of Burgos et al.
182 
However,
 a notable disadvantage of this synthetic route in the preparation 
of a series of derivatives for rapid pharmacological evaluation is that only a 
limited number of enantiomerically pure, substituted aromatic epoxides are 
commercially available, with some being extremely expensive. 
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3.1.2  Metal Mediated Reactions of 3 Bromopyridine  
 
3.1.2 .1 Sonogashira Cross Coupling Reactions 
 
3.1.2.1.1 Preamble 
 
This  section  describes  our  investigation  of  Sonogashira  cross coupling 
reactions of 3 bromopyridine 120 with a range of 4 substitutedarylalkynes 
147a,c f  to  give  3 ((4 substitutedphenyl)ethynyl)pyridine  derivatives 
144a,c f. Functional group interconversion via the acidic hydrolysis of the 
alkyne  and  subsequent  reduction  gave  ketones  78a,c f  (compounds 
previously  described  in  Chapter  2)  (Scheme  49).  This  approach  has 
already proven successful and versatile for the synthesis and elaboration 
of 2 (4 substitutedphenylethynyl)pyridine derivatives.
183 185 
 
 
Scheme 49. 
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3.1.2.1.2 Introduction 
 
The Sonogashira reaction is one of the most widely employed palladium 
catalysed cross coupling reactions; it involves the reaction of a terminal 
alkyne  with a vinyl or aryl halide in the presence of a palladium (0) or 
palladium (II) ligand, a co catalyst (often CuI) and a base (most commonly 
Et2NH or Et3N) (Figure 16).
186 
 
Figure 16.  Catalytic cycle for Sonogashira cross coupling 
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There  are  many  literature  examples  citing  the  use  of  the  Sonogashira 
reaction as a pivotal step in the synthesis of compounds of, for example, 
pharmacological  interest.
187a j  For  example,  the  synthesis  of  reverse 
transcriptase inhibitor 139 (Scheme 50)
187a and the synthesis of Vibsanol 
143 (Scheme 51)
187c both employed Sonogashira methodology as a main 
synthetic step. 
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Scheme 51. 
 
Additionally,  Sonogashira  reactions  of  2 bromopyridine,
184a,b,188,189  3 
bromopyridine
190 192 and 4 bromopyridine
189 have been reported. Notably 
for this project, 144a,
190 144f
192 and
 144e,
191 have been synthesised using 
Sonogashira  methodology  from  3 bromopyridine  120  in  good  yield 
(Scheme 52). 
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Scheme 52. 
 
3.1.2.1.3  Results and Discussion 
 
Terminal alkynes 147a,e,f were available commercially and were relatively 
inexpensive; others of interest, 147c and 147d, could also be purchased 
commercially but were, however, somewhat more expensive. In this work, 
compounds  147c  and  147d  were  prepared  in  two  steps  from  the 
significantly  cheaper  1 chloro 4 vinylbenzene  145c  and  1 bromo 4 
vinylbenzene 145d, respectively, as starting reagents by modification of a 
literature  procedure  (Scheme  53).
193  Thus,  bromination  of  145c,d  in 
chloroform  followed  by  base catalysed  dehydrobromination  at  elevated 
temperature  gave  terminal  alkynes  147c  and  147d,  which  were  readily 
purified by fractional distillation (83 % and 79 % yield, respectively, over 
two steps).  Page | 93  
 
 
Scheme 53. 
 
The synthesis of acetylene 147a (R = H) was initially investigated through 
Sonogashira  cross coupling  of  120  with  147a  in  the  presence  of 
(Pd(PPh3)2Cl2 (5 mol.%, CuI (2 mol.%), NEt3 (1.5 equiv.) in THF at room 
temperature  (40  %  yield).  No  by products  were  ever  witnessed  in  the 
reaction mixture, with only starting materials and product being detected 
by TLC. Elevation of the reaction temperature (to reflux) gave an improved 
conversion,  with  144a  isolated  in  72%  yield.  Compounds  144c f  were 
similarly  prepared  in  acceptable  yields  (20  –  98  %)  (Scheme  54).  In 
contrast, it is notable that for reaction of 120 with 147d, despite repeated 
attempts  and  wide ranging  modification  to  the  reaction  conditions,  a 
maximum  isolated  yield  for  144d  of  20  %  was  only  ever  achieved  the 
remainder being a complex mixture of unidentified side products. 
 
N
R
144a R = H, 72%
144c R = Cl, 41%
144d R = Br, 20 %
144e R = CH3, 98%
144f R = OCH3, 63%
N
Br
Pd(PPh3)2Cl2
CuI, NEt3,THF
12 h,
R
120
147a,c f
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As  an  improvement,  however,  when  commercially  available  3 
((triethylsilyl)ethynyl)pyridine 136 was stirred with 1 bromo 4 iodobenzene 
in  the  presence  of  (Pd(PPh3)2Cl2  (4  mol.%,  CuI  (2  mol.%),  K2CO3  (3 
equiv.) in THF at room temperature for 18 h, 144d was obtained in an 
unoptimised yield of 54 % (Scheme 55). Notably, alongside the reaction 
product,  only  unreacted  starting  materials  were  recovered  from  the 
reaction  mixture,  suggesting  that  an  improved  yield  of  144d  may  be 
achievable  by  modification  of  the  reaction  conditions  (for  example,  by 
raising the reaction temperature or by employing a stronger base).  
 
 
Scheme 55. 
 
 
Efficient N methylation of the acetylenes 144a,c f to give pyridinium salts 
149a,c f (Scheme 56) was demonstrated by simply refluxing overnight in 
THF in a sealed vessel with 5 equivalents of iodomethane (72 – 97 % 
yields).  
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Scheme 56. 
 
Hydration of alkynes 144a,c f [30 % H2SO4 , 10 mol.% Hg(OAc)2, reflux, 
12 h] proceeded smoothly and in good yield (Scheme 57) to afford, after 
work up and purification, the corresponding ketones 78a,c f (66   77 % 
isolated yields). In all cases, no evidence for the alternate regioproduct 
150 was ever observed during hydration reactions. Hydration reactions of 
144a,c f  to  give  78a,c f  could  also  be  accomplished  under  analogous 
reaction  conditions  in  the  absence  of  Hg(OAc)2,  although  in  slightly 
reduced yield. This may be of particular importance for future development 
purposes,  as  the  synthesis  of  pharmaceuticals  using  mercury  salts  is 
undesirable. 
 
 
Scheme 57. 
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3.1.2.1.4 Summary 
 
In conclusion, this section of work demonstrates an alternative synthetic 
approach  to  that  detailed  in  Chapter  2  for  the  preparation  of  ketones 
78a,c f  using  a  palladium  catalysed  cross coupling  reaction  of  3 
bromopyridine  120  with  various  terminal  alkynes  147a,c f,  followed  by 
acidic hydrolysis. However, for the synthesis of ketones 78a,c f, this two 
step  methodology  presents  no  distinct  advantage  over  the  reaction  of 
(pyridin 2 ylmethyl)lithium with arylnitriles described in Chapter 2.  Notably, 
(i) an additional synthetic step is required; (ii) the combination of starting 
reagents is significantly more expensive; and, (iii) relatively few terminal 
alkynes are available commercially. However, the methodology developed 
has proven important for the synthesis of other novel 3 substituted and 
3,5 disubstituted pyridine derivatives (Chapter 4).  
 
 
3.1.2.2 Heck Coupling Reactions of 3 Bromopyridine 
 
This section describes our investigation of Heck cross coupling reactions 
of 3 bromopyridine 120 with a range of 4 substituted arylalkenes 145a e to 
give  (E) 3 (1 (4 substitutedphenyl)ethen 2 yl)pyridine  derivatives  159a e, 
another series of unsaturated derivatives which may have intrinsic value 
as pharmacologically active compounds. More significantly using 159a e, 
functional  group  interconversion  has  the  potential  to  deliver  novel 
derivatives  appropriate  for  pharmacological  testing  as  nicotinic  receptor 
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3.1.2.2.1 Introduction 
 
The Heck reaction is the palladium catalysed arylation or alkenylation of 
olefins (Figure 17).
194 
 
As with the Sonogashira approach described above, the Heck reaction is 
well known and there are again many literature examples citing the use of 
the Heck reaction as reaction steps in the preparation of compounds of, 
for example, pharmacological interest.
195 
 
 
 
Figure 17.  Heck catalytic cycle 
 
 Page | 98  
 
Schemes 58 and 59 illustrate steps in the synthesis of lasiodiplodin
195a 153 
and  sumatriptan
195b  158  which  possess  anti cancer  and  anti migraine 
activity respectively. 
 
 
Scheme 58. 
 
 
 
 
Scheme 59. 
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A number of Heck reactions using 3 bromopyridine as a substrate have 
been  reported.
196a d  Significant  to  this  project  is  the  synthesis  of  159a 
obtained in excellent yield (93 %) by Cui et al. (Scheme 60).
197 
 
N
Br
N
Pd(OAc)2, K2CO3
1 phenylurea, DMF
2 h, 130 oC
93 %
120 159a  
 
Scheme 60. 
 
 
 
 
3.1.2.2.2 Results and Discussion 
 
An initial reaction Heck reaction using 3 bromopyridine 120 was carried 
out  based  on  the  reaction  conditions  of  a  literature  example;
198  thus 
reaction  of  3 bromopyridine  120  with  the  inexpensive,  styrene  145a 
[Pd(OAc)2 (1 mol%), PPh3 (2 mol%) KOAc (1.5 Equiv.)] in THF at room 
temperature gave, after purification, alkene 159a (40 % yield) (Scheme 
61). As with the Sonogashira reaction, the yield was further improved (54 
%) by repeating the reaction at reflux. When dry triethylamine replaced the 
relatively  insoluble  potassium  acetate  (under  the  same  reaction 
conditions) compound 159a was obtained in 70% yield. These conditions 
were  subsequently  adopted  to  give  a  series  of  (E) 3   (1 (4 substituted 
phenyl)eth 1 en 2 yl)pyridine  derivatives  159a e  (43  –  70  %  yield) 
(Scheme 62). For compounds 159a e, a trans orientation for the alkene Page | 100  
 
was confirmed by the 
3J coupling constant of the ethenylic protons (15 18 
Hz).  
159a, 40%
N
Br
N
120
Pd(OAc)2, PPh3
NaOAc, THF
25 oC, 12 h
R
R
 
 
Scheme 61. 
 
 
Scheme 62. 
 
A similarly efficient, but potentially more cost effective route into alkenes 
159a e  was  also  explored,  via  a  Wittig  reaction  (Scheme  63).  The 
commercially  available  3 (chloromethyl)pyridine  hydrochloride  salt  160 
was first converted to the unstable free base 161 in a biphasic system (aq. 
Na2CO3  /  DCM)  (95  %,  crude  yield).  The  phosphonium  salt  162  was 
simply prepared by refluxing crude 161 with excess PPh3 in MeCN (64 % 
yield).
199 Subsequent treatment of 162 with n BuLi followed by addition of 
4 substitutedbenzaldehydes  163a e  afforded,  after  work up  and 
purification, the desired products 159a e (49   61 % yields). 
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Scheme 63. 
 
Compounds 159a e could be easily converted into their corresponding N 
alkylated salts by refluxing with methyl iodide in THF (67 – 92 % yields) 
(Scheme 64).  
 
 
Scheme 64. 
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3.1.2.2.3 Summary 
 
In  conclusion,  we  have  demonstrated  two  simple  strategies  to  prepare 
alkenyl  derivatives  159a e  using  either  a  Heck  reaction  or  a  Wittig 
reaction.  Alkenyl  derivatives  159a e  offer  a  building  block  for  the 
development  of  a  wide range  of  derivatives  by  simple  functional  group 
manipulation using established literature methodology. Scheme 65 shows 
a  selection  of  transformations  that  have  been  identified  for  future 
investigation  to  access  additional  compounds  with  potential 
pharmacological application. 
 
 
Scheme 65. Page | 103  
 
3.2  Reactions  of  3 Bromo 1 methyl 1H indole  154a,  3 Iodo 1 methyl 
1H indole 154b or 3 Iodo 5 methoxy 1 methyl 1H indole 154c 
 
Using  minor  adaptations  of  either  the  Sonogashira  methodology  or 
halogen lithium  exchange  methodology  developed  above,  novel  indole 
compounds 171a e and 177 could be synthesised from either 3 bromo 1 
methyl 1H indole  169a,  3 iodo 1 methyl 1H indole  169b  or  3 iodo 5 
methoxy 1 methyl 1H indole 169c as detailed in the following Section.  
 
177 R = H, R1 = H
N
CH3
R
R1
OH
171a R = H, R1 = H,
171b R = H, R1 = CH3,
171c R = H, R1 = Cl,
171d R = OCH3 R1 = H,
171e R = OCH3 R1 = CH3,
N
CH3
R
R1
O
 
 
3.2.1 Sonogashira Reactions 
 
The  Sonogashira  cross coupling  of  indoles  has,  to  date,  not  been 
extensively reported. The majority of report thus far involve the coupling of 
variously N substituted 2
200,201 or 3 iodoindoles.
201,202 Two examples of the 
Sonogashira  coupling  of  N substituted 3 iodoindoles  are  given  in 
Schemes 66
202 and 67.
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Scheme 66. 
 
Scheme 67. 
 
Halogenated  indoles  169a,  169b  and  169c  were  not  available 
commercially and were synthesised according to the procedure of Bocchi 
et al.
203 without modification. Thus, bromination of 167a using Br2 in DMF / 
KOH at room temperature occurred in almost quantitative yield (96 %) to 
give  3 bromo 1H indole  168a.  Subsequent  N methylation  of  168a 
occurred rapidly with MeI in acetone / KOH at room temperature to give 3 
bromo 1 methyl 1H indole  169a  (84  %  yield).  Analogously,  3 iodo 1 
methyl 1H indole  169b  and  3 iodo 5 methoxy 1 methyl 1H indole  169c 
were synthesised from indole and 5 methoxyindole, respectively, in two 
steps in good overall yield (Scheme 68). In our hands, 168a, 168b and 
168c were quite unstable, decomposing within four or five days even with 
refrigeration  or  freezing;  N methylation  afforded  some  stability  and Page | 105  
 
compounds 169a, 169b and 169c could be successfully stored for several 
weeks in a freezer without significant decomposition.  
 
 
Scheme 68. 
 
In our hands, Sonogashira reactions of 3 bromo 1H indole 169a, 3 iodo 
1H indole  169b  and  3 iodo 5 methoxy 1H indole  169c  with  arylalkynes 
147a using the methodology described in Section 3.1.2.1.3 [(Pd(PPh3)2Cl2 
(5 mol.%, CuI (2 mol.%), Et3N (3 equiv.) in THF at elevated temperature 
(50  °C  –  reflux)]  gave  only  negligible  yields  of  the  desired  products 
(typically  <  5%).  In  these  reactions,  significant  decomposition  of  the 
indoles 151a c was observed (consistent with the storage problems noted 
above) producing highly complex reaction mixtures. Analogous reaction of 
3 bromo 1 methyl 1H indole  169a  with  arylalkyne  147a  at  room 
temperature  proceeded  sluggishly,  affording  alkyne  171a  in  41  %  yield 
after 2 days. However, when employing the more reactive 3 iodo 1 methyl 
1H indole  169b  and  3 iodo 5 methoxy 1 methyl 1H indole  169c  with 
arylalkynes 147a,c,e reactions proceeded cleanly at room temperature to 
give acceptable yields of 58   81 % in 12 h (Scheme 69). Hydration of the 
alkynes  170a e  using  10  mol.%  Hg(OAc)2  in  30%  H2SO4  at  room 
temperature gave, after work up and purification, ketones 171a e in good Page | 106  
 
yield (57   91 %). Hydration of alkynes 170a e at elevated temperature 
gave  only  poor  yields  of  ketones  171a e  (typically  <  10  %);  in  these 
reactions, significant decomposition was noted. 
 
 
Scheme 69. 
 
Thus,  using  only  a  minor  modification  to  methodology  developed  in 
Section 3.1.2.1, we were able to convert 170a e into ketones 171a e in 
two steps. Unfortunately, however, attempts at hydride reduction (sodium 
borohydride in ethanol at room temperature or reflux; lithium aluminium 
hydride in diethyl ether at room temperature or reflux) of ketones 171a e 
gave none of the expected alcohol products. In all cases, ketone starting 
materials were recovered unchanged. Further work is required to establish 
whether the reduction of 171a e to give alcohol products is possible. 
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3.2.2  Halogen lithium Exchange of 1 Methyl 3 bromo 1H indole 
 
As  reduction  of  ketones  171a c  was  not  successful  in  our  hands,  we 
considered  a  halogen lithium  exchange  of  1 methyl 3 bromo 1H indole 
169a followed by ring opening of aryl epoxides.  
 
To our knowledge, no halogen lithium exchange reactions of 1 methyl 3 
bromo 1H indole have been reported to date.  However, there are several 
reports  detailing  the  halogen lithium  exchange  reaction  of  3 bromo N 
silylprotected  indoles  and  subsequent  reaction  of  the  generated 
organolithium  with,  for  example,  amides,
204  aldehydes
205  esters
204a  or 
alkylating agents.
204a 
 
Notably, the first step in their synthesis of the sulphonic acid derivative 176 
Ma et al.
206 described the bromine lithium exchange of 173 using t BuLi, 
followed by ring opening of oxirane 174 to give the primary alcohol 175 
which was then reacted in situ to give the tosyl derivative 176 in 84 % 
overall yield (Scheme 70). 
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Scheme 70. 
 
Employing  the  methodology  established  for  halogen lithium  exchange 
using  3 bromopyridine  as  substrate  (Chapter  3.1.1),  we  were  able  to 
demonstrate the synthesis of alcohol 177 by treatment of 169a with n BuLi 
at   100  °C  and  subsequent  addition  of  phenyloxirane  (Scheme  71). 
Alcohol derivative 177 was obtained in an unoptimised yield of 22 % after 
work up and purification. Additional work is required to determine optimum 
conditions so that this reaction may be further extended to use a range of 
arylepoxides as electophiles. 
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Scheme 71. 
 
 
 
3.2.3 Summary 
 
In summary we have successfully prepared indole derivatives 171a e and 
177  using  minor  adaptations  of  the  Sonogashira  and  alkyne  hydrolysis 
methodology developed in Chapter 3.1.1.2. Hydride reduction of ketones 
171 was, unfortunately, unsuccessful and additional work is required to 
develop halogen lithium exchange reactions using 3 bromo 1 methyl 1H 
indole  as  substrate  as  an  alternative  approach  to  analogues  of alcohol 
177. Page | 110  
 
Chapter 4 
 
After establishing robust synthetic approaches to a range of 3 substituted 
pyridine analogues with potential pharmacological activity as described in 
Chapters  2  and  3,  we  next  turned  our  attention  to  developing  these 
methodologies  for  the  synthesis  of  3,5 disubstituted  pyridine  derivatives 
typified by the general stuctures given in Figure 18. It should be noted that 
attempts to prepare these compounds via lithiation methodology using 3,5 
dimethylpyridine  as  a  starting  reagent  were  unsuccessful  in  our  hands 
(Chapter  2.3).  This  Chapter  details  our  approaches  to  prepare  3,5 
disubstituted  derivatives  using  the  commercially  available  3,5 
dibromopyridine 178 as starting reagent. 
 
 
 
 
Figure 18. 
 
 
4.1 Halogen Lithium Exchange Reactions of 3,5 Dibromopyridine 
 
4.1.1 Introduction 
 
Very few examples exist in the literature for the formation of pyridin 3,5 
yldilithium  179  by  halogen lithium  exchange  using  3,5 dibromopyridine 
178  as  substrate.  Encouragingly,  however,  Mysliborski  et  al.
207  recently 
described  a  successful  bis(halogen lithium)  exchange  reaction  of  3,5 Page | 111  
 
dibromopyridine  with  n BuLi  in  THF,  followed  by  reaction  with 
benzaldehyde as electrophile to give the bis(alcohol) 180 (46 %) (Scheme 
72). 
 
 
Scheme 72. 
 
 
4.1.2 Results and Discussion 
 
Attempted bromine lithium exchange reaction of 3,5 dibromopyridine 178 
using  1  equiv.  n BuLi  in  toluene  at  both   60 
°C  and   100 
°C  (solubility 
issues were noted at this lower temperature), followed by addition of 1 
equiv.  of  epoxide  100a  (revisiting  the  methodology  employed  for  the 
synthesis of alcohols 75a e in Chapter 3.1.1.2) gave only a highly complex 
mixture  of  starting  materials  and  products  from  which  no  identifiable 
reaction  products  could  be  isolated.  However,  by  performing  a  similar 
reaction at  100 
oC in diethyl ether we were able to isolate, after work up 
and  purification  of  the  complex  reaction  mixture,  the  desired 
mono(alcohol)  181a,  in  an  unoptimised  22  %  yield  (Scheme  73). 
Unfortunately, no other reaction products could be identified.  
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Scheme 73. 
 
Perhaps not surprisingly, in an attempt to prepare and react pyridin 3,5 
yldilithium 179 by first treating 178 with 2 equiv. of n BuLi at  100 
°C in 
diethyl  ether  followed  by  addition  of  2  equiv.  epoxide  100a,  neither 
bis(alcohol)  182a  (GC/MS  evidence)  or  even  mono(alcohol)  181a  were 
ever witnessed after work up; again, only a complex mixture of starting 
materials  and  unidentified  products  was  obtained  (Scheme 74).  Further 
reactions were not attempted. 
 
 
Scheme 74. 
 
There  is  literature  precedent for  ortho lithiation  at  the 4 position of  3,5 
dibromopyridine  using  LDA  and  subsequent  reaction  with  a  range  of 
electrophiles (e.g. Scheme 75);
208 it is possible that similar ortho lithiations Page | 113  
 
complicated the reactions of 3,5 dibromopyridine with n BuLi, thus leading 
to the observed complex reaction mixtures. 
 
 
Scheme 75. 
 
 
4.2 Sonogashira Reactions of 3,5 Dibromopyridine 
 
4.2.1 Introduction 
 
 
In light of the results achieved in this project using the Sonogashira cross 
coupling  reaction  of  3 bromopyridine  120  and  arylalkynes  147a,c f  and 
subsequent  acid catalysed  hydration  of  the  products  144a,c f  to  give 
ketones  78a,c f  (Chapter  3),  this  methodology  was  further  investigated 
using 3,5 dibromopyridine as a substrate. We envisaged that this could 
offer  an  adaptable  route  from  which  a  number  of  novel  3,5 substituted 
pyridine derivatives with varying functionality could be derived. 
 
To  our  knowledge,  reports  of  Sonogashira  cross coupling  of  3,5 
dibromopyridine  178  in  the  literature  are  limited;  relevant  examples  are 
given in Scheme 76. Karchava et al.
209 and Yamamoto et al.
210 described 
the  coupling  of  2 methyl 5 ethynylpyridine  185  and  4 ethynylpyridine 
hydrochloride  187  with  178  to  give  the  bis(alkynes)  186  and  188, Page | 114  
 
respectively.  Rajadurai  et  al.
211  synthesised  the  mono(alkyne)  192  in 
acceptable yield by Sonogashira coupling of 4 ethynylbenzaldehyde 191 
with 178, however, this group also obtained a significant amount of the 
corresponding bis(alkyne) 193. More recently, Roppe et al. reported the 
synthesis  of  the  glutamate  receptor  antagonist  190  in  excellent  yield; 
noteworthy in this report is the Bu4NF mediated in situ demasking of the 
terminal alkyne 189.
212 
 
 
Scheme 76. 
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4.2.2 Results and Discussion 
 
 
The  pivotal  intermediates  194a c  were  readily  synthesised,  alongside 
some  bis(alkyne)  195,  by  the  Sonogashira  cross coupling  of  3,5 
dibromopyridine 178 with 1 equiv. of arylalkynes 147a,c,e in the presence 
of Pd(PPh3)2Cl2 (4 mol.%), CuI (2 mol.%), Et3N (3 equiv.) in THF at 50 
°C 
(Scheme  77).  It  is  notable  that,  even  when  these  reactions  were 
performed  at  room  temperature  with  less  than  1  equiv.  of  arylalkynes, 
some bis(alkyne) 195 was usually always obtained (typically ~ 10%). 
 
 
Scheme 77. 
 
The  isolated  mono(alkynes)  194a d  were  readily  converted  to  the 
symmetrical or asymmetrically substituted bis(alkynes) 195a e by a further 
Sonogashira coupling reaction at elevated temperature in either THF or 
DMF  (80 
°C)  (52  –  92  %  yields)  (Scheme  78,  Method  A).  Analogous 
reactions performed at temperatures below 80 
°C gave somewhat lower 
isolated yields (in the range of 50   60 %) and no improvement in isolated 
yield was noted at reaction temperatures above 80 
°C. Page | 116  
 
 
Scheme 78. 
 
As expected, the symmetrically substituted bis(alkynes) 195a and 195b 
were easily obtained in one step under Sonogashira conditions by cross 
coupling of 3,5 dibromopyridine 178 with 2 equiv. of arylalkynes 147a,e in 
the presence of Pd(PPh3)2Cl2 (5 mol.%), CuI (2 mol.%), Et3N (3 equiv.) in 
THF or DMF at 80 
°C (Scheme 79, Method B). In these reactions, only 
trace amounts of the mono(alkyne) 194 was ever isolated (< 5 %).   
 
 
Scheme 79. 
 
Additionally,  we  were  able  to  achieve  the  synthesis  of  asymmetrically 
substituted  bis(alkynes)  195c e  using  a  two step  ‘one pot’  methodology Page | 117  
 
(Scheme  80,  Method  C).  Interestingly,  symmetrically  substituted 
bis(alkynes)  195a  and  195b  were  not  observed  and,  therefore, 
complications in purification were not encountered. Yields obtained via this 
approach were comparable to those achieved by a second Sonogashira 
coupling reaction of the isolated mono(alkyne) (Scheme 78). This ‘one pot’ 
strategy  is  advantageous  in  terms  of  reduced  reaction  and  purification 
times  and  also  in  terms  of  cost  (the  quantity  of  expensive  palladium 
catalyst employed can be reduced). 
 
 
Scheme 80. 
 
Bis(alkynes)  195a c  were  key  compounds  for  the  preparation  of 
bis(ketones)  196a c,  (bis)alcohols  182a c  and  their  respective  alkylated 
derivatives  198a c  and  183a c  (Schemes  81  and  82).  N Alkyation  of Page | 118  
 
bis(alkynes) 195a c with excess methyl iodide in refluxing THF furnished 
salts  197a c  in  good  yield.  Hydration  of  bis(alkynes)  195a c  into  their 
corresponding bis(ketones) 195a c was readily accomplished by refluxing 
in 30 % 
w/v H2SO4 in the presence of 10 mol.% Hg(OAc)2 (no alternative 
regioisomeric  products  were  obtained).  In  our  hands,  N alkylation  of 
bis(ketones) 196a c using excess methyl iodide in refluxing THF gave, on 
each occasion attempted, a semi solid product which we were unable to 
sufficiently  purify  for  elemental  analysis.  However,  N alkylation  of 
bis(ketones)  196a c  proceeded  smoothly  by  reaction  at  elevated 
temperature  with  methyl  trifluoromethanesulfonate  to  afford 
trifluoromethanesulfonate salts 198a c in good yield (69   83 %). 
 
 
 
 
Scheme 81. Page | 119  
 
As  expected,  bis(ketones)  196a c  underwent  smooth  hydride  reduction 
using  4  equiv.  of  NaBH4  in  EtOH  at  room  temperature  to  afford 
bis(alcohols)  182a c  in  high  yield;  subsequent  N methylation  of  182a c 
with excess methyl iodide in refluxing THF led to the pyridinium derivatives 
199a c (Scheme 82). 
 
182a, R1 = H, R2 = H, 88 %
182b, R1 = CH3, R2 = CH3, 82 %
182c, R1 = H, R2 = CH3, 94 %
N
O O
R2 R1
N
OH OH
R2 R1
199a, R1 = H, R2 = H, 87 %
199b, R1 = CH3, R2 = CH3, 83 %
199c, R1 = H, R2 = CH3, 58 %
N
OH OH
R2 R1
CH3 I
NaBH4 (4 equiv.)
EtOH, 25 oC, 5 h
MeI, THF
, 12 h
196a R1 = H, R2 = H
196b R1 = CH3, R2 = CH3
196c R1 = H, R2 = CH3
 
Scheme 82. 
 
 
After having prepared bis(ketones) 196a c and bis(alcohols) 199a c, we 
next  investigated  approaches  to  target  compounds  202.  Initially,  we 
anticipated that 202 could be prepared in two steps by an initial halogen 
lithium exchange reaction of the key intermediate 194 using n BuLi (in a 
similar fashion to that described in Chapter 3) to give [5 (4 substituted 
phenylethynyl)pyridin 3 yl]lithium  species  201;  trapping  of  201  with  the Page | 120  
 
epoxide 100, followed by hydration of alkyne 202 was then expected to 
furnish  the  target  derivative  203  (Scheme  83).  Unfortunately,  despite 
repeated attempts, we were unable to effect ring opening of the epoxide 
100 using the organometallic 200 under a variety of reaction conditions 
(reactions were carried out at both  78 
°C and  100 
°C in various solvents 
e.g. toluene, THF and ether). However, we believed that a halogen lithium 
exchange  reaction  had  occurred  as  the  dehalogenated  compound  144 
was recovered in all cases from reaction mixtures (50   70 % yield) (in 
addition, a distinctive colour change from yellow to orange was witnessed 
upon the addition of n BuLi to a cooled solution of 194 in either toluene, 
THF or ether).  Page | 121  
 
N
Br
R1
N
R1
OH
N
Li
R1
n BuLi (1.1 equiv.)
ether or THF
 100 oC, 0.5 h
N
OH O
R2 R1
Hg(OAc)2
H2SO4
N
R1
194 200
201 202
144
R2
O i,
 100 oC to rt, 0.5 h
ii, NH4Cl
R2
O i,
 100 oC to rt, 0.5 h
ii, NH4Cl
 
 
Scheme 83. 
 
This observation can only be rationalised by a successful halogen lithium 
exchange reaction followed by quenching of the resultant organometallic 
200 on addition of water (the organometallic 200 is suggested to be of 
insufficient reactivity to ring open the epoxide 100). 
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To confirm that organometallic 200 had been generated under the reaction 
conditions  employed,  we  attempted  to  react  200  with  an  alternate 
electrophile. Pleasingly, the addition of benzaldehyde to a solution of 200a 
in  ether  at   100 
°C  proceeded  smoothly  and  afforded  phenyl(5 
(phenylethynyl)pyridin 3 yl)methanol 203a (58 %). Similarly, we were able 
to  prepare  compounds  203b d  in  consistently  good  yields  (60  – 72  %) 
(Scheme 84). Hydration of 203a d in 30% 
w/v H2SO4 in the presence of 10 
mol.% Hg(OAc)2 gave compounds 204a d (55 – 82 % yield). 
 
N
Br
R1
N
R1
N
Li
R1
OH
R2
O
H
R2
N
OH
R2 O
R1
204a R1 = H, R2 = H, 55 %
204b R1 = Me, R2 = H, 82 %
204c R1 = H, R2 = Cl, 64 %
204d R1 = Me, R2 = Cl, 74 %
30 % H2SO4
Hg(OAc)2
, 12 h
203a R1 = H, R2 = H, 58 %
203b R1 = Me, R2 = H, 72 %
203c R1 = H, R2 = Cl, 68 %
203 R1 = Me, R2 = Cl, 60 %
194a R1 = H
194b R1 = CH3
200a R1 = H
200b R1 = CH3
n BuLi, ether
 100 oC, 0.5 h
i,
 100 oC, 0.5h
 100 oC to rt, 1 h
ii, NH4Cl
 
Scheme 84. 
 
As an alternative approach to compounds 202a c, the pathways shown in 
Scheme  85  were  investigated.  Ketones  189a,b  were  readily  obtained 
through mercury catalysed hydration of the alkynes 177a,b and sodium Page | 123  
 
borohydride  reduction  of  ketones  205a,b  smoothly  afforded  the 
corresponding alcohols 181a,b. 
 
Sonogashira  coupling  reactions  of  arylalkynes  147a,b  with  alcohols 
181a,b [(Pd(PPh3)2Cl2 (5 mol.%), CuI (2 mol.%), Et3N (4 equiv.)] at 110 
°C 
in DMF was rapid and efficient (1 h, 50 62 % isolated yield); TLC analysis 
indicated that, under these reaction conditions, conversion was complete 
in  under  1  h.  Unfortunately,  using  similar  reaction  conditions  for 
Sonogashira coupling of ketones 205a,b and arylalkynes 147a,b resulted 
only  in  the  recovery  of  unreacted  starting  materials.  Also,  Sonogashira 
coupling  reactions  of  arylalkynes  147a,b  with  alcohols  181a,b  was 
ineffective at 80 °C, and resulted only in the recovery of unreacted starting 
materials, even after greater than 48 h at 80 
°C. 
 
Initial attempts to hydrate the alkyne functionality present in 201a using 10 
mol.% Hg(OAc)2 in 30 % 
w/v H2SO4 at reflux gave only dehydrated product 
207a after work up and purification. After varying the reaction conditions, 
we successfully achieved a hydration of 201a using 10 mol.% Hg(OAc)2 in 
3 % 
w/v H2SO4 to afford the 202a (50 % yield), with no dehydration product 
207  isolated.  However,  under  these  conditions,  reaction  times  were 
greater than 48 h and significant quantities of recovered starting material 
were  obtained  (~50  %).  A  more  optimum  hydration  reaction  using  10 
mol.%  Hg(OAc)2  in  5  %
  w/v  H2SO4  at  reflux  gave  the  desired  products 
203a c in only 12 h (65   77 %) [in these reactions, starting material was Page | 124  
 
again  recovered  (~10  %)  and  there  was  no  evidence  for  dehydration 
products 207a c] (Scheme 85). 
 
 
4.3 Summary 
 
In  summary,  robust  methodology  for  the  synthesis  of  3,5 disubstituted 
pyridine derivatives 182, 195 199, 201 and 202 204 has been developed. 
All  compounds  were  prepared  of  sufficient  purity  for  pharmacological 
evaluation  by  Institut  de  Recerches  Servier  (Chapter  5  gives  a  brief 
overview  of  the  pharmacological  data  obtained).  The  methodology 
described herein is ripe for expansion; additional work could rapidly deliver 
further examples in each class and, thus, aid development of structure 
activity relationships that may be used to inform the development of future 
synthetic targets to further the course of the project. P
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Chapter 5 
 
5.1 Pharmacological Testing  
 
The aim of this project was to develop heterocyclic derivatives as potential 
agents for treatment of neurodegenerative diseases. During the course of 
the project, the compounds described in Chapters 2 4 were sent to our 
collaborators  at  Institut  de  Recherches  Servier  for  pharmacological 
evaluation.  This  Chapter  gives  a  brief  summary  of  the  initial  results 
obtained from in vitro pharmacological investigations of the α7 neuronal 
nicotinic receptor binding affinities of these compounds. 
 
As the project was synthetic in nature, a detailed discussion of the relevant 
pharmacological  techniques  utilised  by  our  co workers  is  beyond  the 
scope of this work.  The contribution of Dr. Denis Guedin and Dr. Pierre 
Lestage,  Institut  de  Reserches,  Croissy sur Seine,  France  for  providing 
the data presented in this Chapter is gratefully acknowledged. 
 
5.1.1 Binding and Functional Assays 
 
The  compounds  synthesised  in  Chapters  2 4  were  tested  at  the  α7 
neuronal nicotinic receptor for their binding relative (in competition) to a 
radiolabelled  tracer  ([
125I]  α bungarotoxin).  The  receptor  used  for  the 
studies was a chimera of the human α7 receptor extracellular domain and 
the transmembrane section of the mouse 5HT3 receptor. As closing of the Page | 127 
 
cloned receptor (by desensitisation) occurs at a much slower rate than in 
native human α7 alone, the active state is easier to detect. 
 
Functional  assays  were  performed  using  a  fluorescence  membrane 
potential  assay  which  is  a  highly  sensitive  and  rapid  technique,  and  is 
preferred over an electrophysiological technique such as ‘patch clamping’ 
for high throughput screening and determination of subtype specificity. 
 
In  general  terms,  transefected  cells  (which  express  the  nicotinic  α7 
subtype)  are  loaded with  a  membrane potential  sensitive  dye.  The  dye 
serves to give an indication of ionic flux in the cells upon application of the 
test compound, hence, the measurement of fluorescence (both pre and 
post application) gives a measure of nicotinic receptor activation.  
 
For the α7 nAChR functional assay data (Table 2) obtained in this study: 
(i)  Agonism was determined by detecting the receptor response to 
the investigated compound alone. 
(ii)  Antagonism was determined by the modification of the receptor 
response  elicited by  acetylcholine  when  both  the  investigated 
compound and 60  M acetylcholine were applied. 
(iii)  Partial agonism was detected by the addition of the investigated 
compound  with  1  mM  5 hydroxyindole,  a  positive  allosteric 
modulator (PAM) which boosts agonist response, thus allowing 
detection.P
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5.2 Discussion of Biological Data 
 
5.2.1 α7 Neuronal Nicotinic Receptor Binding Affinities 
 
The following definitions apply to the final classification and discussion of 
the compounds investigated pharmacologically: 
 
Orthosteric Ligand 
A  compound  which  binds  to  the  active  site  of  the  α7  neuronal 
nicotinic chimera receptor and produces a quantifiable binding and 
functional response. 
 
Inactive 
A compound for which binding at the α7 neuronal nicotinic chimera 
receptor and other functional properties cannot be measured. 
 
Negative Allosteric Modulator (NAM) 
A compound which does not bind to the neuronal nicotinic orthosteric 
(native)  receptor  site  and  does  not  display  any  other  functional 
effects (e.g. down regulation or antagonism of the AChR). 
 
Hyperpolarizing compound 
A  compound  which  exhibits  no  binding  affinity  for  the  neuronal 
nicotinic  receptor  orthosteric  site,  but  does  display  measurable 
functional  parameters  (e.g.  down regulation  or  antagonism  of  the 
AChR). Page | 132  
 
Positive Allosteric Modulator (PAM) 
A compound which exhibits no binding at the α7 neuronal nicotinic 
receptor but may stabilise the receptor in the active state, increasing 
the response of the agonist. 
 
The compounds tested in this project (Table 2) showed no measurable 
binding  affinity  for  the  α7  neuronal  nicotinic  chimera  receptor  at 
concentrations of up to 200  M, regardless of the functional group present 
or whether the pyridine ring existed as the free base or the N alkylated 
form. When compared to compound 70 (IC50 38  M) (the direct 2 position 
analogue of 98d), and other active 2 position ligands, it is clear that, for 
the compounds investigated, all affinity for the α7 AChR is removed when 
substitution occurs at the 3 position of the pyridine ring.  
 
Sheridan  et  al.,
113  suggested  that  compounds  should  possess,  as 
essential  parts  of  their  pharmacophore,  a  hydrogen  bond  acceptor 
(carbonyl)  and  a  positively  charged  nitrogen  separated  by  between  4.6 
and  6.3  Å  for  the  compound  to  show  reasonable  binding  affinity  at 
nAChRs.  Basic  calculations  (Figure  19,  minimised  energy,  Chem3D
®) 
suggest that both the orthosteric ligand 70 and the 3 position analogue 
98d  have  separations  between  the  carbonyl  oxygen  (hydrogen  bond 
acceptor) and the pyridine nitrogen which fulfil this requirement (70, 4.6 Å; 
98d, 5.9 Å); it is perhaps noteworthy that compounds 70 and 98d have 
carbonyl   pyridinium  nitrogen  separations  at  the  lower  and  upper  limit, 
respectively. Page | 133  
 
 
 
Figure 19. Minimised representation of compounds 70 and 98d (Chem3D
®).  
 
Through functional assays a number of compounds (110c, 112c,d, 99c,d, 
205a,b)  have  been  identified  as  NAMs  which  do  not  have  an  intrinsic 
effect. These compounds may bind to similar or distinct allosteric sites on 
the  receptor  as  other  NAMs;  however,  although  binding  occurs,  no 
functional modulation of the nAChR could be detected.  NAMs (or non 
competitive binders) bind to a site on the receptor away from the active 
binding site and, without interaction with the receptor, cause a perturbation 
or alteration in the conformation of the nAChR. In this case, binding at the 
allosteric  site  reduced  the  response  of  the  agonist  probe  for  the 
allosterically  modulated  (conformationally  altered)  nAChR.  For  our Page | 134  
 
purposes,  these  compounds  can  be  considered  to  be  allosteric 
‘antagonists’. 
 
One  compound  159a  possesses  positive  allosteric  modulation  (PAM) 
properties without exhibiting any intrinsic effects. This compound may also 
bind  allosterically  but,  unfortunately,  no  functional  response  (i.e. 
upregulation  of  nAChR  response)  could  be  detected.  PAMs  are  of 
increasing  interest  for  the  treatment  of  cognitive  neurodegenerative 
disorders  such  as  AD  for  their  ability  to  modulate  the  release  of 
neurotransmitters  and  increase  sensitivity  of  the  receptor  response  to 
ACh.
213 
  
The  remainder  of  the  compounds  tested  have  been  identified  as 
hyperpolarising  compounds.  Hyperpolarising  compounds  cause  an 
increase in cell membrane potential, effecting an opening of ion channels 
allowing the efflux of K
+ ions from the cell; this results in a net decrease in 
the  membrane  potential  and  subsequent  hyperpolarisation. 
Disappointingly, further testing, using a cell line untransfected by the α7 
receptor  (chinese  hamster  ovary  cell  line)  showed  the  same  dose 
dependent  hyperpolarisation  response  to  the  original  cell  line,  implying 
that  the  hyperpolarisation  effect  of  these  compounds  is  not  due  to  the 
target α7 receptor. 
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5.2.2  Further Testing 
 
In the course of the initial pharmacological investigations on this project, 
candidates  showing  promising  α7 neuronal  nicotinic  receptor  binding 
affinities would routinely undergo in vitro safety studies as well as ADME 
(Adsorbtion;  Distribution;  Metabolism;  Excretion)  studies  to  establish 
suitability  for further  investigation  and  development.  This  testing  initially 
consists of: 
 
￿  cardiac  safety  profile  by  monitoring  affinity  for  the  hERG 
channel; 
￿  Ames test to indicate potential mutagenicity; 
￿  biomembrane permeability tests using Caco 2 cells; 
￿  initial  in  vitro  metabolic  stability  screening  using  liver 
microsomes from mice, rats and humans. 
 
 
5.2.2.1 hERG Affinity 
 
The hERG (human ether a go go related gene), or KCHN2, is responsible 
for  encoding  of  the  cardiac  potassium  ion  channel  Kv11.1  which  is 
intimately involved in the timing of ventricular repolarisation. Unfortunately, 
however, the hERG channel is known to be blocked by a wide range of 
structurally diverse small molecules due mainly to:  (i) the large central ion 
channel and (ii) the presence of two aromatic rings from aromatic amino Page | 136  
 
acid side chains within the channel which can interact (π cation) with a 
positively  charged  nitrogen  (these  are  commonly  present  in  molecules 
which interact strongly with hERG).
214a,b It is these unwanted interactions 
that can often lead to reduced potassium levels and resultant physiological 
conditions  such  as  acquired  long  Q T  (the  interval  denoted  by  the 
electrocardiogram) syndrome and potentially fatal arrhythmia (commonly 
known as torsades de pointes).  It is for these reasons that, in 2005, the 
regulatory  authorities  recommended  that  preclinical  studies  must  first 
establish the cardiac safety of potential pharmaceuticals.
215 Over the last 
15 years several widely prescribed drugs including Propulsid
® (cisapride, 
Janssen), Raxar
® (grepafloxacin, GSK) and Seldane
® (terfenadine, Merrell 
Dow Pharmaceuticals) have been withdrawn from the market due to their 
hERG binding properties.
216 
 
Determination  of  hERG  affinity  is  commonly  performed  using  a  ‘patch 
clamp’ assay on HEK293 cells which have expressed the hERG channel 
gene.
217 hERG affinity of the test compound is determined at a series of 
concentrations.  
 
 
5.2.2.2 Permeability Profiling in vitro 
 
Initial permeability studies are often performed in vitro using the Caco 2 
permeability  assay  in  order  to  assess  the  transit  of  the  test  compound 
across the intestinal epithelial cell barrier and, hence, predict the extent to Page | 137  
 
which  the  compound  may  be  absorbed  intestinally.
218  Caco 2  cells  are 
human  colonic  adenocarcinoma  cells  and  are  cultured  over  a  21  day 
period  to  form  a  mono layer  around  a  microporous  membrane.  The 
membrane  is  suspended  in  a  microwell  and  the  compound  of  interest 
placed in the upper chamber of the microwell; aliquots are then removed 
from the lower chamber at regular intervals. Analysis of the samples using 
UV  or  HPLC/MS/MS,  for  example,  allows  the  quantification  of  the  test 
substance which has crossed the mono layer.  In common with other pre 
clinical screening tests this type of assay is easily automated to allow high 
throughput screening of libraries of potential drug substances. 
 
 
5.2.2.3 Ames Testing 
 
The  Ames  test  is  a  rapid  bacterial  assay  based  on  the  Salmonella 
typhimurium  bacterial  strain  which  carry  a  mutation  in  the  gene 
responsible  for  the  synthesis  of  the  essential  amino acid  histidine.  The 
Ames test is used for the rapid screening of potential drug substances to 
determine  mutagenicity  and,  indirectly,  carcinogenicity  (as  a  strong 
correlation exists between mutagenicity and carcinogenicity). 
 
In practice, the bacteria and a limiting amount of histidine are applied to an 
agar plate, after which the test compound is introduced (often absorbed on 
blotting  paper)  and  the  plate  incubated.  Compounds  which  possess 
mutagenic  properties  can  induce  mutation  of  the  bacteria;  the  mutated Page | 138  
 
bacteria then revert to producing their own histidine, allowing division and 
the formation of colonies. Conversely, if the bacteria are exposed to non 
mutagenic compounds, once the small amount of histidine is expended, 
they cannot divide any further or produce colonies, as they remain unable 
to synthesise their own histidine.
219 An adaptation of this technique, which 
is often employed by pharmaceutical companies, involves the addition of 
S9 liver enzymes to the agar plate containing the bacteria. Monitoring of 
the metabolism of the test compound gives an indication of the potential 
mutagenicity of both the parent compound and its metabolites. 
 
Ames  II,  a  second  generation  Ames  test,  is  in  routine  use  by  most 
pharmaceutical  companies  and  is  based  on  the  same  principle  as  the 
original Ames test, also using Salmonella typhimurium. Ames II, however, 
employs a liquid culture media; this reduces the quantity of test compound 
and  reagents  required  and,  more  importantly,  allows  for  automated 
preparation and reading using microwell plates. 
 
 
5.2.2.4 Metabolic Stability 
 
Metabolic stability testing is commonly performed using rat, mouse and 
human liver microsomes. Microsomes are subcellular fractions responsible 
for  phase  I  metabolism  (i.e.  oxidation,  hydrolysis  and  reduction)  and 
involve enzymes such as the cytochrome P450 enzymes. 
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For  analysis,  the  compound  is  exposed  to  liver  microsomes  and  an 
enzyme co factor (NADPH) and compared to a control sample, prepared 
using  the  test  compound,  microsomes  but  no  co factor.  Samples  are 
removed  at  various  time  intervals  and  analysed,  often  by  a  mass 
spectrometry technique such as LC/MS/MS to determine the percentage 
of parent compound remaining and hence give an indication of systemic 
metabolic stability. 
 
 
5.3 Summary of Pharmacological Testing 
 
In  summary,  the  intention  of  this  project  was  to  synthesise  novel  3 
substituted pyridine based compounds which displayed orthosteric binding 
for  neuronal  nicotinic  acetylcholine  receptors.  Several  compounds  were 
found to be negative allosteric modulators, i.e. the compounds bind to a 
receptor at a site other than the active site, causing a perturbation in the 
conformation of the receptor and, thus, prevent binding of the probe (in 
this case [
125I] α  bungarotoxin). Unfortunately, little therapeutic benefit can 
be  derived  from  this  type  of  compound;  however,  recent  work  has 
suggested that these compounds may have some benefit in the treatment 
of nicotine addiction.
220 
 
A number of compounds synthesised in this project have a hyperpolarising 
effect,  which  upon  further  investigation  was  found  (by  observation  of 
identical dose dependent hyperpolarisation response in the transefected Page | 140  
 
and an untransefected cell line) to be independent of the α7 receptor. At 
this point the target through which hyperpolarisation proceeds is unknown. 
 
Unfortunately, in this study no useful biological activity was observed at 
the  neuronal  nicotinic  acetylcholine  receptor  subtype  tested  in  terms  of 
nicotinic  receptor  agonism.  Hence,  it  can  be  concluded  that  the  3 
substituted  pyridine  derivatives  synthesised  in  this  project,  although 
meeting Barlow’s criteria in terms of internuclear separation, do not adopt 
a conformation appropriate for efficient binding at the active site of the α7 
nAChR. 
 
To progress this project, further work should focus around the synthesis 
and pharmacological testing of the analogous, novel and somewhat less 
conformationally restricted 3 substituted piperidine derivatives identified in 
Scheme 40 (Section 2.5). Such derivatives have hydrogen bond acceptor   
hydrogen  bond  donor  separations  within  the  4.6  and  6.5  Å  range 
suggested  by  Barlow  et  al.  Additionally,  it  is  worthwhile  noting  that  the 
highly  selective  and  potent  α7  agonist  PNU 282987  25  (Figure  6.) 
possesses  a  similar  (although  conformationally  restricted)  structure  to 
those identified in Scheme 40. Page | 141  
 
Chapter 6   Experimental 
 
6.1 General 
 
IR  spectra  were  collected  on  a  Perkin Elmer  Spectrum  BX  FT IR 
instrument  fitted  with  a  PIKE  MIRacle  clamp.  Reaction  progress  was 
monitored using pre coated aluminium TLC plates (Merck silica gel type 
60  HF254).  Melting  points  were  determined  using  a  Stuart  SMP10  or 
Reichart and are uncorrected. 
1H and 
13C NMR spectra were recorded at 
300  and  75  MHz  respectively  on  a  Brüker  Avance  with  deuterated 
chloroform unless stated otherwise. ‘Petrol’ refers to the fraction boiling at 
60 80
  oC,  ‘ether’  refers  to  diethyl  ether.  Elemental  analyses  were 
performed  by  Medac  Ltd,  Brunel  Science  Centre  or  ChemiSPEC, 
University  of  Sunderland.  THF  was  dried  over  sodium  /  benzophenone 
ketyl under nitrogen and stored over 3Å molecular sieves. Toluene was 
dried  over  calcium  hydride.  3 Methylpyridine  was  distilled  over  calcium 
hydride onto 3Å molecular sieves. DMPU was distilled and stored over 3Å 
molecular  sieves,  all  other  reagents  were  reagent  grade  and  used  as 
supplied.  All  glassware  was  flame  dried  under  vacuum.  Reactions 
requiring anhydrous conditions were performed under argon or nitrogen. 
Chemical shifts, given in ppm, are relative to tetramethylsilane (TMS). Spin 
multiplicities are described as b (broad), bs (broad singlet), s (singlet), d 
(doublet),  t  (triplet),  dd  (doublet  of  doublets),  dt  (doublet  of  triplets),  td 
(triplet  of  doublets),  tt  (triplet  of  triplets),  ddd  (doublet  of  doublet  of 
doublets). NMR spectra were fully assigned using a combination of 
1H, 
13C, DEPT 135, COSY, HMBC and HMQC. Page | 142  
 
6.2 General Synthetic Procedures 
 
6.2.1  General  Procedure  1  (GP  1)     formation  of  (pyridin 3 
ylmethyl)lithium 73c and subsequent reaction with electrophiles 
 
To a stirred solution of LDA (10 mL, 2.0 M, 20 mmol) in dry THF (60 mL) 
maintained  at  0
  °C  under  an  atmosphere  of  argon  was  added  3 
methylpyridine 72 (10 mmol) dropwise over 5 min. The mixture was stirred 
for  a  further  5  min,  followed  by  dropwise  addition  over  5  min  of  the 
electrophile  (11  mmol)  in  dry  THF  (10  mL).  The  resulting  solution  was 
stirred  at  0 
°C  for  1  h  then  quenched  with  water  (60  mL),  the  phases 
separated and the aqueous phase extracted using DCM (3 x 20 mL). The 
combined organic extracts were dried (MgSO4) and the solvent removed 
under reduced pressure to yield red / brown residues which were purified 
by  column  chromatography  (SiO2;  EtOAc  /  petrol,  60  /  40 
v/v)  and 
recrystallisation, as appropriate. Page | 143  
 
6.2.2  General Procedure 2 (GP 2)   Sodium borohydride reduction of 
ketones 
 
To a stirred solution of ketone (10 mmol) in ethanol (40 mL), was added 
sodium borohydride (0.76 g, 20 mmol). The resulting solution was stirred 
at room temperature for 2 h followed by the addition of water (90 mL). The 
aqueous  layer  was  extracted  with  DCM  (3  x  40  mL)  and  the  organic 
extracts combined, washed with brine (50 mL) and dried (MgSO4). The 
solvent was removed under reduced pressure to yield the crude products 
which were subsequently purified by recrystallisation from EtOAc.  
 
GP 2 was used for the synthesis of alcohols 75a,c f, 112a,c f and 181a,b.  Page | 144  
 
6.2.3 General Procedure 3 (GP 3)   pyridine N alkylation 
 
To a stirred solution of pyridine substrate (5 mmol) in dry THF (3 mL) was 
added iodomethane (1.6 mL, 25 mmol). The mixture was stirred at reflux 
overnight. After cooling, the resulting precipitate was filtered to give crude 
N alkylated products, which were subsequently purified by recrystallisation 
from ethanol. 
 
GP  3  was  used  for  the  synthesis  of  pyridinium  salts  98a,c f,  99a,c f, 
111a,c f, 113a,c f, 149a,c f and 164a e. 
 
General Procedure 4 (GP4) – Hydration of Alkynes 
 
Acetylene  (10  mmol)  and  Hg(OAc)2  (0.32  g,  1  mmol,  10  mol.%)  were 
dissolved in a mixture of 30 % 
w/v H2SO4 (8 mL) and acetone (4 mL). The 
mixture was stirred at reflux for 12 h. After cooling, the mixture was diluted 
with water (80 mL), neutralised with 10 % NaOH and extracted with EtOAc 
(3  x  25  mL).  The  combined  organic  extracts  were  dried  (MgSO4), 
evaporated under reduced pressure, and the residue purified by column 
chromatography  (SiO2;  EtOAc:petrol,  70:30)  and  the  solid  obtained 
recrystallised. 
 
GP4 was used for the synthesis of ketones 78a d, 205a,b and 196a c Page | 145  
 
6.3 Synthetic Work, Chapter 2 
 
6.3.1.   3 Butylpyridine (96a) 
 
 
Using  GP  1  with  butyl  iodide  (1.87  g)  as  electrophile;  (0.74  g,  53  %); 
colourless oil; FTIR (neat) 2957, 2929, 2859, 1574, 1421, 712 cm
 1; 
1H 
NMR (CDCl3) δ 8.47 (d, J = 2.1, 1H, H2), 8.42 (dd, J = 4.8, 2.1, 1H, H6), 
7.51 (dt, J = 7.8, 2.1, 1H, H4), 7.22 (dd, J = 7.8, 4.8, 1H, H5), 2.63 (t, J = 
7.5, 2H, H1'), 1.64 (p, J = 7.5, 2H, H2'), 1.38 (tt, J = 7.5, 7.2, 2H, H3'), 0.96 
(t, J = 7.2, 3H, H4'); 
13C NMR (CDCl3) δ 149.9 (C6), 147.1 (C2), 138.0 (q, 
C3), 135.8 (C4), 123.2 (C5), 33.2 (C2'), 32.7 (C1'), 22.2 (C3'), 13.8 (C4'). 
Spectroscopic data were identical to that reported in literature.
228 
 
6.3.2.   3 Phenylethylpyridine (96b) 
 
 
 
Using GP 1 with benzyl bromide (1.88 g) as electrophile. (0.68 g, 37 %); 
colourless oil; FTIR (neat) 3026, 1494, 1452, 1422, 1027, 758, 713, 698 
cm
 1;
 1H NMR (CDCl3) δ 8.41 (dd, J = 4.8, 1.8, 1H, H6), 8.28 (d, J = 1.8, Page | 146  
 
1H, H2), 7.31 7.19 (m, 4H, H3'', H4'', H4'), 7.13 7.06 (m, 3H, H2'', H5'), 
3.06  2.94 (m, 4H, H1', H2'); 
13C NMR (CDCl3) δ 150.2 (C2), 147.1 (C6), 
143.3 (q, C1''), 135.9 (q, C3), 136.7 (C4), 128.5 (C2'' or C3''), 128.4 (C2'' 
or C3''), 126.5 (C4''), 123.0 (C5), 42.8 (C2'), 39.4 (C1'). Spectroscopic data 
were identical to that reported in literature.
229 
 
6.3.3.   1 Phenyl 3 pyridin 3 yl propan 2 ol (96c)  
 
 
 
Using GP 1 with phenylacetaldehyde (1.32 g) as electrophile. (0.68 g, 32 
%); cream solid; m.p. 67 68 
°C (from EtOAc); FTIR (neat solid) 3149 br, 
2919, 1578, 1425, 1071, 1047, 747, 711, 700, 618 cm
 1; 
1H NMR (CDCl3) 
δ 8.38 (s, 1H, H2'), 8.34 (d, J = 3.3, 1H, H6'), 7.55 (d, J = 7.8, 1H, H4'), 
7.30 7.10 (m, 6H, H2'', H3'', H4'', H5'), 3.99 (tt, J = 8.1, 4.5, 1H, H2), 3.57 
(bs, 1H, OH), 2.79 (dd, J = 14.1, 4.5, 1H, H3A or H1A), 2.79 (dd, J = 13.2, 
4.5, 1H, H3A or H1A), 2.69 (dd, J = 13.2, 8.1, 1H, H3B or H1B), 2.68 (dd, J 
= 14.1, 8.1, 1H, H3B or H1B); 
13C NMR (CDCl3) δ 149.8 (C2'), 146.8 (C6'), 
138.0 (2C; C4' and q, C1''), 134.9 (q, C3'), 129.4 (C2''), 128.7 (C3''), 126.7 
(C4''),  123.6  (C5'),  72.9  (C2),  43.8  (C1),  40.3  (C3).  HRMS  calcd  for 
C14H15NO (M + H)
+ required 214.1233, found 214.1224. 
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6.3.4.   2 Phenyl 1 pyridin 3 yl propan 2 ol (96d) 
 
 
 
Using GP 1 with acetophenone (1.32 g) as electrophile. (0.59 g, 28 %); 
colourless oil;
 FTIR (neat) 3216 br, 1578, 1492, 1425, 1067, 764, 699 cm
 1 
 
1H NMR (CDCl3) δ 8.26 (dd, J = 4.5, 1.2, 1H, H6'), 8.14 (d, J =1.2, 1H, 
H2'), 7.30 7.13 (m, 6H, H2'', H3'', H4'', H4'), 7.01 (dd, J = 7.8. 4.5, 1H, 
H5'), 3.05 (bs, 1H, OH), 2.97 (d, J = 13.5, 1H, H1A), 2.93 (d, J = 13.5, 1H, 
H1B), 1.50 (s, 3H, C3);
 13C NMR (CDCl3) δ 151.1 (C2), 147.2 (C6), 147.1 
(q, C1''), 138.3 (C4), 133.1 (q, C3'), 128.2 (C3''), 126.9 (C4''), 125.0 (C2''), 
122.8 (C5'), 74.3 (q, C2), 47.8 (C1), 29.4 (C3). HRMS calcd for C14H15NO 
(M + H)
+ required 214.1233, found 214.1229. 
 
6.3.5.   1 Pyridin 3 yl pentan 3 ol (96e) 
 
 
 
Using GP 1 with 1,2 epoxybutane (0.79 g) as electrophile. (0.98 g, 59 %); 
colourless oil; FTIR (neat) 3289, 2959, 2924, 2873, 1578, 1423, 712 cm
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1H NMR (CDCl3) δ 8.39 (s, 1H, H2'), 8.34 (d, J = 5.1, 1H, H6'), 7.47 (d, J = 
7.8, 1H, H4'), 7.14 (dd, J = 7.2, 5.1, 1H, H5'), 3.49  3.43 (m, 1H, H3), 2.89 
(s, br, 1H, OH), 2.81 2.57 (m, 2H, H1), 1.72 1.65 (m, 2H, H2), 1.50 1.36 
(m, 2H, H4), 0.87 (t, J = 7.5, 3H, H5); 
13C NMR (CDCl3) δ 149.6 (C2'), 
146.9 (C6'), 137.9 (q, C3'), 136.2 (C4'), 123.4 (C5'), 72.0 (C3), 38.2 (C2), 
30.4 (C1), 29.2 (C4), 9.9 (C5). Spectroscopic data were identical to that 
reported in literature.
230 
 
6.3.6.   2 Phenyl 3 pyridin 3 yl propan 1 ol (102a) 
 
 
 
Using  GP  1  with  (±) 100a  (1.32  g)  as  electrophile.  (0.36  g,  17%); 
colourless solid; m.p. 91 
°C (from EtOAc / petrol ); IR (neat solid) 3216, 
1577, 1423, 1068, 1030, 761, 704 cm
 1; 
1H NMR (CDCl3) δ 8.25 (dd, J = 
4.8, 1.8, 1H, H6'), 8.20 (d, J = 1.8, 1H, H2'), 7.23 (dt, J = 7.8, 1.8, 1H, H4'), 
7.12 7.06 (m, 3H, H44'', H3''), 7.02 (dd, J = 7.8, 4.8, 1H, H5'), 3.72 (d, J = 
6.0, 2H, H1), 3.05 (dd, J = 12.9, 6.3, 1H, H3A), 2.95 (dd, J = 13.8, 6.3, 1H, 
H2), 2.78 (dd, J = 12.9, 7.8, 1H, H3B), 2.42 (bs, 1H, OH);
 13C NMR (CDCl3) 
δ  150.2  (C2'),  147.3  (C6'),  141.1  (q,  C1''),  136.6  (C4'),  135.5  (q,  C3'), 
128.7 (C3''), 128.1 (C2''), 127.0 (C4''), 123.1 (C5'), 66.1 (C1), 50.1 (C2), 
35.7 (C3); Anal. Calcd for C14H15NO: C, 78.84; H, 7.09; N, 6.57. Found: C, 
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6.3.7  2 Phenyl 1 pyridin 3 yl ethanol (131) 
 
 
 
Using exchange with phenylacetaldehyde (1.32 g) as electrophile. (0.94 
g, 47 %); white solid; m.p. 101 102 
°C (from EtOAc); FTIR (neat solid) 
3157 br, 2904, 1580, 1492, 1424, 1065, 700, 544 cm
 1; 
1H NMR (CDCl3) δ 
8.30 (d, J = 1.8, 1H, H2'), 8.28 (dd, J = 4.8, 1.8, 1H, H6'), 7.57 (dt, J = 7.8, 
1.8, 1H, H4'), 7.22 7.11 (m , 4H, H5', H3'', H4''), 7.06 (dd, J = 7.8, 1.5, 2H, 
H2''), 4.81 (t, J = 6.6, 1H, H1), 3.45 (bs, 1H, OH), 2.92 (d, J = 6.6, 2H, H2);
 
13C NMR (CDCl3) δ 148.4 (C2), 147.6 (C6), 139.6 (q, C3), 137.4 (q, C1''), 
134.0 (C4'), 129.6 (C2''), 128.6 (C3''), 126.8 (C4''), 123.4 (C5), 72.9 (C1), 
46.0 (C2). Anal. Calcd for C13H13NO: C, 78.36; H, 6.58; N, 7.03. Found: C, 
78.40; H, 6.60; N, 7.19. 
 
6.3.8  Synthesis of compounds 78a e 
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1 Phenyl 2 pyridin 3 yl ethanone  (78a),  using  97a  (1.13  g).  (1.41  g, 
71%); pale yellow solid; m.p. 41 42 
°C (from EtOAc); lit. 43 
°C.
221 FTIR 
(neat solid) 3031, 1679, 1592, 1577, 1107, 993, 761, 713 cm
 1; 
1H NMR 
(CDCl3) δ 8.51 (d, J = 1.5, 1H, H2'), 8.49 (dd, J = 5.0, 1.5, 1H, H6'), 8.00 
(dd, J = 7.2, 1.2, 2H, H2''), 7.59 (tt, J = 7.2, 1.2, 1H, H4''), 7.58 (dt, J = 7.6, 
1.2, 1H, H4'), 7.48 (t, J = 7.2, 6.3 2H, H3''), 7.25 (dd, J = 7.6, 5.0 1H, H5'), 
4.29 (s, 2H, H2); 
13C NMR (CDCl3) δ 196.5 (q, C1), 150.7 (C2'), 148.4 
(C6'), 137.3 (C4'), 136.4 (q, C1''), 133.6 (C4''), 130.3 (q, C3'), 128.9 (C3''), 
128.5 (C2''), 123.5 (C5'), 42.4 (C2); Anal. Calcd for C13H11NO: C, 79.17; H, 
5.62; N, 7.10. Found: C, 78.51; H, 5.59; N, 7.10. 
 
1 (4 Chlorophenyl) 2 pyridin 3 yl ethanone  (78c),  using  97c  (1.51  g). 
(1.52 g, 66 %); pale yellow solid; m.p. 64 65 
°C (from EtOAc); lit. 65 – 68 
oC;
227  FTIR  (neat  solid)  3047,  1687,  1592,  1481,  839  cm
 1; 
1H  NMR 
(CDCl3) δ 8.55 (d, J = 4.8, 1.8, 1H, H6'), 8.54 (d, J = 1.8, 1H, H2'), 7.97 (d, 
J = 8.7, 2H, H2''), 7.62 (dt, J = 7.8, 1.8 1H, H4'), 7.48 (d, J = 8.7, 2H, H3''), 
7.30 (dd, J = 7.8, 4.8 1H, H5'), 4.29 (s, 2H, H2); 
13C NMR (CDCl3) δ 194.3 
(q, C1), 149.6 (C2'), 147.5 (C6'), 139.2 (q, C4''), 136.3 (C4'), 133.7 (q, 
C1'), 129.8 (C2''), 129.0 (q, C3'), 128.3 (C3''), 122.6 (C5'), 41.4 (C2); Anal. 
Calcd for C13 H10ClNO: C, 67.40; H, 4.35; N, 6.05. Found: C, 67.51, H, 
4.40; N, 6.03. 
 
1 (4 Bromophenyl) 2 pyridin 3 yl ethanone  (78d),  using  97d  (2.00  g). 
(1.10 g, 40 %); yellow solid; m.p. 88 89 
°C (from EtOAc); FTIR (neat solid) 
3047, 1677, 1585, 1479, 817 cm
 1; 
1H NMR (CDCl3) δ 8.48 (dd, J = 5.4, Page | 151  
 
1.8, 1H, H6'), 8.45 (d, J = 1.8, 1H, H2'), 7.80 (d, J = 6.9, 2H, H2''), 7.56 (d, 
J = 6.9, 2H, H3''), 7.53 (dt, J = 8.4, 1.8 1H, H4'), 7.21 (dd, J = 8.4, 5.4 1H, 
H5'),  4.19  (s,  2H,  H2); 
13C  NMR  (CDCl3)  δ  195.8  (q,  C1),  150.9  (C2'), 
148.8 (C6'), 137.6 (C4'), 135.4 (q, C1''), 132.6 (C3''), 130.3 (C2''), 130.3 (q, 
C3'), 129.2 (q, C4''), 123.9 (C5'), 42.7 (C2); Anal. Calcd for C13 H11BrNO: 
C, 56.55; H, 3.65; N, 5.07; Found: C, 56.72; H, 3.75; N, 5.11. 
 
2 Pyridin 3 yl 1 (4 methylphenyl) ethanone  (78e),  using  97e  (1.29  g). 
(1.71 g, 81%); pale yellow solid; m.p. 76 77 
°C (from EtOAc); FTIR (neat 
solid) 3035, 1683, 1602, 1482, 819 cm
 1; 
1H NMR (CDCl3) δ 8.43 (d, J = 
1.8, 1H, H2'), 8.42 (dd, J = 5.0, 1.8, 1H, H6'), 7.83 (d, J = 8.2, 2H, H2''), 
7.52 (dt, J = 7.8, 1.8 1H, H4'), 7.15 – 7.21 (m, 3H, H5', H3''), 4.18 (s, 2H, 
H2), 2.34 (s, 3H, 4'' CH3); 
13C NMR (CDCl3) δ 196.4 (q, C1), 151.0 (C2'), 
148.7 (C6'), 144.8 (q, C4''), 137.5 (C4'), 134.2 (q, C1''), 130.8 (q, C3'), 
129.8  (C3''),  129.0  (C2''),  123.7  (C5'),  42.6  (C2),  22.0  (C4'' CH3);  Anal. 
Calcd for C14H13NO: C, 79.59; H, 6.20; N, 6.63. Found: C, 79.50; H, 6.18; 
N, 6.59. 
 
1 (4 Methoxyphenyl) 2 pyridin 3 yl ethanone (78f), using 97f (1.46 g). 
(1.50g, 66%); pale yellow solid; m.p. 73 74 
°C (from EtOAc); FTIR (neat 
solid) 3047, 1677, 1598, 1509, 835 cm
 1; 
1H NMR (CDCl3) δ 8.44 (d, J = 
1.8, 1H, H2'), 8.41 (dd, J = 4.8, 1.8, 1H, H6'), 7.91 (d, J = 8.7, 2H, H2''), 
7.52 (dt, J = 7.8, 1.8 1H, H4'), 7.17 (dd, J = 7.8, 4.8 1H, H5'), 6.86 (d, J = 
8.7, 2H, H3''), 4.15 (s, 2H, H2), 3.78 (s, 3H, 4'' OCH3); 
13C NMR (CDCl3) δ 
195.4 (q, C1), 164.2 (q, C4''), 151.0 (C2'), 148.6 (C6'), 137.5 (C4'), 131.2 Page | 152  
 
(C2''), 131.0 (q, C3'), 129.7 (q, C1''), 123.8 (C5'), 114.4 (C3''), 55.9 (C4'' 
OCH3), 42.4 (C2); Anal. Calcd for C14H13NO2: C, 73.99; H, 5.77; N, 6.16 
%. Found: C, 73.89; H, 5.72; N, 6.15. 
 
6.3.9  Synthesis of compounds 98a e 
 
 
 
Compounds 98a,c f were prepared using GP 3. There was obtained: 
 
1 Methyl 3 (2 oxo 2 phenylethyl)pyridinium  iodide  (98a),  using  78a 
(0.99 g). (1.47 g, 86 %); yellow solid; m.p. 122 123 
°C (from EtOH); FTIR 
(neat solid) 3031, 1673, 1604, 1504 cm
 1; 
1H NMR (DMSO d6) δ 8.95 (bs, 
1H, H2), 8.93 (d, J = 6.0, 1H, H6), 8.50 (d, J = 8.1, 1H, H4), 8.15 (dd, J = 
7.8, 6.0 1H, H5), 8.09 (d, J = 6.9, 2H, H2'), 7.71 (tt, J = 7.8, 6.9, 1H, H4'), 
7.62 (t, J = 7.8, 2H, H3'), 4.81 (s, 2H, H1''), 4.38 (s, 3H, 1 CH3); 
13C NMR 
(DMSO d6) δ 195.3 (q, C2''), 146.6 (C4), 145.8 (C2), 143.6 (C6), 135.9 (q, 
C3), 135.7 (q, C1'), 133.7 (C4'), 128.8 (C3'), 128.1 (C2'), 126.8 (C5), 47.8 
(1 CH3), 41.1 (C1''); Anal. Calcd for C14 H14INO: C, 49.58; H, 4.16; N, 4.13. 
Found: C, 49.67; H, 4.16; N, 4.02. 
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3 [2 (4 Chlorophenyl) 2 oxoethyl] 1 methylpyridinium  iodide  (98c), 
using 78c (1.16 g). (1.59 g, 85 %); yellow solid; m.p. 183 184 
°C (from 
EtOH); FTIR (neat solid) 3010, 1688, 1587, 1511 cm
 1; 
1H NMR (DMSO 
d6) δ 8.96 (bs, 1H, H2), 8.94 (d, J = 6.6, 1H, H6), 8.49 (d, J = 8.1, 1H, H4), 
8.15 (dd, J = 8.1, 6.6 1H, H5), 8.13 (d, J = 7.6, 2H, H2'), 7.69 (d, J = 7.6, 
2H, H3'), 4.81 (s, 2H, H1''), 4.38 (s, 3H, 1 CH3);
  13C NMR (DMSO d6) δ 
195.0 (q, C2'), 147.3 (C4), 146.5 (C6), 144.3 (C2), 139.3 (q, C4'), 136.2 (q, 
C1'), 135.0 (q, C3), 130.7 (C2'), 129.5 (C3'), 127.5 (C5), 48.5 (1 CH3), 41.8 
(C1''); Anal. Calcd for C14H13ClINO: C, 45.01; H, 3.55; N, 3.77. Found:  C, 
45.07; H, 3.52; N, 3.78. 
 
3 [2 (4 Bromophenyl) 2 oxo ethyl] 1 methylpyridinium  iodide  (98d), 
using 78d (1.38 g). (1.86 g, 89 %); pale yellow crystals; m.p. 215 216 
°C 
(from EtOH); FTIR (neat solid) 3015, 1691, 1583, 1511, 817 cm
 1; 
1H NMR 
(DMSO d6) δ 8.95 (s, br, 1H, H2), 8.94 (d, J = 6.6, 1H, H6), 8.50 (d, J = 
7.8, 1H, H4), 8.15 (dd, J = 7.8, 6.6 1H, H5), 8.03 (d, J = 8.7, 2H, H2'), 7.83 
(d, J = 8.7, 2H, H3'), 4.80 (s, 2H, H1''), 4.38 (s, 3H, 1 CH3);
  13C NMR 
(DMSO d6) δ 194.6 (q, C2'), 146.6 (C4), 145.8 (C6), 143.7 (C2), 135.6 (q, 
C3), 134.7 (q, C1'), 131.8 (C2'), 130.1 (C3'), 127.8 (q, C4'), 126.9 (C5), 
47.9 (1 CH3), 41.1 (C1''); Anal. Calcd for C14H13BrINO:  C, 40.22; H, 3.12; 
N, 3.35. Found: C, 40.49; H, 3.20; N, 3.32. 
 
1 Methyl 3 [2 oxo 2-(4 methylphenyl)-ethyl]pyridinium  iodide  (98e), 
using 78e (1.06 g). (1.52 g, 86 %); yellow solid; m.p. 158 159 
°C (from 
EtOH); FTIR (neat solid) 3018, 1675, 1606, 1506 cm
 1; 
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d6) δ 9.29 (bs, 1H, H2), 9.01 (d, J = 6.0, 1H, H6), 8.32 (d, J = 8.1, 1H, H4), 
7.95 (dd, J = 7.8, 6.0 1H, H5), 7.88 (d, J = 8.3, 2H, H2'), 7.22 (d, J = 8.1, 
2H, H3'), 4.68 (s, 2H, C1''), 4.51 (s, 3H, 1 CH3), 2.35 (s, 3H, 4' CH3);
 13C 
NMR (DMSO d6) δ 194.0 (q, C2''), 147.1 (C4), 146.5 (C2), 145.3 (q, C4'), 
143.2 (C6), 136.5 (q, C3), 132.9 (q, C1'), 129.7 (C3'), 128.7 (C2'), 127.3 
(C5), 49.2 (1 CH3), 41.5 (C1''), 21.7 (4' CH3); Anal. Calcd for C15H16INO; 
C, 51.01; H, 4.57; N, 3.96. Found: C, 51.00; H, 4.56; N, 3.84. 
 
3 [2 (4 Methoxyphenyl) 2 oxo ethyl] 1 methylpyridinium  iodide  (98f), 
using 78f (1.14 g). (1.52 g, 82 %); yellow solid; m.p. 184 185 
°C (from 
EtOH); FTIR (neat solid) 3016, 1673, 1602, 1511 cm
 1; 
1H NMR (DMSO 
d6) δ 8.95 (bs, 1H, H2), 8.92 (d, J = 6.3, 1H, H6), 8.48 (d, J = 8.1, 1H, H4), 
8.12 (dd, J = 8.1, 6.3 1H, H5), 8.09 (d, J = 9.0, 2H, H2'), 7.13 (d, J = 9.0, 
2H, H3'), 4.73 (s, 2H, H1''), 4.39 (s, 3H, 1 CH3), 3.87 (s, 3H, 4' OCH3);
 13C 
NMR (DMSO d6) δ 193.5 (q, C2''), 163.5 (q, C4'), 146.6 (C4), 145.8 (C6), 
143.5 (C2), 136.1 (q, C3), 130.5 (C2'), 128.5 (q, C1'), 126.8 (C5), 114.0 
(C3'),  55.6  (C4' OCH3),  47.8  (1 CH3),  40.7  (C1'');  Anal.  Calcd  for 
C15H16INO2: C, 48.80; H, 4.37; N, 3.79. Found: C, 48.80; H, 4.33; N, 3.64. 
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6.3.10.  Synthesis of compounds 75a,c f 
 
 
 
Compounds 75a,c f were synthesised using GP 2. There was obtained: 
 
1 Phenyl 2 pyridin 3 yl ethanol (75a), using 78a (1.97 g). (1.83 g, 92 %); 
yellow solid; m.p. 117 118 
°C (from EtOAc); lit. 120–121 
°C;
135 FTIR (neat 
solid) 3194, 3059, 1577, 1452, 1065 cm
 1; 
1H NMR (CDCl3) δ 8.34 (dd, J = 
4.8, 1.8, 1H, H6'), 8.30 (d, J = 1.8, 1H, H2'), 7.46 (dt, J = 7.8, 1.8, 1H, H4'), 
7.28 7.39 (m, 5H, H2'', H3'', H4''), 7.17 (dd, J = 7.5, 4.8, 1H, H5'), 4.89 (dd, 
J = 7.5,5.7, 1H, H1), 3.51 (bs, 1H, OH), 3.05 (dd, J = 13.8, 7.5, 1H, H2A), 
3.00 (dd, J = 13.8, 7.5, 1H, H2B); 
13C NMR (CDCl3) δ 150.5 (C2'), 147.4 
(C6'), 143.8 (q, C1''), 137.4 (C4'), 134.0 (q, C3'), 128.5 (C3'''), 127.7 (C4''), 
126.0 (C2''), 123.2 (C5'), 74.7 (C1), 43.0 (C2); Anal. Calcd for C13H13NO:  
C, 78.36; H, 6.58; N, 7.03. Found: C, 78.28; H, 6.59; N, 7.16. 
 
1 (4 Fluorophenyl) 2 pyridin 3 yl ethanol  (75b)  using  78b  (1.37  g,  63 
%); pale yellow solid; m.p. 126 
°C (from EtOAc); FTIR (neat solid) 3180 
(br), 2918, 1601, 1508, 1427, 1209, 1063, 831, 824, 712 cm
 1; 
1H NMR 
(CDCl3) δ 8.40 (dd, J = 4.8, 1.5, 1H, H6'), 8.36 (d, J = 1.5, 1H, H2'), 7.60 
(dt, J = 7.8, 1.5, 1H, H4'), 7.35 (dd, J = 8.4, 5.7, 2H, H2''), 7.29 (dd, J = 
7.8, .48, 1H, H5'), 7.12 (t, J = 8.7, 2H, H3''), 5.44 (bs, 1H, OH), 4.81 (t, J = 
6.6, 1H, H1), 2.91 (d, J = 6.6, 2H, H2); 
13C NMR (CDCl3) δ 161.6 (q, JC F = 
242, C4''), 150.7 (C2'), 147.3 (C6'), 141.8 (q, JC F = 3, C1''), 137.8 (C4'), Page | 156  
 
134.9 (q, C3'), 128.3 (JC F = 8, C2''), 123.6 (C5'), 115.1 (JC F = 21, C3''), 
72.8 (C1), 42.9 (C2). Anal. Calcd for C13H12FNO: C, 71.88; H, 5.57; N, 
6.45. Found: C, 71.74; H, 5.74; N, 6.18. 
 
1 (4 Chlorophenyl) 2 pyridin 3 yl ethanol  (75c),  using  78c  (2.32  g). 
(1.33 g, 57 %); yellow solid; m.p. 119 121 
°C (from EtOAc); FTIR (neat 
solid) 3176, 2923, 1600, 1509, 1211, 1064 cm
 1; 
1H NMR (CDCl3) δ 8.20 
(d, J = 4.2, 1H, H6'), 8.15 (s, 1H, H2'), 7.34 (d, J = 7.8, 1H, H4'), 7.20 (d, J 
= 8.4, 2H, H3''), 7.12 (d, J = 8.4, 2H, H2''), 7.06 (dd, J = 7.5, 4.8, 1H, H5'), 
4.76 (dd, J = 7.2, 6.0, 2H, H2''), 3.60 (s, br, 1H, OH), 2.88 (dd, J = 13.8, 
7.2, 1H, H2A), 2.86 (dd, J = 13.8, 6.0, 1H, H2B); 
13C NMR (CDCl3) δ 150.4 
(C2'), 147.4 (C6'), 142.4 (q, C1''), 137.5 (C4'), 133.7 (q, C3'), 133.3 (q, 
C4''), 128.6 (C3''), 127.3 (C2''), 123.3 (C5'), 73.9 (C1), 43.0 (C2); Anal. 
Calcd for C13H12ClNO: C, 66.81; H, 5.18; N, 5.99. Found: C, 66.96; H, 
5.22; N, 5.92. 
 
1 (4 Bromophenyl) 2 pyridin 3 yl ethanol  (75d),  using  78d  (2.76  g). 
(2.28 g, 82 %); yellow solid; m.p. 114 
°C (from EtOAc); FTIR (neat solid) 
3260, 2971, 1567, 1487, 1058 cm
 1; 
1H NMR (CDCl3) δ 8.18 (s, 1H, H6'), 
8.14 (s, 1H, H2'), 7.36 – 7.33 (m, 3H, H3'', H4'), 7.08 – 7.03 (m, 3H, H2'', 
H5'), 4.76 (m, 1H, H1), 3.77 (s, br, 1H, OH), 2.89 (m, 2H, H2); 
13C NMR 
(CDCl3) δ 150.4 (C2'), 147.4 (C6'), 143.9 (q, C1''), 137.5 (C4'), 133.7 (q, 
C3'), 131.5 (C3''), 127.7 (C2''), 123.2 (C5'), 121.2 (q, C4''), 73.9 (C1), 43.0 
(C2); Anal. Calcd for C13H12BrNO: C, 56.14; H, 4.35; N, 5.04. Found: C, 
56.02; H, 4.30; N, 4.94. 
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2 Pyridin 3 yl 1 (4 methylphenyl)ethanol  (75e),  using  78e  (2.11  g). 
(1.96  g,  92  %);  white  solid; m.p.  127 128 
°C  (from  EtOAc);  FTIR  (neat 
solid) 3188, 3050, 1578, 1459, 1067 cm
 1; 
1H NMR (CDCl3) δ 8.39 (dd, J = 
5.7, 1.8, 1H, H6'), 8.34 (d, J = 1.8, 1H, H2'), 7.49 (dt, J = 7.8, 1.8, 1H, H4'), 
7.16 7.24 (m, 5H, H2'', H3'', H5'), 4.87 (dd, J = 7.5, 5.7, 1H, H1), 3.05 (dd, 
J = 13.8, 7.5, 1H, H2A), 2.96 (dd, J = 13.8, 5.7, 1H, H2B), 2.85 (bs, 1H, 
OH), 2.38 (s, 3H, 4'' CH3);
  13C NMR (CDCl3) δ 150.6 (C2'), 147.5 (C6'), 
140.7 (q, C1''), 137.5 (q, C4''), 137.3 (C4'), 134.0 (q, C3'), 129.2 (C3''), 
125.9 (C2''), 123.2 (C5'), 74.7 (C1), 42.9 (C2), 21.1 (4'' CH3); Anal. Calcd 
for C14H15NO: C, 78.84; H, 7.12; N, 6.56 %. Found: C, 78.84; H, 7.10; N, 
6.54. 
 
1 (4 Methoxyphenyl) 2 pyridin 3 yl ethanol  (75f),  using  78f  (2.27  g). 
(1.83 g, 80 %); pale yellow solid; m.p. 123 124 
°C (from EtOAc); FTIR 
(neat  solid)  3158,  3028,  1509,  1236,  1028,  824,  712  cm
 1; 
1H  NMR 
(CDCl3) δ 8.31 (dd, J = 4.8, 1.8, 1H, H6'), 8.26 (d, J = 1.8, 1H, H2'), 7.39 
(dt, J  = 7.8, 1.8, 1H, H4), 7.14 (d, J = 8.4, 2H, H2''), 7.11 (dd, J = 8.1, 5.1, 
1H, H5'), 6.78 (d, J = 8.4, 2H, H3''), 4.76 (dd, J = 7.5, 5.7, 1H, H1), 3.72 (s, 
3H, 4'' OCH3), 2.92 (dd, J = 13.8, 7.5, 1H, H2A), 2.87 (dd, J = 13.8, 5.7, 
1H, H2B); 
13C NMR (CDCl3) δ 159.2 (q, C4''), 150.1 (C2'), 147.1 (C6'), 
137.7 (C4'), 135.7 (q, C3'), 134.1 (q, C1''), 127.2 (C2''), 125.3 (C5'), 113.9 
(C3''), 74.5 (C1), 55.3 (4'' OCH3), 42.8 (C2); Anal. Calcd for C14H15NO2: C, 
73.34; H, 6.59; N, 6.11. Found: C, 73.18; H, 6.60; N, 6.07. 
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6.3.11.  Synthesis of compounds 99a,c f 
 
 
 
Compounds 99a,c f were prepared using GP 3. There was obtained: 
 
3 (2 Hydroxy 2 phenylethyl) 1 methylpyridinium  iodide  (99a)  using 
75a (1.00 g). (1.43 g, 84 %); white solid; m.p. 162 
°C (from EtOH); FTIR 
(neat solid) 3343, 3036, 1050, 798, 702, 674 cm
 1; 
1H NMR (DMSO d6) δ 
8.92 (bs, 1H, H2), 8.85 (d, J = 6.1, 1H, H6), 8.39 (d, J = 7.8, 1H, H4), 8.05 
(dd, J = 7.8, 6.1, 1H, H5), 7.41 7.27 (m, 5H, H2'', H3'', H4''), 5.56 (d, J = 
4.5, 1H, OH), 4.89 (m, 1H, H2), 4.34 (s, 3H, 1 CH3), 3.16 (dd, J = 13.5, 
3.6, 1H, H1'A), 3.01 (dd, J = 13.5, 8.7, 1H, H1'B);
 13C NMR (DMSO d6) δ 
146.3 (C4), 146.1 (C2), 145.0 (q, C3), 143.6 (C6), 140.2 (q, C1''), 128.6 
(C3''), 127.7 (C5), 127.3 (C4''), 126.3 (C2''), 72.3 (C1'), 48.3 (1 CH3), 42.2 
(C2'); Anal. Calcd for C14H16INO: C, 49.28; H, 4.73; N, 4.10. Found: C, 
49.34; H, 4.77; N, 4.01. 
 
3 [2 (4 Chlorophenyl) 2 hydroxyethyl] 1 methylpyridinium  iodide 
(99c), using 75c (1.17 g). (1.50 g, 80 %); yellow solid; m.p.152 153 
°C 
(from EtOH); FTIR (neat solid) 3328, 3050, 1603, 1485, 1062, 823 cm
 1; 
1H NMR (DMSO d6) δ 8.95 (s, 1H, H2), 8.86 (d, J = 6.3, 1H, H6), 8.38 (d, J 
= 7.8, 1H, H4), 8.05 (dd, J = 7.8, 6.3, 1H, H5), 7.41 (s, 4H, H2'', H3''), 5.63 Page | 159  
 
(d, J = 4.8, 1H, OH), 4.92 (ddd, J = 8.7, 4.8, 3.6, 1H, H2'), 4.35 (s, 3H, 1 
CH3), 3.11 (dd, J = 13.5, 8.7, 1H, H1'A), 2.99 (dd, J = 13.5, 3.6, 1H, H1'B); 
13C NMR (DMSO d6) δ 146.3 (C4), 146.1 (C2), 143.9 (q, C1''), 143.7 (C6), 
139.9 (q, C3), 132.1 (q, C4''), 128.6 (C3''), 128.2 (C2''), 127.3 (C5), 71.6 
(C2'), 48.3 (1 CH3), 41.9 (C1'); Anal. Calcd for C14H15ClINO: C, 44.77; H, 
4.02; N, 3.73. Found: C, 44.84; H, 4.02, N, 3.66. 
 
3 [2 (4 Bromophenyl) 2 hydroxy ethyl] 1 methylpyridinium  iodide 
(99d), using 75d (1.39 g). (1.68 g, 80 %); yellow solid; m.p. 172 173 
°C 
(from EtOH); FTIR (neat solid) 3319, 3034, 1588, 1481, 1061, 820 cm
 1; 
1H NMR (DMSO d6) δ 8.93 (bs, 1H, H2), 8.86 (d, J = 5.7, 1H, H6), 8.39 (d, 
J = 7.8, 1H, H4), 8.05 (dd, J = 7.8, 5.7, 1H, H5), 7.55 (d, J = 8.4, 2H, H3''), 
7.35 (d, J = 8.4, 2H, H2''), 5.65 (d, J = 3.9, 1H, OH), 4.89 (m, 1H, H1'), 
4.33 (s, 3H, 1 CH3), 3.16 (dd, J = 13.5, 3.6, 1H, H1'A), 2.96 (dd, J = 13.5, 
8.7, 1H, H1'B);
  13C NMR (DMSO d6) δ 146.3 (C4), 146.1 (C2), 144.4 (q, 
C1''),  143.7  (C6),  139.9  (q,  C3),  131.5  (C3''),  128.6  (C2''),  127.3  (C5), 
120.6  (q,  C4''),  71.6  (C2'),  48.3  (1 CH3),  41.9  (C1');  Anal.  Calcd  for 
C14H15BrINO:  C, 40.03; H, 3.60; N, 3.35. Found: C, 39.57; H, 3.57; N, 
3.32. 
 
3 [2 Hydroxy 2 (4 methylphenyl) ethyl] 1 methylpyridinium  iodide 
(99e), using 75e (1.07 g). (1.42 g, 80 %); pale yellow solid; m.p. 172 173 
°C (from EtOH); FTIR (neat solid) 3338, 3053, 1632, 1504, 1062, 819, 677 
cm
 1; 
1H NMR (DMSO d6) δ 8.92 (s, br, 1H, H2), 8.84 (d, J = 6.0, H6), 8.37 
(d, J = 7.8, 1H, H4), 8.04 (dd, J = 7.8, 6.0, 1H, H5), 7.26 (d, J = 7.8, 2H, Page | 160  
 
H2''), 7.16 (d, J = 7.8, 2H, H3''), 4.84 (dd, J = 8.7, 4.2, 1H, H2'), 4.34 (s, 
3H, 1 CH3), 3.25 (s, br, 1H, OH), 3.13 (dd, J = 13.8, 4.2, 1H, H1'A), 2.99 
(dd, J = 13.8, 8.7, 1H, H1'B), 2.30 (s, 3H, 4'' CH3);
 13C NMR (DMSO d6) δ 
146.2 (C4), 146.0 (C2), 143.6 (C6), 142.0 (q, C1''), 140.2 (q, C4''), 136.7 
(q, C3), 129.1 (C3''), 127.3 (C5), 126.2 (C2''), 72.2 (C2'), 48.3 (CH3), 42.2 
(C1'), 21.2 (4'' CH3); Anal. Calcd for C15H18INO: C, 50.72; H, 5.11; N, 3.94. 
Found: C, 50.79; H, 5.11; N, 3.83. 
 
3 [2 Hydroxy 2 (4 methoxyphenyl)ethyl] 1 methylpyridinium  iodide 
(99f), using 75f (1.15 g). (1.74 g, 94 %); yellow solid; m.p. 153 
°C (from 
EtOH); FTIR (neat solid) 3368, 3037, 1608, 1510, 1241, 1054, 678 cm
 1; 
1H NMR (DMSO d6) δ 8.91 (bs, 1H, H2), 8.84 (d, J = 6.0, 1H, H6), 8.36 (d, 
J = 8.1, 1H, H4), 8.04 (dd, J = 8.1, 6.3, 1H, H5), 7.30 (d, J = 8.7, 2H, H2''), 
6.91 (d, J = 8.7, 2H, H3''), 5.45 (d, J = 4.5, OH), 4.84 (ddd, J = 8.7, 4.5, 
4.2, 1H, H2'), 4.34 (s, 3H, 1 CH3), 3.75 (s, 3H, 4'' OCH3), 3.10 (dd, J = 
13.5, 4.2, 1H, H1'A), 3.00 (dd, J = 13.5, 8.7, 1H, H1'B);
 13C NMR (DMSO 
d6) δ 158.9 (q, C4''), 146.2 (C4), 146.0 (C2), 143.6 (C6), 140.2 (q, C1''), 
136.9 (q, C3), 127.5 (C2''), 127.3 (C5), 114.0 (C3''), 71.9 (C2'), 55.6 (4'' 
OCH3), 48.3 (1 CH3), 42.2 (C1'); Anal. Calcd for C15H18INO2: C, 48.53; H, 
4.89; N, 3.77. Found: C, 48.52; H, 4.85; N, 3.78. 
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6.3.12  Synthesis of compounds 101a e 
 
 
 
Compounds 101a e were prepared using GP 1. There was obtained: 
 
1 Phenyl 3 pyridin 3 yl propan 1 ol  (101a),  using  (±) 100a  (1.32  g). 
(1.34 g, 63 %); colourless solid; m.p. 74 
°C (from EtOAc / petrol); FTIR 
(neat solid) 3178 (br), 3024, 2907, 1578, 1426, 1059, 714, 700 cm
 1; 
1H 
NMR (CDCl3) δ 8.21 (d, J = 1.8, 1H, H2'), 8.18 (dd, J = 4.8, 1.8, 1H, H6'), 
7.37 (dt, J = 7.8, 1.8, 1H, H4'), 7.25 7.14 (m, 5H, H2'', H3'', H4''), 7.05 (dd, 
J = 4.8, 1.8, 1H, H5), 4.54 (dd, J = 8.1, 5.4, 1H, H1), 4.05 (s, br, OH), 2.57 
2.68 (m, 2H, H3A, H3B), 2.09 1.88 (m, 2H, H2);
13C NMR (CDCl3) δ 149.6 
(C2'), 146.9 (C6'), 144.9 (q, C1''), 137.4 (q, C3'), 136.0 (C4'), 128.4 (C3''), 
127.4  (C4''),  125.9  (C2''),  123.3  (C5'),  73.0  (C1),  40.2  (C2),  29.2  (C3); 
Anal. Calcd for C14H15NO: C, 78.85; H, 7.13; N, 6.45. Found: C, 78.84; H, 
7.09; N, 6.57. 
 
1 (4 Fluorophenyl) 3 pyridin 3 ylpropan 1 ol  (101b).  Using  (±) 100b  ( 
1.52 g) (0.95 g, 41 %); colourless oil; FTIR (neat) 3188 (br), 2924, 2863, 
1603, 1508, 1424, 1219, 1069, 836, 712 cm
 1; 
1H NMR (DMSO d6) δ 8.35 
(d, J = 1.5, 1H, H2'), 8.32 (dd, J = 4.5, 1.5, 1H, H6'), 7.54 (dt, J = 7.8, 1.5, 
1H, H4'), 7.31 (dd, J = 9.0, 5.7,2H, H2''), 7.22 (dd, J = 7.8, 4.8, 1H, H5'), Page | 162  
 
7.07 (t, J = 9.0, 2H, H3''), 5.28 (d, J = 4.5, 1H, OH), 4.48 (td, J = 6.3, 4.5, 
1H, H1), 2.63 (dd, J = 14.1, 7.8, 1H, H3A), 2.53 (dd, J =14.1, 7.8, 1H, H3B), 
1.86 1.79 (m, 2H, H2);
 13C NMR (DMSO d6) δ 161.6 (q, JC F = 242, C4''), 
150.0 (C2'), 147.5 (C6'), 142.6 (q, JC F = 3, C1''), 137.8 (q, C3'), 136.2 
(C4'), 128.1 (JC F = 8, C2''), 123.9 (C5'), 115.1 (JC F = 21, C3''), 71.4 (C1), 
41.0  (C2),  29.1  (C3).  HRMS  calcd  for  C14H14FNO  (M  +  H)
+  required 
232.1138, found 232.1139. 
 
1 (4 Chlorophenyl) 3 pyridin 3 ylpropan 1 ol  (101c),  using  (±) 100c 
(1.70 g). (1.02 g, 41 %); pale yellow solid; m.p. 54 55 
°C (from EtOAc / 
petrol); FTIR (neat solid) 3181 (br), 2916, 1482, 1421, 1070, 1016, 826, 
813, 707 cm
 1; 
1H NMR (DMSO d6) δ 8.42 (d, J = 1.5, 1H, H2'), 8.39 (dd, J 
= 4.5, 1.5, 1H, H6'), 7.62 (dt, J = 7.8, 1.5, 1H, H4'), 7.38 (s, 4H, H2'', H3''), 
7.29 (dd, J = 7.8, 4.5, 1H, H5), 5.41 (d, J = 4.8, 1H, OH), 4.56 (td, J = 6.3, 
4.8, 1H, H1), 2.71 (dd, J = 14.1, 7.8, 1H, H3A), 2.60 (dd, J = 14.1, 7.8, 1H, 
H3B), 1.93 1.86 (tt, J = 7.8, 6.3, 2H, H2);
  13C NMR (DMSO d6) δ 150.0 
(C2'), 147.5 (C6'), 145.4 (q, C4''), 137.8 (q, C3'), 136.2 (C4'), 131.6 (q, 
C1''), 128.4 (C2'' or C3''), 128.1 (C2'' or C3''), 123.9 (C5'), 71.3 (C1), 40.8 
(C2), 29.0 (C3); HRMS calcd for C14H14ClNO (M + H)
+ required 248.0843, 
found 248.0844. 
 
1 (4 Bromophenyl) 3 pyridin 3 ylpropan 1 ol  (101d),  using  (±) 100d 
(2.19 g). (1.39 g, 48 %); yellow solid; m.p. 72 
°C (from EtOAc / petrol); 
FTIR (neat solid) 3234 (br), 2959, 2919, 1578, 1480, 1427, 1068, 1010, 
821, 810, 712 cm
 1; 
1H NMR (DMSO d6) δ 8.43 (d, J = 1.5, 1H, H2'), 8.39 Page | 163  
 
(d, J = 4.8, 1.5, 1H, H6'), 7.62 (dt, J = 7.8, 1.5, 1H, H4'), 7.52 (d, J = 8.4, 
2H, H3''), 7.32 (d, J = 8.4, 2H, H2''),  7.29 (dd, J = 7.8, 4.8, 1H, H5'), 5.42 
(d, J = 4.5, 1H, OH), 4.55 (td, J = 6.0, 4.5, 1H, H1), 2.71 (dd, J = 14.1, 7.8, 
1H, H3A), 2.60 (dd, J = 14.1, 7.8, 1H, H3B), 1.89 (tt, J = 7.8, 6.0, 2H, H2);
 
13C NMR (DMSO d6) δ 150.0 (C2'), 147.5 (C6'), 145.9 (q, C1''), 137.8 (q, 
C3'), 136.2 (C4'), 131.4 (C3''), 128.5 (C2''), 123.9 (C5'), 120.1 (q, C4''), 
71.3 (C1), 40.8 (C2), 29.0 (C3). HRMS calcd for C14H14BrNO (M + H)
+ 
required 292.0338, found 292.0344. 
 
6.3.13.  Synthesis of compounds 110a,c f 
 
 
 
To a stirred solution of LDA (10 mL, 2.0 M, 20 mmol) in dry THF (60 mL) 
maintained  at  0
  °C  under  an  atmosphere  of  argon  was  added  3,5 
dimethylpyridine 108 (1.07 g, 10 mmol) dropwise over 5 min. The mixture 
was stirred for a further 5 min, followed by dropwise addition over 5 min of 
the  electrophile  97a,c f  (11  mmol)  in  dry  THF  (10  mL).  The  resulting 
solution was stirred at 0 
°C for 1 h then quenched with water (60 mL), the 
phases separated and the aqueous phase extracted using DCM (3 x 20 
mL). The combined organic extracts were dried (MgSO4) and the solvent 
removed under reduced pressure to yield red / brown residues which were Page | 164  
 
subjected to column chromatography (SiO2; EtOAc / petrol, 60 / 40 
v/v) and 
the solids obtained recrystallised. There was obtained: 
 
2 (5 Methylpyridin 3 yl) 1 phenyl ethanone  (110a),  using  97a  (1.13  g) 
(1.90 g, 90 %); pale yellow crystals; m.p. 59 60 
°C (from EtOAc); lit. 54–55 
°C
167; FTIR (neat solid) 3028, 1682, 1596, 1456, 753, 691 cm
 1; 
1H NMR 
(CDCl3) δ 8.38 (d, J = 1.8, 1H, H2''), 8.37 (d, J = 1.8, 1H, H6''), 8.05 (dd, J 
= 7.2, 1.5, 2H, H2'), 7.64 (tt, J = 7.2, 1.5, 1H, H4'), 7.49 (td, J = 7.2, 1.5, 
2H, H3'), 7.45 (t, J = 1.8, 1H, H4''), 4.29 (s, 2H, H2), 2.82 (s, 3H, 5'' CH3);
 
13C NMR (CDCl3) δ 196.6 (q, C1), 148.8 (C2''), 147.7 (C6''), 137.8 (C4''), 
136.3 (q, C1'), 133.4 (C4'), 132.9 (q, C5''), 129.7 (q, C3''), 128.8 (C3'), 
128.4 (C2'), 42.2 (C2), 18.3 (5'' CH3); Anal. Calcd for C12H13NO: C, 79.59; 
H, 6.20; N, 6.63. Found: C, 79.52; H, 6.24; N, 6.60. 
 
1 (4 Chlorophenyl) 2 (5 methylpyridin 3 yl)ethanone (110c), using 97c 
(1.51 g). (1.20 g, 49 %); yellow solid; m.p. 78 79 
°C (from EtOAc); FTIR 
(neat solid) 3024, 1680, 1587, 1488, 824 cm
 1; 
1H NMR (CDCl3) δ 8.27 (d, 
J = 1.8, 1H, H6''), 8.23 (d, J = 1.8, 1H, H2''), 7.86 (d, J = 8.7, 2H, H2'), 7.37 
(d, J = 8.7, 2H, H3'), 7.31 (t, J = 1.8, 1H, H4''), 4.23 (s, 2H, H2), 2.33 (s, 
3H, 5'' CH3); 
13C NMR (CDCl3) δ 195.4 (q, C1), 149.0 (C6''), 147.7 (C2''), 
140.0 (q, C4'), 137.7 (C4''), 134.6 (q, C1'), 133.1 (q, C5''), 129.9 (C2'), 
129.3  (q,  C3''),  129.1  (C3'),  42.2  (C2),  18.3  (5'' CH3);  Anal.  Calcd  for 
C14H12ClNO: C, 68.44; H, 4.92; N, 5.70. Found: C, 68.63; H, 4.98; N, 5.90. 
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1 (4 Bromophenyl) 2 (5 methylpyridin 3 yl)ethanone (110d), using 97d 
(2.00 g). (0.64 g, 22 %); yellow solid; m.p. 74 
°C (from EtOAc); FTIR (neat 
solid) 3085, 1683, 1583, 1483 cm
 1; 
1H NMR (CDCl3) δ 8.26 (d, J = 1.5, 
1H, H6''), 8.22 (d, J = 1.5, 1H, H2''), 7.79 (d, J = 8.7, 2H, H2'), 7.56 (d, J = 
8.7, 2H, H3'), 7.32 (t, J = 1.5, 1H, H4''), 4.14 (s, 2H, H2), 2.24 (s, 3H, 5'' 
CH3);
 13C NMR (CDCl3) δ 195.6 (q, C1), 148.9 (C2''), 147.5 (C6''), 137.8 
(C4''), 135.0 (q, C1'), 133.2 (q, C5''), 132.1 (C3'), 130.4 (q, C3''), 130.0 
(C2'),  129.6  (q,  C4'),  42.2  (C2),  18.3  (5'' CH3);  HRMS  calcd  for 
C14H12BrNO (M + H)
+ required 290.0181, found 290.0190. 
 
2 (5 Methylpyridin 3 yl) 1 (4 methylphenyl)ethanone (110e). using 97e 
(1.29 g). (1.91 g, 85 %); pale yellow solid; m.p. 67 68 
°C (from EtOAc); 
FTIR (neat solid) 3027, 1681, 1604, 811 cm
 1; 
1H NMR (CDCl3) δ 8.34 (bs, 
2H, H2'', H6''), 7.94 (d, J = 8.1, 2H, H2'), 7.48 (bs, 1H, H4''), 7.30 (d, J = 
8.1, 2H, H3'), 4.27 (s, 2H, H2), 2.45 (s, 3H, 5'' CH3), 2.36 (s, 3H, 4' CH3); 
13C NMR (CDCl3) δ 196.2 (q, C1), 148.9 (C6''), 147.7 (C2''), 144.4 (q, C4'), 
137.6 (C4''), 133.9 (q, C1'), 132.9 (q, C5''), 129.8 (q, C3''), 129.5 (C3'), 
128.6  (C2'),  42.1  (C2),  21.7  (4' CH3),  18.3  (5'' CH3);  Anal.  Calcd  for 
C15H15NO: C, 79.97; H, 6.71; N, 6.22. Found: C, 79.85; H, 6.75; N, 6.16. 
 
1 (4 Methoxyphenyl) 2 (5 methylpyridin 3 yl)ethanone  (110f),  using 
97f (1.46 g). (1.57 g, 65 %); pale yellow solid; m.p. 85 86 
°C (from EtOAc); 
FTIR (neat solid) 3071, 1675, 1601, 1508, 831 cm
 1; 
1H NMR (CDCl3) δ 
8.33 (s, 2H, H2'', H6''), 8.00 (d, J = 8.9, 2H, H2'), 7.41 (s, 1H, H4), 6.95 (d, 
J = 8.7, 2H, H3'), 4.20 (s, 2H, H2), 3.87 (s, 3H, 4' OCH3), 2.31 (s, 3H, 5'' Page | 166  
 
CH3); 
13C NMR (CDCl3) δ 195.4 (q, C1), 160.0 (q, C4'), 149.1 (C6''), 147.7 
(C2''), 137.6 (C4''), 136.8 (q, C1'), 134.6 (q, C3''), 133.0 (q, C5''), 129.9 
(C2'), 129.2 (C3'), 55.3 (4’ OCH3), 42.2 (C2), 18.3 (5'' CH3); Anal. Calcd 
for C15H15NO2: C, 74.67; H, 6.27; N, 5.80. Found: C, 74.70; H, 6.30; N, 
5.91. 
 
6.3.1.4.  Synthesis of compounds 111a,c f 
 
 
 
Compounds 111a,c f were prepared using GP 3. There was obtained: 
 
1,3 Dimethyl 5 (2 oxophenylethyl)pyridinium iodide (111a), using 110a 
(1.06 g). (1.48 g, 84 %); pale yellow solid; m.p. 153 154 
°C (from EtOH); 
FTIR (neat solid) 3017, 1684, 1211, 764, 690, 666 cm
 1; 
1H NMR (DMSO 
d6) δ 8.87 (s, 1H, H6), 8.80 (s, 1H, H2), 8.35 (s, 1H, H4), 8.01 (d, J = 7.2, 
2H, H2'), 7.76 (t, J = 7.2, 1H, H4'), 7.60 (t, J = 7.2, 2H, H3'), 4.77 (s, 2H, 
H1''),  4.33  (s,  3H,  1 CH3),  2.50  (s,  3H,  3 CH3);
  13C  NMR  (DMSO d6)  δ 
196.0 (q, C2''), 147.5 (C4), 143.9 (C2 or C6), 143.8 (C2 or C6), 137.9 (q, 
C3), 136.3 (q, C1'), 135.8 (q, C5), 134.4 (C4'), 129.4 (C2'), 128.7 (C3'), 
48.3  (1 CH3),  41.7  (C1''),  18.2  (3 CH3);  Anal.  Calcd  for  C15H16INO:  C, 
51.01; H, 4.57; N, 3.97. Found: C, 50.88; H, 4.54; N, 3.73. Page | 167  
 
3 [2 (4 Chlorophenyl) 2 oxoethyl] 1,5 dimethylpyridinium  iodide 
(111c), using 110c (1.23 g). (1.65 g, 85 %); yellow solid; m.p. 168 169 
°C 
(from EtOH); FTIR (neat solid) 3020, 1694, 1585, 1497, 821 cm
 1; 
1H NMR 
(DMSO d6) δ 8.89 (s, 1H, H6), 8.80 (s, 1H, H2), 8.35 (s, 1H, H4), 8.11 (d, J 
= 6.9, 2H, H2''), 7.69 (d, J = 6.9, 2H, H3''), 4.76 (s, 2H, H1'), 4.34 (s, 3H, 1 
CH3), 2.50 (s, 3H, 5 CH3); 
13C NMR (DMSO d6) δ 195.1 (q, C2'), 147.5 
(C4), 143.9 (C2 or C6), 143.8 (C2 or C6), 139.2 (q, C4''), 138.0 (q, C5), 
135.6 (q, C3), 135.0 (q, C1''), 130.7 (C2''), 129.5 (C3''), 48.3 (1 CH3), 41.7 
(C1'), 18.2 (5'' CH3); Anal. Calcd for C15H15ClINO: C, 46.48; H, 3.90; N, 
3.61. Found: C, 46.26; H, 3.90; N, 3.54. 
 
3 [2 (4 Bromophenyl) 2 oxoethyl] 1,5 dimethylpyridinium  iodide 
(111d), using 110d (1.45 g). (1.47 g, 68 %); yellow solid; m.p. 210 211 
°C 
(from EtOH); FTIR (neat solid) 3027, 1676, 1582, 1488, 1068, 753, 688 
cm
 1; 
1H NMR (DMSO d6) δ 8.87 (s, 1H, H6), 8.79 (s, 1H, H2), 8.34 (s, 1H, 
H4), 8.02 (d, J = 8.7, 2H, H3''), 7.83 (d, J = 8.7, 2H, H2''), 4.75 (s, 2H, H2'), 
4.33 (s, 3H, 1 CH3), 2.50 (s, 3H, 5 CH3);
 13C NMR (DMSO d6) δ 195.3 (q, 
C1'), 147.5 (C4), 143.9 (C2 or C6), 143.8 (C2 or C6), 138.0 (q, C5), 135.6 
(q, C4''), 135.3 (q, C3), 132.5 (C2''), 130.7 (C3''), 128.5 (q, C1''), 48.3 (1 
CH3), 41.7 (C2'), 18.2 (5 CH3); Anal. Calcd for C15H15BrINO: C, 41.70; H, 
3.50; N, 3.24. Found: C, 41.53; N, 3.48; N, 3.15. 
 
1,3 Dimethyl 5 [2 oxo 2 (4 methylphenylethyl]pyridinium  iodide 
(111e), using 110e (1.13 g). (1.62 g, 88 %); pale yellow solid; m.p. 147 
148 
°C (from EtOH); FTIR (neat solid) 3018, 1681, 1606, 816, 677 cm
 1; 
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NMR (DMSO d6) δ 8.87 (s, 1H, H6), 8.80 (s, 1H, H2), 8.35 (s, 1H, H4), 
8.00 (d, J = 8.1, 2H, H2'), 7.42 (d. J = 8.1, 2H, H3'), 4.73 (s, 2H, H1''), 4.34 
(s, 3H, 1 CH3), 2.52 (s, 3H, 3 CH3), 2.43 (s, 3H, 4' CH3);
 13C NMR (DMSO 
d6) δ 195.5 (q, C2'), 147.5 (C4), 144.9 (q, C4''), 143.8 (C2 + C6), 143.8 
(C2),  137.9  (q,  C3),  135.9  (q,  C5),  133.8  (q,  C1''),  129.9  (C3''),  128.9 
(C2''), 48.3 (1 CH3), 41.5 (C1'), 21.7 (4'' CH3), 18.2 (3 CH3); Anal. Calcd 
for C16H18INO: C, 52.33; H, 4.94; N, 3.81. Found: C, 51.86; H, 4.90; N, 
3.85. 
 
3 [2 (4 Methoxyphenyl) 2 oxoethyl] 1,5 dimethylpyridinium  iodide 
(111f), using 110f (1.21 g). (1.80 g, 94 %); yellow solid;  m.p. 217 
°C (from 
EtOH); FTIR (neat solid) 3039, 1679, 1598, 1470, 1170, 844 cm
 1; 
1H NMR 
(DMSO d6) δ 8.86 (s, 1H, H6), 8.79 (s, 1H, H2), 8.34 (s, 1H, H4), 8.08 (d, J 
= 9.0, 2H, H2''), 7.12 (d, J = 9.0, 2H, H3''), 4.69 (s, 2H, H2'), 4.33 (s, 3H, 1 
CH3), 3.88 (s, 3H, 4'' OCH3), 2.50 (s, 3H, 5 CH3); 
13C NMR (DMSO d6) δ 
194.2 (q, C1'), 164.2 (q, C4''), 147.5 (C4), 143.8(C2 + C6), 137.9 (q, C5), 
136.1 (q, C3), 131.1 (C2''), 129.2 (q, C1''), 114.6 (C3''), 56.2 (4'' OCH3), 
48.2 (1 CH3), 41.3 (C2'), 18.2 (5 CH3); Anal. Calcd for C16H18ClINO2: C, 
50.15; H, 4.73; N, 3.65. Found: C, 50.13; H, 4.71; N, 3.52. 
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6.3.15.  Synthesis of compounds 112a e 
 
 
 
Compounds 112a,c f were synthesised using GP 2. There was obtained: 
 
2 (5 Methylpyridin 3 yl) 1 phenylethanol  (112a),  using  111a  (2.11  g). 
(1.98 g, 93 %); white solid; m.p. 117 
°C (from EtOAc); FTIR (neat solid) 
3440 3050, 3029, 1636, 1447, 1063, 698 cm
 1; 
1H NMR (CDCl3) δ 8.21 (d, 
J = 1.5, 1H, H6''), 8.15 (d, J = 1.5, 1H, H2''), 7.38 – 7.31 (m, 6H, H2', H3', 
H4'), 4.90 (d, J = 7.5, 1H, H1), 3.14 (s, br, 1H, OH), 2.99 (d, J = 7.5, 2H, 
H2);
  13C NMR (CDCl3) δ 148.0 (C6''), 147.6 (C2''), 143.9 (q, C1'), 138.0 
(C4''), 133.6 (q, C3''), 132.7 (q, C5''), 128.5 (C3'), 127.7 (C4'), 125.9 (C2'), 
74.8 (C1), 42.9 (C2), 18.3 (5'' CH3); Anal. Calcd for C14H15NO: C, 78.84; 
H, 7.09; N, 6.57. Found: C, 78.65; H, 7.06; N, 6.62. 
 
1 (4 Chlorophenyl) 2 (5 methylpyridin 3 yl)ethanol  (112c),  using  111c 
(2.46 g). (1.78 g, 72 %); yellow solid; m.p. 94 95 
°C (from EtOAc); FTIR 
(neat solid) 3450 3050, 2915, 1567, 1487, 1058, 1012, 836, 710 cm
 1; 
1H 
NMR (CDCl3) δ 8.67 (s, 1H, H6'), 8.60 (s, 1H, H2'), 8.30 (s, 1H, H4'), 7.40 
(bs, 4H, H2'', H3''), 4.88 (dd, J = 8.7, 6.3, 1H, H1), 3.92 (s, br, 1H, OH), 
3.15 (dd, J = 12.8, 6.3, 1H, H2A), 2.97 (dd, J = 12.8, 8.7, 1H, H2B), 2.46 (s, 
3H, 5' CH3);
 13C NMR (CDCl3) δ 147.7 (C4'), 144.2 (q, C1''), 139.6 (C2'), Page | 170  
 
139.3 (C6'), 138.8 (q, C5'), 137.4 (q, C3'), 132.0 (q, C4''), 128.5 (C3''), 
128.2  (C2''),  71.7  (C1),  41.8  (C2),  18.2  (5' CH3);  Anal.  Calcd  for 
C14H14ClNO: C, 67.88; H, 5.70; N, 5.65. Found: C, 67.81; H, 5.84; N, 5.73. 
 
1 (4 Bromophenyl) 2 (5 methylpyridin 3 yl)ethanol (112d), using 111d 
(2.90 g). (2.33 g, 80 %); pale yellow solid; m.p. 113 
°C (from EtOAc); FTIR 
(neat solid) 3260 b, 3074, 1567, 1487, 1058, 1012 cm
 1; 
1H NMR (CDCl3) 
δ 8.16 (bs, 1H, H6'), 8.11 (bs, 1H, H2'), 7.38 (d, J = 7.8, 2H, H3''), 7.19 
(bs, 1H, H4'), 7.10 (d, J = 7.8, 2H, H3''), 4.78 (t, J = 6.6, 1H, H1), 2.92 (s, 
br, 1H, OH), 2.89 (d, J = 6.6, 2H, H2), 2.21 (s, 3H, 5' CH3); 
13C NMR 
(CDCl3) δ 147.2 (C6'), 146.8 (C2'), 142.8 (q, C1''), 138.4 (C4'), 133.5 (q, 
C5'), 131.2 (q, C3'), 131.6 (C3''), 127.6 (C2''), 121.5 (q, C4''), 73.9 (C1), 
42.8 (C2), 18.3 (5' CH3); Anal. Calcd for C14H14BrNO: C, 57.55; H, 4.83; N, 
4.79. Found: 57.28; H, 4.79; N, 4.51. 
 
2 (5 Methylpyridin 3 yl) 1 (4 methylphenyl) ethanol (112e), using 111e 
(2.25 g). (2.16 g, 95 %); white solid; m.p. 107 108 
°C (from EtOAc); FTIR 
(neat solid) 3400 3100, 3028, 1585, 1441, 814 cm
 1; 
1H NMR (CDCl3) δ 
7.97 (s, 1H, H6''), 7.93 (s, 1H, H2''), 7.17 (s, 1H, H4''), 7.14 (d, J = 7.8, 2H, 
H2'), 7.02 (d, J = 7.8, 2H, H3'), 4.69 (dd, J = 7.5, 5.4, 1H, H1), 2.84 (dd, J 
= 12.9, 7.5, 1H, H2A), 2.77 (dd, J = 12.9, 5.4, 1H, H2B), 2.49 (s, br, 1H, 
OH), 2.23 (s, 3H, 4' CH3), 2.12 (s, 3H, 5'' CH3); 
13C NMR (CDCl3) δ 147.6 
(C2'' or C6''), 147.5 (C2'' or C6''), 141.2 (q, C1'), 138.0 (C4''), 137.1 (q, 
C4'), 133.7 (q, C3''), 132.5 (q, C5''), 129.0 (C3'), 125.9 (C2'), 74.4 (C1), Page | 171  
 
42.9  (C2),  21.1  (4' CH3),  18.2  (5'' CH3);  Anal.  Calcd  for  C15H17NO:  C, 
79.26; H, 7.54; 6.16. Found: C, 79.01; H, 7.56; N, 6.11. 
 
1 (4 Methoxyphenyl) 2 (5 methylpyridin 3 yl)ethanol (112f), using 111f 
(2.41 g). (1.90 g, 78 %); pale yellow solid; m.p. 99 100 
°C (from EtOAc); 
FTIR (neat solid) 3260, 3074, 1569, 1487, 1059, 1013, 840 cm
 1; 
1H NMR 
(CDCl3) δ 8.05 (bs, 1H, H6'), 8.03 (bs, 1H, H2'), 7.24 (bs, 1H, H4'), 7.13 (d, 
J = 8.7, 2H, H2''), 6.76 (d, J = 8.7, 2H, H3''), 4.73 (dd, J = 7.5, 5.4, 1H, 
H1), 4.08 (s, br, 1H, OH), 3.70 (s, 3H, 4'' OCH3), 2.88 (dd, J = 12.9, 7.5, 
1H, H2A), 2.82 (dd, J = 12.9, 5.4, 1H, H2B), 2.17 (s, 3H, 5' CH3); 
13C NMR 
(CDCl3) δ 159.1 (q, C4''), 146.7 (C6' and C2'), 138.9 (C4'), 136.0 (q, C1''), 
133.2 (q, C3'), 131.1 (q, C5'), 127.1 (C2''), 113.8 (C3''), 74.2 (C1), 55.3 (4'' 
OCH3), 42.8 (C2), 18.3 (5' CH3); Anal. Calcd for C15H17NO2:  C, 74.05; H, 
7.04; N, 5.76. Found: C, 73.84; H, 7.11; N, 5.71. 
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6.3.16.  Synthesis of compounds 113a,c f 
 
 
 
Compounds 113a,c f were prepared using GP 3. There was obtained: 
 
3 (2 Hydroxy 2 phenylethyl) 1,5 dimethylpyridinium  iodide  (113a), 
using 112a (1.07 g). (1.76 g, 99 %); yellow solid; m.p. 117 118 
°C (from 
EtOH); FTIR (neat solid) 3254, 3039, 1497, 1038, 758, 689 cm
 1; 
1H NMR 
(DMSO d6) δ 8.78 (s, 1H, H6), 8.76 (s, 1H, H2), 8.27 (s, 1H, H4), 7.41 
7.27 (m, 5H, H2'', H3'', H4''), 5.54 (d, J = 4.5, 1H, OH), 4.88 (dd, J = 9.0, 
4.5, 3.8, 1H, H2'), 4.29 (s, 3H, 1 CH3), 3.09 (dd, J = 13.8, 3.9, 1H, H1'A), 
2.95 (dd, J = 13.8, 9.0, 1H, H1'B), 2.50 (s, 3H, 5 CH3);
 13C NMR (DMSO 
d6) δ 146.7 (C4), 145.1 (q, C1''), 143.4 (C2), 143.2 (C6), 139.6 (q, C3), 
137.7 (q, C5), 128.6 (C3''), 127.7 (C4''), 126.2 (C2''), 72.4 (C2'), 48.1 (1 
CH3), 42.2 (C1'), 18.2 (5 CH3); Anal. Calcd for C15H18INO: C, 50.72; H, 
5.11; N, 3.94. Found: C, 50.71; H, 5.30; N, 3.54. 
 
3 [2 (4 Chlorophenyl) 2 hydroxyethyl] 1,5 dimethylpyridinium  iodide 
(113c), using 112c (1.24 g). (1.50 g, 77 %); pale yellow solid; m.p. 139 
140 
°C (from EtOH); FTIR (neat solid) 3314, 2948, 2362, 1488, 1062, 848, 
674 cm
 1; 
1H NMR (DMSO d6) δ 8.79 (s, 1H, H2), 8.77 (s, 1H, H6), 8.29 (s, Page | 173  
 
1H, H4), 7.42 (s, 4H, H2'', H3''), 5.61 (d, J = 4.5, 1H, OH), 4.91 (ddd, J = 
8.7, 4.5, 3.6, 1H, H2'), 4.30 (s, 3H, 1 CH3), 3.11 (dd, J = 13.5, 3.6, 1H, 
H1'A), 2.92 (dd, J = 13.5, 9.0, 1H, H1'B), 2.45 (s, 3H, 5 CH3); 
13C NMR 
(DMSO d6) δ 146.7 (C4), 144.1 (q, C1''), 143.4 (C6), 143.3 (C2), 139.3 (q, 
C5), 137.8 (q, C3), 132.1 (q, C4''), 128.6 (C3''), 128.1 (C2''), 71.7 (C2'), 
48.1 (1 CH3), 41.9 (C1'), 18.2 (5 CH3); Anal. Calcd for C15H17ClINO: C, 
46.24; H, 4.40; N, 3.59. Found: C, 46.22; H, 4.36; N, 3.68. 
 
3 [2 (4 Bromophenyl) 2 hydroxyethyl] 1,5 dimethylpyridinium  iodide 
(113d), using 112d (1.46 g). (1.71 g, 79 %); pale yellow solid; m.p.177 
°C 
(from EtOH); FTIR (neat solid) 3319, 3005, 2363, 1485, 1063, 839, 668, 
579 cm
 1; 
1H NMR (DMSO d6) δ 8.79 (s, 1H, H2), 8.77 (s, 1H, H6), 8.30 (s, 
1H, H4), 7.57 (d, J = 8.1, 2H, H3''), 7.37 (d, J = 8.1, 2H, H2''), 5.63 (d, J = 
4.2, 1H, OH), 4.89 (ddd, J = 9.0, 4.5, 2.7, 1H, H2'), 4.30 (s, 3H, 1 CH3), 
3.11 (dd, J = 13.2, 2.7, 1H, H1'A), 2.95 (dd, J = 13.2, 9.0, 1H, H1'B), 2.51 
(s, 3H, 5 CH3); 
13C NMR (DMSO d6) δ 146.7 (C4), 144.5 (q, C1''), 143.4 
(C6), 143.3 (C2), 139.3 (q, C3), 137.8 (q, C5), 131.5 (C2''), 128.5 (C3''), 
120.6 (q, C4''), 71.7 (C1'), 48.1 (1 CH3), 41.9 (C2'), 18.2 (5 CH3); Anal. 
Calcd for C15H17BrINO: C, 41.50; H, 3.95; N, 3.23. Found: C, 41.46; H, 
3.91; N, 3.20. 
 
3 [2 Hydroxy 2 (4 methylphenyl) ethyl] 1,5 dimethylpyridinium  iodide 
(113e), using 112e (1.14 g). (1.37 g, 74 %); white solid; m.p. 156 
°C (from 
EtOH); FTIR (neat solid) 3327, 3026, 1635, 1506, 1030, 824 cm
 1; 
1H NMR 
(DMSO d6) δ 8.78 (s, 1H, H2), 8.76 (s, 1H, H6), 8.28 (s, 1H, H4), 7.28 (d, J Page | 174  
 
= 7.8, 2H, H2''), 7.16 (d, J = 7.8, 2H, H3''), 5.45 (d, J = 4.5, 1H, OH), 4.84 
(ddd, J = 9.0, 4.5, 3.9, 1H, H2'), 4.30 (s, 3H, 1 CH3), 3.08 (dd, J = 13.8, 
3.9, 1H, H1'A), 2.96 (dd, J = 13.8, 9.0, 1H, H1'B), 2.45 (s, 3H, 5 CH3), 2.30 
(s, 3H, 4'' CH3);
 13C NMR (DMSO d6) δ 146.7 (C4), 143.3 (C6), 143.1 (C2), 
142.1 (q, C1''), 139.7 (q, C3), 137.7 (q, C5), 136.7 (q, C4''), 129.1 (C3''), 
126.2 (C2''), 72.2 (C1'), 48.1 (1 CH3), 42.2 (C2'), 21.2 (4'' CH3), 18.2 (5 
CH3); Anal. Calcd for C16H20INO: C, 52.05; H, 5.46; N, 3.79. Found: C, 
51.97; H, 5.44; N, 3.75. 
 
3 [2 Hydroxy 2 (4 methoxyphenyl)ethyl] 1,5 dimethylpyridinium 
iodide (113f), using 112f (1.22 g). (1.33 g, 69 %); pale yellow solid; m.p. 
178 179 
°C (from EtOH); FTIR (neat solid) 3319, 3035, 1624, 1499, 825 
cm
 1; 
1H NMR (DMSO d6) δ 8.77 (s, 1H, H2), 8.74 (s, 1H, H6), 8.26 (s, 1H, 
H4), 7.31 (d, J = 8.7, 2H, H2''), 6.92 (d, J = 8.7, 2H, H3''), 5.43 (d, J = 4.5, 
1H, OH), 4.82 (ddd, J = 8.7, 4.5, 3.9, 1H, H2'), 4.29 (s, 3H, 1 CH3), 3.75 (s, 
3H, 4'' OCH3), 3.08 (dd, J = 12.5, 3.9, 1H, H1'A), 2.93 (dd, J = 13.5, 8.7, 
1H,  H1'B),  2.45  (s,  3H,  5 CH3);
  13C  NMR  (DMSO d6)  δ  158.9  (q,  C4''), 
146.6 (C4), 143.3 (C6), 143.1 (C2), 139.7 (q, C1''), 137.7 (q, C5), 137.1 (q, 
C3), 127.4 (C2''), 114.0 (C3''), 72.0 (C1'), 55.6 (4'' OCH3), 48.1 (1 CH3), 
42.3 (C2'), 18.2 (5 CH3); Anal. Calcd for C16H20INO2: C, 49.88; H, 5.23; N, 
3.64. Found: C, 49.87; H, 5.22; N, 3.55. 
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6.3.17.  (S,S) or (R,S) Acetoxyphenylacetic acid 2 pyridin 3 yl 1 (4 
methylphenyl)ethyl ester (118). 
 
N
O
CH3
O
O
1''
2''
3''
4''
5''
6''
1
2
1'
2'
3'
3'
4
2'
1''''
2''''
3''''
4''''
3''''
2''''
1'''
2'''
O
CH3
1'''''
2'''''
 
 
To a stirred solution of 2 pyridin 3 yl 1 (4 methylphenyl)ethanol 75c (1.28 
g, 6 mmol) and DMAP (2.20 g, 18 mmol) in dry DCM (35 mL) under an 
atmosphere of argon was added DCC (12.4 g, 60 mmol) and (S) O acetyl 
mandelic  acid  (2.33  g,  12  mmol)  in  DCM  (60  mL)  via  cannula.  The 
resulting white suspension was allowed to warm to room temperature and 
stirred for a further 3 h, after which time the suspended urea was removed 
by  filtration  and  the  filtrate  concentrated  in  vacuo  to  give  a  yellow  oil. 
Subsequent column chromatography (SiO2; ether, 100 %) furnished the 
title compound 118 as a colourless oil (2.00 g, 85 %). Recrystallisation 
from EtOAc / petrol gave a single diastereomer as a white solid; de > 98 
%; m.p. 76 – 77 
°C; FTIR (neat solid) 3028, 1748, 1203, 1218, 1168, 1050, 
808, 746, 711, 698 cm
 1;
  1H NMR (CDCl3) δ 8.42 (dd, J = 4.8, 1.5, 1H, 
H6''), 8.16 (d, J = 1.5, 1H, H2''), 7.44 7.39 (m, 5H, H2'''', H3'''', H4''''), 7.17 
(bs, 4H, H2', H3'), 7.14 (dt, J = 7.8, 1.5, 1H, H4''), 7.02 (dd, J = 7.8, 4.8, 
1H, H5''), 5.98 (dd, J = 7.8, 5.4, 1H, H1), 5.98 (s, 1H, H2'''), 3.09 (dd, J = 
14.1, 7.8, 1H, H2A), 3.02 (dd, J = 14.1, 5.4, 1H, H2B), 2.37 (s, 3H, 4' CH3), Page | 176  
 
2.18 (s, 3H, H2'''''); 
13C NMR (CDCl3) δ 170.1 (q, C1'''''), 167.9 (q, C1'''), 
149.9 (C2''), 147.3 (C6''), 138.2 (q, C4'), 137.3 (C4''),  135.5 (q, C1''''), 
133.8 (q, C1'), 132.3 (q, C3''), 129.3 (C3'), 128.9 (C2'''' or C3''''), 128.8 
(C2'''' or C3''''), 127.7 (C4'''' and C3''''), 126.2 (C2'), 123.2 (C5''), 77.1 (C1), 
74.4  (C2'''),  39.7  (C2),  21.2  (4' CH3),  20.7  (C2''''').  Anal.  Calcd  for 
C23H23NO4: C, 73.19; H, 61.4; N, 3.71. Found: C, 73.13; H, 6.01; N, 3.59. 
 
de  >  98 %;  Colourless  oil;  FTIR  (neat) 3026,  1751,  1202, 1218,  1168, 
1048, 808, 745, 711, 698 cm
 1;
 1H NMR (CDCl3) δ 8.28 (bs, 1H, H6''), 8.04 
(bs, 1H, H2''), 7.27 7.23 (m, ^H, H2'''', H3'''', H4'''', H4''), 6.88 (d, J = 8.1, 
2H, H2'), 6.86 (J = 7.8, 4.8, H, H5''), 6.69 (d, J = 8.1, 2H, H3'), 5.86 (s, 1H, 
H2''), 5.83 (dd, J = 7.8, 5.4, 1H, H1), 2.97 (dd, J = 14.1, 7.8, 1H, H2A), 2.90 
(dd, J = 14.1, 5.4, 1H, H2B), 2.19 (s, 3H, 4' CH3), 2.05 (s, 3H, H2'''''); 
13C 
NMR (CDCl3) δ 170.2 (q, C1'''''), 167.8 (q, C1'''), 150.9 (C2''), 148.1 (C6''), 
138.2 (q, C4'), 137.0 (C4''), 135.3 (q, C1''''), 133.5 (q, C1'), 131.9 (q, C3''), 
129.2  (C3'),  128.9  (C2''''  or  C3''''),  128.7  (C2''''  or  C3''''),  127.8  (C4''''), 
126.0 (C2'), 123.0 (C5''), 77.3 (C1), 75.5 (C2'''), 39.9 (C2), 21.1 (4' CH3), 
20.7  (C2''''');  HRMS  calcd  for  C24H23NO4  (M  +  H)
+  required  390.1706, 
found 390.1707. 
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6.3.18.  2 Pyridin 3 yl 1 (4 methylphenyl)ethanol (R) or (S) 75e. 
 
 
 
 
A solution of KOH (88 mg, 1.6 mmol) and compound 118 (0.24 g, 0.6 
mmol)  in  MeOH  (3  mL)  was  stirred  at  room  temperature  overnight. 
Filtration and removal of the solvent in vacuo, followed by recrystallisation 
from EtOAc furnished single enantiomers of the product 75c as a white 
solids (0.13 g, 98 %); m.p. 105  106 
°C (EtOAc); [α]
24 =
  + 16.2° (c = 0.34, 
CHCl3); (0.12 g, 87 %); m.p. 103 
°C (EtOAc); [α]
22 =
    14.8° (c = 0.19, 
CHCl3);
 1H NMR (CDCl3) δ 8.43 (bs, 1H, H2'), 8.40 (bs, 1H, H6'), 7.66 (dt, 
J = 7.8, 1.8, 1H, H4'), 7.34 (dd, J = 7.8, 5.1, 1H, H5'), 7.24 (d, J = 8.1, 2H, 
H2''), 7.15 (d, J = 8.1, 2H, H3''), 5.36 (bs, 1H, OH), 4.79 (t, J = 6.6, 1H, 
H1), 2.96 (bs, 1H, H2A), 2.94 (d, J = 1.5, 1H, H2B), 2.32 (s, 3H, 4'' CH3);
 
13C NMR (CDCl3) δ 150.5 (C2'), 147.1 (C6'), 142.7 (q, C3'), 138.0 (C4'), 
136.3 (q, C4''), 135.2 (q, C1''), 128.9 (C3''), 126.4 (C2''), 123.7 (C5'), 73.3 
(C1), 42.9 (C2), 21.2 (4'' CH3).  
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6.4 Synthetic Work, Chapter 3 
Procedure for Halogen Lithium Exchange of 3 Bromopyridine 
Synthesis of 75a e  
 
 
 
A solution of 3 bromopyridine 120 (1.58 g, 10 mmol) in dry ether (60 mL) 
was cooled to  100 
oC followed by the dropwise addition of n BuLi (4.4 mL, 
2.5M,  11  mmol)  in  ether  (10  mL)  over  15 20  min.  The  resulting  bright 
yellow solution was stirred at  100 
oC for a further 30 min. and a solution of 
100a (1.32 g, 11 mmol), 100b (1.52 g, 11 mmol), 100c (1.70 g, 11 mmol) 
or 100d (2.19 g, 11 mmol) in ether (15 mL) added dropwise over 10 min. 
The reaction mixture was stirred at  100 
oC for 30 min., allowed to warm to 
room temperature for a further 1h and poured into water (80 mL). The 
phases were separated and the aqueous phase extracted with EtOAc (3 x 
30 mL). The combined organic phases were washed with brine (40 mL), 
dried (MgSO4) and concentrated in vacuo. Purification of the residue by 
column  chromatography  (SiO2;  EtOAc  /  petrol,  90  /  10 
v/v)  and 
recrystallisation from EtOAc gave 75a e. There was obtained compounds 
78a (1.22 g, 61 %), 78b (1.11 g, 51 %), 78c (1.26 g, 54 %) and 78d (0.86 
g, 31 %). Analytical data were identical to those described in 6.4.1. 
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Synthesis of 78a d by oxidation of 75a d 
 
 
 
To a suspension of PCC (1.62 g, 7.5 mmol), in DCM (50 mL) was added 
75a (0.99 g, 5 mmol), 75b (1.08 g, 5 mmol) 75c (1.16 g, 5 mmol) or 75d 
(1.38 g, 5 mmol) and the resulting mixture stirred at room temperature for 
2h.  whereupon 10  %  aqueous  NaOH  solution  was  added  (15 mL),  the 
phases separated and the aqueous phase extracted with DCM (2 x 20 
mL).  The  combined  organic  extracts  were  washed  with  brine  (30  mL), 
dried (MgSO4) and the solvent removed under reduced pressure. Column 
chromatography of the resulting residues (SiO2; EtOAc / petrol, 90 / 10 
v/v) 
gave compounds 78a d. 78a (0.81 g, 82 %), 78b (0.80 g, 74 %), 78d (0.96 
g, 83 %) and 78e (0.97, 70 %). Analytical data were identical to those 
described in 6.3.8. 
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Synthesis of 146c and 146d 
 
 
 
Bromine (5.3 mL, 104 mmol.) was added dropwise to a stirred solution of 
145c (11.1 g, 80 mmol) or 145c (14.6 g, 80 mmol) in chloroform (150 mL) 
at  room  temperature.  The  resulting  mixture  was  stirred  at  room 
temperature  overnight.  A  5  %  aq.  sodium  metabisulphite  solution  was 
added  until  the  bromine  colour  had  dissipated.  The  phases  were 
separated and the aqueous phase extracted with DCM (3 x 60 mL) and 
the  combined  organic  extracts  dried  (MgSO4),  filtered,  concentrated  in 
vacuo  and  the  resulting  solids  recrystallised  from  EtOAc  /.  petrol. 
Analytical data were identical to literature reports.
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Synthesis of 147c and 147d 
 
 
146c (14.9 g, 50 mmol) or 146d (17.3 g, 50 mmol) and KOH (16.8 g, 300 
mmol) were placed in a flask containing MeOH (300 mL) and the mixture 
heated  at  reflux  for  12h.  The  mixture  was  concentrated  under  reduced 
pressure  at  room  temperature,  the  resulting  residue  dissolved  in  water Page | 181  
 
(150 mL) and extracted using DCM (3 x 30 mL). The combined organic 
extracts  were  dried  (MgSO4)  and  the  volatiles  removed  which  were 
recrystallised from 40/60 petrol. Analytical data were identical to literature 
reports.
232 
 
6.4.1 Preparation of alkynes 144a,c f 
 
 
To a stirred solution of 3 bromopyridine 120 (2.93 mL, 30 mmol) in dry 
THF under an atmosphere of N2 was sequentially added one of terminal 
alkyne 147a (3.22 g, 31.5 mmol), 147c (4.30 g, 31.5 mmol), 147d (5.70 g, 
31.5  mmol),  147e  (3.66  g,  31.5  mmol)  or  147f  (4.16  g,  31.5  mmol), 
bis(triphenylphosphine) palladium (II) chloride (1.05 g, 1.5 mmol, 5 mol.%), 
triethylamine (6.27 mL, 45 mmol), and copper iodide (0.11 g, 0.6 mmol, 2 
mol.%)  The resulting solution was stirred at reflux overnight. After cooling, 
the  solvent  was  evaporated  to  give  a  brown  residue  which  was 
chromatographed (SiO2; petrol : ether, 70 : 30 
v/v) and the solid obtained 
recrystallised to yield the products. There was obtained: 
 
3 Phenylethynylpyridine (147a). (3.86 g, 72 %); pale yellow solid; m.p. 
49 
°C (from petrol / EtOAc); lit. 50 51 
oC;
222 FTIR (neat solid) 3027, 2210, 
1597, 1488, 1421, 890, 754, 689 cm
 1; 
1H NMR (CDCl3) δ 8.78 (s, 1H, H2), Page | 182  
 
8.55 (dd, J = 5.1, 1.8, 1H, H6), 7.80 (dt, J = 7.8, 1.8, 1H, H4), 7.58 7.54 
(m, 2H, H2''), 7.38 – 7.36 (m, 3H, H4'', H3''), 7.27 (dd, J = 7.8, 5.1, 1H, 
H5); 
13C NMR (CDCl3) δ 152.7 (C2), 149.0 (C6), 138.8 (C4), 132.1 (C2''), 
129.2 (C4''), 128.8 (C3''), 123.4 (C5), 123.0 (q, C1''), 120.9 (q, C3), 93.1 
(q, C2'), 86.4 (q, C1'); Anal. Calcd for C13H9N: C, 87.12; H, 5.06; N, 7.81. 
Found: C, 86.62; H, 5.01; N, 7.75. 
 
3 (4 Chlorophenylethynyl)pyridine (147c). (2.62 g, 41 %); pale yellow 
solid; m.p. 87 
°C (from petrol / EtOAc); FTIR (neat solid) 3026, 2219, 1488, 
1089, 824 cm
 1; 
1H NMR (CDCl3) δ 8.70 (bs, 1H, H2), 8.50 (dd, J = 4.8, 
1.2, 1H, H6), 7.74 (dt, J = 7.8, 1.8, 1H, H4), 7.40 (d, J = 8.4, 2H, H3''), 7.26 
(d, J = 8.4, 2H, H2''), 7.23 (dd, J = 7.8, 4.8, 1H, H5); 
13C NMR (CDCl3) δ 
152.5 (C2), 149.0 (C6), 138.9 (C4), 133.3 (q, C4''), 132.9 (C2''), 128.9 (q, 
C1''), 128.9 (C3''), 123.5 (C5), 121.0 (q, C3), 91.6 (q, C2'), 86.8 (q, C1'); 
Anal. Calcd for C13H8ClN: C, 73.08; H, 3.77; N, 6.56. Found: C, 73.01; H, 
3.88; N, 6.48. 
 
3 (4 Bromophenylethynyl)pyridine (147d). (1.55 g, 20 %); cream solid; 
m.p.  97 
°C  (from  petrol  /  EtOAc);  FTIR  (neat  solid)  2926,  2217,  1484, 
1405, 1186, 1069, 1008, 818, 804, 700 cm
 1; 
1H NMR (CDCl3) δ 8.69 (d, J 
= 1.5, 1H, H2), 8.50 (dd, J = 5.1, 1.5, 1H, H6), 7.77 (dt, J = 7.8, 1.5, 1H, 
H4), 7.43 (d, J = 8.4, 2H, H3''), 7.33 (d, J = 8.4, 2H, H2''), 7.25 (dd, J = 7.8, 
5.1,  1H,  H5); 
13C  NMR  (CDCl3)  δ  151.6  (C2),  148.1  (C6),  139.0  (C4), 
133.1 (C2''), 131.8 (C3''), 128.6 (q, C4''), 123.3 (C5), 121.4 (q, C1''), 120.5 Page | 183  
 
(q, C3), 92.0 (q, C2'), 86,8 (q, C1'). Anal. Calcd for C13H8BrN: C, 60.49; H, 
3.12; N, 5.43. Found: C, 60.35; H, 3.16; N, 5.34. 
 
3 (4 Methylphenylethynyl)pyridine (147e). (5.50 g, 95 %); white or pale 
yellow solid; m.p. 90 
°C (from petrol / EtOAc); lit. 87 88 
°C;
191a FTIR (neat 
solid) 3018, 2219, 1573, 1508, 1400, 1011, 879, 821, 692 cm
 1; 
1H NMR 
(CDCl3) δ 8.68 (bs, 1H, H2), 8.46 (dd, J = 5.1, 1.5, 1H, H6), 7.71 (dt, J = 
7.8, 1.5, 1H, H4), 7.38 (d, J = 8.1, 2H, H2''), 7.20 (dd, J = 7.8, 5.1, 1H, H5), 
7.10 (d, J = 8.1, 2H, H3''), 2.31 (s, 3H, 4'' CH3); 
13C NMR (CDCl3) δ 152.6 
(C2),  148.8  (C6), 139.4  (q,  C4''),  138.7  (C4),  132.0  (C2''),  129.6  (C3''), 
123.4 (C5), 119.9 (q, C3), 119.9 (q, C1''), 93.3 (q, C2'), 85.7 (q, C1'), 21.9 
(4'' CH3); Anal. Calcd for C14H11N: C, 87.01; H, 5.74; N, 7.24. Found: C, 
86.26; H, 5.75; N, 7.05.  
 
3 (4 Methoxyphenylethynyl)pyridine (147f). (3.95 g, 63 %); pale yellow 
solid; m.p. 53 
°C (from petrol / EtOAc); lit 46 – 48 
°C;
192 FTIR (neat solid) 
3046, 2217, 1602, 1506, 1244, 1020 cm
 1; 
1H NMR (CDCl3) δ 8.69 (bs, 
1H, H2), 8.47 (dd, J = 5.1, 1.8, 1H, H6), 7.72 (dt, J = 8.1, 1.8, 1H, H4), 
7.40 (d, J = 9.0, 2H, H2''), 7.24 (dd, J = 7.8, 5.1, 1H, H5), 6.82 (d, J = 9.0, 
2H, H3''), 3.77 (s, 3H, 4'' CH3); 
13C NMR (CDCl3) δ 160.1 (q, C4''), 151.9 
(C2), 147.9 (C6), 138.6 (C4), 133.3 (C2''), 123.2 (C5), 121.2 (q, C3), 114.5 
(q, C1''), 114.2 (C3''), 93.1 (q, C2'), 84.5 (q, C1'), 55.4 (4'' OCH3); Anal. 
Calcd for C14H11NO: C, 80.36; H, 5.30; N, 6.69.  Found: C, 80.37; H, 5.36; 
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6.4.2.  Alternate procedure for the synthesis of 3 (4 
bromophenylethynyl)pyridine (147d). 
 
3 [(Triethylsilyl)ethynyl]pyridine  148  (3.4  mL,  18  mmol)  was  added  to  a 
stirred solution of bis(triphenylphosphine) palladium (II) chloride (0.63 g, 
0.9  mmol,  5  mol.%),  copper  iodide  (69  mg,  0.36  mmol,  2  mol.%), 
potassium carbonate (7.46 g, 54 mmol) and 1 bromo 4 iodobenzene (4.2 
g, 15 mmol) in DMF (30 mL) and the mixture stirred at room temperature 
for 12 h. The mixture was then poured into H2O (100 mL) and extracted 
into  ether  (4  x  20  mL).  The  combined  organic  extracts  were  dried 
(MgSO4), the solvent removed under reduced pressure and the residue 
purified by column chromatography (SiO2;  petrol : ether, 70 : 30 
v/v) to 
furnish the title product as a yellow solid (2.56 g, 54 %). Analytical data 
were identical to those described in Section 6.4.1. 
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6.4.4.  Alternate  synthesis  of  compounds  78a,c f  (from  compounds 
147a,c f) 
 
 
 
Compounds 78a,c f were synthesised using GP 4. There was obtained: 
78a using 147a (1.79 g, 10 mmol). (1.52 g, 77 %); 78c using 147c (2.14 g, 
10 mmol). (1.64 g, 71 %); 78d using 147d (2.58 g, 10 mmol).(2.04 g, 74 
%); 78e using 147e (1.93 g, 10 mmol). (1.39 g, 66 %); 78f using (2.09 g, 
10 mmol). (1.57 g, 69 %). 
 
6.4.5.  Preparation of compounds 149a,c f 
 
 
 
Compounds 149a,c f were prepared using GP 3. There was obtained: 
 
1 Methyl 3 phenylethynyl  pyridinium  iodide  (149a),  using  147a  (0.90 
g). (1.37 g, 85 %); yellow solid; m.p. 172 
°C (from EtOH); FTIR (neat solid) Page | 186  
 
3072, 2223, 1504, 756, 670 cm
 1; 
1H NMR (DMSO d6) δ 9.38 (s, 1H, H2), 
9.00 (d, J = 6.0, 1H, H6), 8.72 (d, J = 8.1, 1H, H4), 8.18 (dd, J = 8.1, 6.0, 
1H, H5), 7.68 7.65 (m, 2H, H2''), 7.54 7.51 (m, 3H, H3'', H4''), 4.37 (s, 3H, 
1 CH3); 
13C NMR (DMSO d6) δ 148.2 (C2), 146.8 (C4), 145.3 (C6), 132.3 
(C2''), 130.8 (C4''), 129.6 (C3''), 128.1 (C5), 123.1 (q, C3), 120.8 (q, C1''), 
95.5  (q,  C2'),  83.1  (q,  C1'),  48.7  (1 CH3);  Anal.  Calcd  for  C14H12IN:  C, 
52.36; H, 3.77; N, 4.36. Found: C, 52.30; H, 3.69; N, 4.33. 
 
3 (4 Chlorophenylethynyl) 1 methylpyridinium  iodide  (149c),  using 
147c (1.07 g). (1.53 g, 86 %); pale yellow crystals; m.p. 189 190 
°C (from 
EtOH); FTIR (neat solid) 3064, 3052, 2220, 1503, 1086, 1008, 830, 819, 
721, 670 cm
 1; 
1H NMR (DMSO d6) δ 9.38 (s, 1H, H2), 9.01 (d, J = 6.3, 1H, 
H6), 8.74 (d, J = 8.1, 1H, H4), 8.19 (dd, J = 8.1, 6.3, 1H, H5), 7.70 (d, J = 
8.7, 2H, H2''), 7.60 (d, J = 8.7, 2H, H3''), 4.37 (s, 3H, 1 CH3); 
13C NMR 
(DMSO d6) δ 148.3 (C2), 146.9 (C4), 145.5 (C6), 135.7 (q, C4''), 134.0 
(C2''), 129.8 (C3''), 128.2 (C5), 122.9 (q, C3), 119.7 (q, C1''), 95.2 (q, C2'), 
84.0 (q, C1'), 48.7 (1 CH3); Anal. Calcd for C14H11ClIN: C, 47.29; H, 3.12; 
N, 3.94. Found: C, 47.23; H, 3.10; N, 3.75.    
 
3 (4 Bromophenylethynyl) 1 methyl pyridinium  iodide  (149d),  using 
147d (1.29 g). (1.94 g, 97 %); yellow solid; m.p. 193 194 
°C (from EtOH); 
FTIR (neat solid) 3069, 2219, 1573, 1501, 1064, 1006, 826, 819, 713, 670 
cm
 1;
  1H NMR (DMSO d6) δ 9.40 (s, 1H, H2), 9.02 (d, J = 5.7, 1H, H6), 
8.75 (d, J = 7.8, 1H, H4), 8.20 (dd, J = 7.8, 5.7, 1H, H5), 7.74 (d, J = 8.4, 
2H, H3''), 7.62 (d, J = 8.4, 2H, H2''), 4.38 (s, 3H, 1 CH3); 
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d6) δ 148.3 (C2), 146.9 (C4), 145.5 (C6), 134.2 (C2''), 132.7 (C3''), 128.2 
(C5), 124.5 (q, C4''), 122.9 (q, C3), 120.1 (q, C1''), 95.3 (q, C2'), 84.2 (q, 
C1'), 48.7 (1 CH3); Anal. Calcd for C14H11BrNI: C, 42.03; H, 2.77; N, 3.50. 
Found: 41.95; H, 2.77; N, 3.42. 
 
1 Methyl 3 (4 methylphenyl)ethynylpyridinium  iodide  (149e),  using 
147e (0.97 g). (1.29 g, 77 %); pale yellow solid; m.p. 217 
°C (from EtOH); 
FTIR  (neat  solid)  3030,  2929,  2216,  1514,  810,  667  cm
 1; 
1H  NMR 
(DMSO d6) δ 9.35 (s, 1H, H2), 8.99 (d, J = 6.0, 1H, H6), 8.70 (d, J = 8.4, 
1H, H4), 8.17 (dd, J = 8.4, 6.1, 1H, H5), 7.54 (d, J = 8.1, 2H, H2''), 7.32 (d, 
J = 8.1, 2H, H3''), 4.37 (s, 3H, 1 CH3), 2.37 (s, 3H, 4'' CH3);
  13C NMR 
(DMSO d6) δ 148.1 (C2), 146.7 (C4), 145.1 (C6), 140.9 (q, C4''), 132.2 
(C2''), 130.2 (C3''), 128.1 (C5), 123.3 (q, C3), 117.8 (q, C1''), 96.9 (q, C2'), 
82.6 (q, C1'), 48.7 (1 CH3), 21.7 (s, 3H, 4'' CH3); Anal. Calcd for C15H14IN: 
C, 53.75; H, 4.21; N, 4.18. Found: C, 53.70; H, 4.20; N, 4.11. 
 
3 (4 Methoxyphenylethynyl) 1 methylpyridinium  iodide  (149f),  using 
147f (1.05 g). (1.26 g, 72 %); yellow solid; m.p. 222 223 
°C (from EtOH); 
FTIR  (neat  solid)  3003,  2215,  1581,  1513,  818,  665  cm
 1; 
1H  NMR 
(DMSO d6) δ 9.32 (s, 1H, H2), 8.95 (d, J = 6.0, 1H, H6), 8.67 (d, J = 8.1, 
1H, H4), 8.15 (dd, J = 8.1, 6.3, 1H, H5), 7.60 (d, J = 8.7, 2H, H2''), 7.07 (d, 
J = 8.7, 2H, H3''), 4.35 (s, 3H, 1 CH3), 3.83 (s, 3H, 4'' OCH3); 
13C NMR 
(DMSO d6) δ 161.2 (q, C4''), 147.9 (C2), 146.5 (C4), 144.8 (C6), 134.1 
(C2''), 128.1 (C5), 123.6 (q, C3), 112.6 (q, C1''), 115.3 (C3''), 97.2 (q, C2'), Page | 188  
 
82.1 (q, C1'), 56.0 (4'' OCH3), 48.6 (1 CH3); Anal. calcd for C15H14NOI: C, 
51.30; H, 4.02;  N, 3.99. Found: C, 51.31; H, 4.02; N, 4.01. 
 
6.4.6.  Synthesis of compounds 159a e 
 
 
 
Styrene 145a (2.60 g, 25 mmol), 145b (3.05 g, 25 mmol), 145c (3.46 g, 25 
mmol), or 145d (2.95 g, 25 mmol), 3 bromopyridine (1.95 mL, 20 mmol), 
palladium  (II)  acetate  (44  mg,  0.2  mmol,  1  mol.%),  triphenylphosphine 
(0.10 g, 0.4 mmol, 2 mol.%) and triethylamine (4.18 mL, 30 mmol) were 
dissolved in dry THF (60 mL) and the mixture stirred overnight under N2 at 
reflux. After cooling, ether (60 mL) was added and the solution washed 
with water (2 x 200 mL). The organic phases were dried (MgSO4) and the 
solvent removed under vacuum to yield brown / yellow solids which were 
purified  by  chromatography  (SiO2;  EtOAc  /  petrol,  60  :  40 
v/v)  and 
subsequent recrystallisation. There was obtained: 
 
3 [(E) Phenylvinyl]pyridine  (159a).  (2.54    g,  70  %);  pale  yellow  solid; 
m.p. 81 82 
°C (from petrol / EtOAc); lit. 80 
°C;
223 FTIR (neat solid) 3024, 
1564, 1492, 1448, 1409, 1022, 963, 800, 752 cm
 1; 
1H NMR (CDCl3) δ 
8.78 (s, 1H, H2), 8.54 (d, J = 3.9, 1H, H6), 7.89 (d, J = 7.8, 1H, H4). 7.58 
(d, J = 7.2, 2H, H2''), 7.43 (t, J = 7.2, 2H, H3''), 7.37 7.34 (m, 2H, H5, H4''), 
7.21 (d, J = 16.2, 1H, H2'), 7.10 (d, J = 16.2, 1H, H1'); 
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148.2 (C2 and C6), 136.6 (q, C1''), 133.2 (q, C3), 133.0 (C4), 131.1 (C2'), 
128.8 (C3''), 128.3 (C4''), 126.7 (C2''), 124.8 (C1'), 123.7 (C5); Anal. Calcd 
for C13H11N: C, 86.15; H, 6.12; N, 7.22. Found: C, 86.21; H, 6.10; N, 7.70. 
 
3 [(E) 2 (4 Fluorophenyl)vinyl]pyridine  (159b).  (2.19  g,  55  %);  palye 
yellow solid; m.p. 59 60 
°C (from petrol / EtOAc); FTIR (neat solid) 3023, 
1595, 1507, 1411, 1227, 1214, 1157, 965, 823, 701 cm
 1; 
1H NMR (CDCl3) 
δ 8.63 (s, 1H, H2), 8.41 (bd, J = 3.9, 1H, H6), 7.73 (dt, J = 8.1, 1.5, 1H, 
H4), 7.41 (dd, J = 8.4, 5.1, 2H, H2''), 7.20 (dd, J = 8.1, 3.9, 1H, H5), 7.03 
(d, J = 16.2, 1H, H1'), 6.98 (dt, J = 6.6, 2H, H3''), 6.89 (d, J = 16.2, 1H, 
H2');
 13C NMR (CDCl3) δ 162.8 (d, J = 249, C4''), 148.3 (C2), 148.2 (C2), 
133.0 (q, C1''), 132.9 (C4), 132.8 (q, C3), 129.8 (C1'), 128.3 (d, J = 8, 
C2''),  124.6  (C2'),  123.7  (C5),  115.8  (d,  J  =  22,  C3'');  Anal.  Calcd  for 
C13H10FN: C, 78.37; H, 5.06; N, 7.03. Found: C, 78.39; H, 5.07; N, 6.95. 
 
3 [(E) 2 (4 Chlorophenyl)vinyl]pyridine  (159c).  (2.81  g,  65  %);  yellow 
solid; m.p. 84 85 
°C (from petrol / EtOAc); FTIR (neat solid) 3120, 1567, 
1489, 1419, 1088, 965, 821, 711, 529 cm
 1; 
1H NMR (CDCl3) δ 8.64 (d, J = 
1.5, 1H, H2), 8.41 (dd, J = 4.8, 1.5, 1H, H6), 7.73 (dt, J = 8.1, 1.5, 1H, H4), 
7.35 (d, J = 8.4, 2H, H2''), 7.24 (d, J = 8.4, 2H, H3''), 7.21 (dd, J = 8.1, 4.8, 
1H, H5), 7.02 (d, J = 16.5, 1H, H2'), 6.93 (d, J = 16.5, 1H, H1'); 
13C NMR 
(CDCl3) δ 148.5 (C6), 148.2 (C2), 135.2 (q, C1''), 134.0 (q, C4''), 133.0 
(C4),  132.9  (q,  C3), 129.7  (C2'),  129.0  (C3''),  127.9  (C2''), 125.4  (C1'), 
123.7 (C5); Anal. Calcd for C13H10ClN: C, 72.40; H, 4.67; N, 6.49. Found: 
C, 72.42; H, 4.69; N, 6.39. Page | 190  
 
3 [(E) 2 (4 Bromophenyl) vinyl]pyridine (159d). (2.65 g, 51 %); yellow 
solid; m.p. 94 95 
°C (from petrol / EtOAc); FTIR (neat solid) 3022, 1488, 
1073, 874, 820, 708 cm
 1; 
1H NMR (CDCl3) δ 8.65 (d, J = 1.8, 1H, H2), 
8.43 (dd, J = 4.5, 1.8, 1H, H6), 7.75 (dt, J = 7.8, 1.8, 1H, H4), 7.42 (d, J = 
8.7, 2H, H3''), 7.30 (d, J = 8.7, 2H, H2''), 7.22 (dd, J = 7.8, 4.5, 1H, H5), 
7.02 (d, J = 16.2, 1H, H2'), 6.95 (d, J = 16.2, 1H, H1');
 13C NMR (CDCl3) δ 
148.4 (C6), 148.2 (C2), 135.6 (q, C1''), 133.1 (C4), 132.9 (q, C3), 132.0 
(C3''), 129.8 (C2'), 128.2 (C2''), 125.5 (C1'), 123.7 (C5), 122.2 (q, C4''). 
Anal. Calcd for C14H13BrN: C, 41.82; H, 3.26; N, 3.48. Found: 41.61; H, 
3.40; N, 3.14.  
 
3 [(E) 2 (4 Methylphenyl)vinyl]pyridine  (159e).  (1.68  g,  43  %);  cream 
solid; m.p. 106 107 
°C (from petrol / EtOAc) ; FTIR (neat solid) 3024, 1508, 
1421, 1174, 1022, 972, 816, 714 cm
 1; 
1H NMR (CDCl3) δ 8.63 (d, J = 1.8, 
1H, H2), 8.39 (dd, J = 4.8, 1.8, 1H, H6), 7.75 (dt, J = 8.1, 1.8, 1H, H4), 
7.34 (d, J = 8.1, 2H, H2''), 7.21 (dd, J = 8.1, 4.8, 1H, H5), 7.10 (d, J = 8.1, 
2H, H3''), 7.06 (d, J = 16.2, 1H, H2'), 6.93 (d, J = 16.2, 1H, H1'); 
13C NMR 
(CDCl3) δ 148.0 (C2), 147.9 (C6), 138.4 (q, C4''), 133.9 (q, C1''), 133.5 (q, 
C3), 133.0 (C4), 131.1 (C2'), 129.6 (C3''), 126.7 (C2''), 123.7 (C5 and C1'), 
21.3 (4'' CH3); Anal. Calcd for C14H13N: C, 86.12; H, 6.71; N, 7.17. Found: 
C, 86.03; H, 6.73; N, 7.14. 
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6.4.7.  Synthesis of compounds 164a e 
 
 
 
Compounds 164a e were synthesised using GP 3. There was obtained:  
 
1 Methyl 3 ((E) styryl) pyridinium  iodide  (164a),  from  159a  (0.91  g). 
(1.08 g, 67 %); pale yellow solid; m.p. 216 217 
°C (from EtOH); FTIR (neat 
solid) 3026, 1642, 1627, 1508, 1224, 804, 747, 691, 670 cm
 1; 
1H NMR 
(DMSO d6) δ 9.32 (s, 1H, H2), 8.86 (d, J = 6.0, 1H, H6), 8.77 (d, J = 8.4, 
1H, H4), 8.13 (dd, J = 8.4, 6.0, 1H, H5), 7.73 (d, J = 16.5, 1H, H2'), 7.69 
(d, J = 7.2, 2H, H2''), 7.50 (t, J = 7.2, 2H, H3''), 7.43 (d, J = 16.5, 1H, H1'), 
7.40 (t, J = 7.2, 1H, H4''), 4.39 (s, 3H, 1 CH3); 
13C NMR (DMSO d6) δ 
143.7 (C2 and C6), 141.5 (C4), 137.6 (q, C3), 136.0 (q, C1''), 135.8 (C2'), 
129.8 (C4''), 129.5 (C3''), 128.0 (C5), 127.7 (C2''), 121.9 (C1'), 48.6 (1 
CH3). Anal. Calcd for C14H14NI: 52.03; H, 4.37; N, 4.33. Found: C, 51.86; 
H, 4.34; N, 4.13. 
 
3 [(E) 2 (4 Fluorophenyl)vinyl] 1 methylpyridinium iodide (164b), from 
159b (1.00 g). (1.64 g, 96 %); cream solid; m.p. 242 243 
°C (from EtOH); 
FTIR (neat solid) 3026, 1642, 1627, 1594, 1508, 1224, 1157, 972, 826, 
668 cm
 1;
 1H NMR (DMSO d6) δ 9.30 (s, 1H, H2), 8.86 (d, J = 5.7, 1H, H6), Page | 192  
 
8.75 (d, J = 8.1, 1H, H4), 8.13 (dd, J = 8.1, 5.7, 1H, H5), 7.74 (dd, J = 8.4, 
5.4, 2H, H2''), 7.73 (d, J = 16.5, 1H, H2'), 7.38 (d, J = 16.5, 1H, H1'), 7.32 
(t, J = 8.4, 2H, H3''), 4.39 (s, 3H, 1 CH3); 
13C NMR (DMSO d6) δ 163.0 (q, 
J C F = 246, C4''), 143.7 (C2 or C6), 143.6 (C2 or C6), 141.4 (C4), 137.5 (q, 
C3), 134.6 (C2'), 132.7 (q, J  C F = 3, C1''), 129.8 (J  C F = 8, C2''), 128.0 
(C5), 121.8 (C1'), 116.5 (J  C F = 22, C3''), 48.6 (1 CH3). Anal. Calcd for 
C14H13FNI: C, 49.29; H, 3.84; N, 4.11. Found: C, 49.12; H, 3.84; N, 3.99. 
 
3 [(E) 2 (4 Chlorophenyl)vinyl] 1 methylpyridinium  iodide  (164c), 
using 159c (1.08 g). (1.47 g, 82 %); yellow solid; m.p. 196 197 
°C (from 
EtOH); FTIR (neat solid) 3030, 1644, 1625, 1509, 1487, 1158, 1086, 968, 
810, 666 cm
 1; 
1H NMR (DMSO d6) δ 9.31 (s, 1H, H2), 8.91 (d, J = 5.7, 1H, 
H6), 8.79 (d, J = 8.4, 1H, H4), 8.17 (dd, J = 8.4, 5.7, 1H, H5), 7.74 (d, J = 
16.5, 1H, H2'), 7.74 (d, J = 8.4, 2H, H2''), 7.58 (d, J = 8.4, 2H, H3''), 7.48 
(d, J = 16.5, 1H, H1'), 4.42 (s, 3H, 1 CH3);
 13C NMR (DMSO d6) δ 143.9 
(C2 or C6), 143.8 (C2 or C6), 141.5 (C4), 137.4 (q, C3''), 135.0 (q, C1''), 
134.4 (C2'), 134.2 (q, C4''), 129.6 (C3''), 129.4 (C2''), 128.0 (C5), 122.8 
(C1'), 48.6 (1 CH3). Anal. Calcd for C14H13ClNI: 47.02; H, 3.66; N, 3.92. 
Found: C, 46.75; H, 3.84; N, 4.01. 
 
3 [(E) 2 (4 Bromophenyl)vinyl] 1 methylpyridinium  iodide  (164d), 
using 159d (1.30 g). (1.97 g, 98 %); yellow solid; m.p. 231 232 
°C; FTIR 
(neat solid) 3032, 1644, 1624, 1510, 968, 808, 666 cm
 1;
 1H NMR (DMSO 
d6) δ 9.30 (s, 1H, H2), 8.87 (d, J = 5.7, 1H, H6), 8.76 (d, J = 8.4, 1H, H4), 
8.14 (dd, J = 8.4, 5.7, 1H, H5), 7.73 7.61 (m, 5H, H2'', H3'', H2'), 7.46 (d, J Page | 193  
 
= 16.5, 1H, H1'), 4.39 (s, 3H, 1 CH3);
 13C NMR (DMSO d6) δ 143.9 (C2 or 
C6), 143.8 (C2 or C6), 141.6 (C4), 137.3 (q, C3), 135.3 (q, C1''), 134.5 
(C2'), 132.5 (C3''), 129.6 (C2''), 128.0 (C5), 122.9 (q, C4''), 122.8 (C1'), 
48.6  (1 CH3).  Anal.  Calcd  for  C14H13BrIN:  C,  41.82;  H,  3.26;  N,  3.48. 
Found: 41.62; H, 3.40; N, 3.14. 
 
1 Methyl 3 [(E) 2 4 methylphenylvinyl] pyridinium iodide (164e), from 
159e (0.98 g). (1.55 g, 92 %); pale yellow solid; m.p. 247 
°C (from EtOH); 
FTIR (neat solid) 3026, 3008, 1640, 1625, 1507, 1208, 969, 859, 665 cm
 1; 
1H NMR (DMSO d6) δ 9.28 (s, 1H, H2), 8.84 (d, J = 6.0, 1H, H6), 8.74 (d, J 
= 8.4, 1H, H4), 8.12 (dd, J = 8.4, 6.0, 1H, H5), 7.68 (d, J = 16.5, 1H, H2'), 
7.58 (d, J = 8.1, 2H, H2''), 7.35 (d, J = 16.5, 1H, H1'), 7.29 (d, J  8.1, 2H, 
H3''), 4.38 (s, 3H, 1 CH3), 2.30 (s, 3H, 4'' CH3);
  13C NMR (DMSO d6) δ 
143.5 (C2), 143.4 (C6), 141.3 (C4), 139.6 (q, C4''), 137.8 (q, C3), 135.8 
(C2'), 133.3 (q, C1''), 130.1 (C3''), 128.0 (C5), 127.7 (C2''), 120.9 (C1'), 
48.6 (1 CH3), 21.5 (4'' CH3). Anal. Calcd for C15H16IN: C, 53.43; H, 4.78; 
N, 4.15; Found: C, 53.40; H, 4.77; N, 4.13. 
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6.4.8.  3 (Chloromethyl)pyridine (161) 
 
 
 
3 Chloromethylpyridinium hydrochloride 160 (3.28 g, 20 mmol) was added 
portionwise over 2 min to a solution of sodium hydrogen carbonate (2.18 
g, 26 mmol) in a mixture of DCM (60 mL) and water (60 mL). The mixture 
was stirred vigorously for 1 h after which time the phases were separated 
and the aqueous phase extracted using DCM (3 x 50 mL). The combined 
organic extracts were dried (MgSO4) and the solvent removed in vacuo to 
furnish the desired product as a pale yellow liquid which was used without 
further purification; (2.42 g, 95 %); FTIR (neat solid) 3033, 1577, 1479, 
1423, 1027, 824, 710 cm
 1; 
1H NMR (CDCl3) δ 8.65 (d, J = 1.8, 1H, H2), 
8.59 (dd, J = 4.8, 1.8, 1H, H6), 7.76 (dt, J = 8.1, 1.8, 1H, H4), 7.33 (dd, J = 
8.1, 4.8, 1H, H5), 4.61 (s, 2H, H1'); 
13C NMR (CDCl3) δ 149.6 (C2), 149.5 
(C6), 136.3 (C4), 133.3 (q, C3), 123.6 (C5), 43.1 (C1'). 
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6.4.9. Triphenyl(pyridine 3 ylmethyl)phosphonium chloride (162). 
 
 
 
To a solution of 161 (2.42 g, 19 mmol) in acetonitrile (80 mL) was added 
triphenylphosphine (4.98 g, 19 mmol) and the mixture refluxed overnight. 
After  cooling,  the  resulting  precipitate  was  collected  by  filtration  and 
washed thoroughly with ether to yield the title compound 162 as a pale 
cream solid, which could be used without further purification; (4.70 g, 64 
%); m.p. 297 
°C; FTIR (neat solid) 2845, 1435, 1110, 717, 692 cm
 1; 
1H 
NMR (D2O) δ 8.46 (dd, J = 4.5, 1.8, 1H, H6'), 8.05 (d, J = 1.8, 1H, H2'), 
7.93 7.88 (m, 3H, H4), 7.71 7.64 (m, 12H, H2, H3), 7.51 (dt, J = 7.8, 1.8, 
1H, H4'), 7.32 (dd, J = 7.8, 4.5, 1H, H5'), 4.86 (d, JH P = 14.7, 2H, H1); 
13C 
NMR (D2O) δ 150.3 (d, JC P = 6, C2'), 148.8 (d, JC P = 4, C6'), 139.7 (d, JC P 
= 5, C4'), 135.6 (d, JC P = 3, C4''), 134.1 (d, JC P = 10, C3''), 130.3 (d, JC P = 
13, C2''), 124.8 (q, d, JC P = 8, C3'),  124.5 (d, JC P = 3, C5'), 116.7 (q, d, 
JC P = 87, C1''), 27.2 (d, JC P = 50, C1); Anal. Calcd for C24H21ClNP: C, 
73.94; H, 5.43; N, 3.59. Found: C, 73.67; H, 5.34; N, 4.07. 
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6.4.10.  Alternative  synthesis  of  alkenes  (159a e)  via  Wittig 
methodology 
 
 
 
To a stirred solution of triphenyl(pyridine 3 ylmethyl) phosphonium chloride 
162 (1.56 g, 4 mmol) in dry THF (20 mL) at  10 
°C under argon was added 
n BuLi (1.6 mL, 2.5 M, 4 mmol). The resulting mixture was stirred at  10 
°C 
for 30 min. The mixture was cooled to  78 
°C and arylaldehyde 163a e (4 
mmol) in dry THF (5 mL) added; the mixture was allowed to warm to room 
temperature overnight with stirring. The reaction was quenched with sat. 
NH4Cl  (50  mL)  and  extracted  into  ether  (3  x  30  mL).  The  combined 
ethereal extracts were dried (MgSO4), and the solvent removed in vacuo 
to yield the desired products. There was obtained 159a (0.44 g, 61 %), 
159b (0.44 g, 55 %), 159c (0.47 g, 55 %), 159d (0.38 g, 49 %) and 159e 
(0.43 g, 51 %). Analytical data were identical to those described in 6.4.6. 
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6.4.11.  Synthesis of compounds 168a c 
 
 
 
To a vigorously stirred solution of powdered potassium hydroxide (5.62 g, 
100 mmol), and either 1H indole 167a (4.68 g, 40 mmol) or 5 methoxy 1H 
indole 167b (5.89 g, 40 mmol) in DMF (70 mL) at room temperature was 
added dropwise over 5 min either iodine (10.25 g, 40.4 mmol) or bromine 
(2.08  mL,  40.4  mmol)  in  DMF  (60  mL).  The  mixture  was  stirred  for  a 
further 45 min at room temperature and then poured into iced aqueous 
sodium metabisulphite (400 mL, 0.1 % 
w/v). The resulting precipitate was 
filtered, washed with cold water (100 mL) and dried under vacuum to yield 
the products. The products were highly unstable and could not be stored 
for  significant  periods  and  were  used  immediately  in  the  next  reaction 
step. There was obtained.
233 
 
3 Bromo 1H indole (168a). (7.05 g, 90 %); tan solid; m.p. 68 69 
°C; lit. 65 
oC  [Hugon]FTIR  (neat  solid)  3400,  1656,  1452,  977,  811, 736  cm
 1;
  1H 
NMR (CDCl3) δ 8.15 (bs, 1H, N H), 7.51 (dd, J = 8.4, 1.2, 1H, H4), 7.26 
(dd,  J  =  8.4,  1.2,  1H,  H7),  7.18 7.10  (m,  3H,  H5,  H6,  H2); 
13C  NMR 
(CDCl3) δ 135.4 (q, C9), 126.9 (q, C8), 123.4 (C5 or C6), 123.2 (C5 or C6), 
120.7 (C2), 19.2 (C4), 111.5 (C7), 91.7 (q, C3). 
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3 Iodo 1H indole  (168b).  (9.33  g,  96%);  tan  solid;  m.p.  71 
°C  (dec.); 
literature 66 
oC (dec.);
225 FTIR (neat solid) 3382, 3051, 1653, 1450, 1236, 
1083, 957, 735 cm
 1; 
1H NMR (DMSO d6) δ 11.52 (bs, 1H, NH), 7.54 (d, J 
= 2.7, 1H, H2), 7.45 (dd, 1H, J = 7.2, 1.5, H4), 7.29 (dd, J = 7.2, 1.5, 1H, 
H7), 7.17 (td, J = 7.2, 1.5, 1H, H6), 7.11 (td, J = 7.2, 1.5, 1H, H5); 
13C 
NMR (DMSO d6) δ 136.4 (q, C9), 130.1 (C2), 129.8 (q, C8), 122.6 (C4), 
120.4 (C6), 120.2 (C5), 112.4 (C7), 56.3 (q, C3). 
 
3 Iodo 5 methoxy 1H indole (168c). (10.49 g, 96%); tan solid; m.p. 78 
79 
°C (dec); FTIR (neat solid) 3329, 3108, 1484, 1435, 1289, 1211, 1160, 
1025, 820, 918, 797 cm
 1; 
1H NMR (DMSO d6) δ 11.38 (bs, 1H, N H), 7.49 
(d, J = 2.4, 1H, H2), 7.33 (d, J = 8.7, 1H, H7), 6.82 (dd, J = 8.7, 2.4, 1H, 
H6), 6.74 (d, J = 2.4, 1H, H4), 3.80 (s, 3H, 5 OCH3);
 13C NMR (DMSO d6) 
δ  154.7  (q,  C5),  131.4  (q,  C9),  130.5  (C2),  130.2  (q,  C8),  113.3  (C6), 
113.1 (C7), 101.6 (C4), 55.8 (2C, q, C3 and 5 OCH3). 
 
 
6.4.12  Synthesis of compounds 169a c 
 
 
 
Either compound 168a (5.88 g, 30 mmol), 168b (7.29 g, 30 mmol) or 168c 
(8.19 g, 30 mmol), was dissolved in acetone (90 mL). The mixture was Page | 199  
 
cooled  to  0 
°C  and  powdered  potassium hydroxide  (8.42  g,  150  mmol) 
added portionwise over 5 min. Iodomethane (3.8 mL, 60 mmol) was added 
and the mixture stirred vigorously at room temperature for 30 min; after 
which, petrol (60 mL) was then added and the solution filtered. The filtrate 
was washed with brine (60 mL), dried (MgSO4) and the solvent removed to 
yield a deep red residue. Column chromatography of the residue (SiO2, 
100 % petrol) afforded the title compounds. The title compounds could be 
stored in a freezer for approx. 30 days without significant decomposition. 
There was obtained: 
 
3 Bromo 1 methyl 1H indole (169a). (5.30 g, 84 %); cream solid; m.p. 
77 78 
°C; FTIR (neat solid) 2900, 1505, 1460, 1237, 1106, 740 cm
 1; 
1H 
NMR (DMSO d6) δ 7.50 (s, 1H, H2), 7.48 7.47 (m, 1H, H4), 7.45 7.44 (m, 
1H, H7), 7.26 (td, J =  6.9, 1.2, 1H, H6), 7.17 (td, J = 6.9, 1.2, 1H, H5), 
3.77 (s, 3H, 1 CH3); 
13C NMR (DMSO d6)  δ 136.5 (q, C9), 129.1 (C2), 
127.0 (q, C8), 122.7 (C4), 120.4 (C6), 118.7 (C5), 110.7 (C7), 88.0 (q, 
C3), 33.2 (1 CH3).  
 
3 Iodo 1 methyl 1H indole (169b). (6.32 g, 82%); cream solid; m.p. 56 
°C; literature 58 59 
°C;
226 FTIR (neat solid) 2905, 1502, 1455, 1236, 1102, 
931, 743 cm
 1; 
1H NMR (DMSO d6) δ 7.52 (s, 1H, br, H2), 7.44 (dd, J = 
7.8, 1.2, 1H, H4), 7.29 (dd, J = 7.8, 1.2, 1H, H7), 7.23 (td, J = 7.8, 1.2, 1H, 
H6), 7.14 (td, J = 7.8, 1.2, 1H, H5) 3.80 (s, 3H, 1 CH3);
 13C NMR (DMSO 
d6) δ 137.1 (q, C9), 133.9 (C2), 130.3 (q, C8), 122.7 (C4), 120.6 (C6), 
120.5 (C5), 110.6 (C7), 54.9 (q, C3), 33.2 (1 CH3).  Page | 200  
 
3 Iodo 5 methoxy 1 methyl 1H indole  (169c).  (8.10  g,  94  %);  cream 
solid;  m.p.  75 76 
°C  (dec.);  FTIR  (neat  solid)  2971,  2359,  1362,  1215, 
1178, 1150, 1129, 1028, 806, 782 cm
 1; 
1H NMR (DMSO d6) δ 7.51 (s, 1H, 
H2), 7.41 (d, J = 9.0, 1H, H7), 6.90 (dd, J = 9.0, 2.4, 1H, H6), 6.76 (d, J = 
2.4, 1H, H4), 3.84 (s, 3H, 5 OCH3), 3.81 (s, 3H, 1 CH3); 
13C NMR (DMSO 
d6) δ 154.8 (q, C5), 134.2 (C2), 132.3 (q, C9), 130.7 (q, C8), 113.0 (C6), 
111.7 (C7), 102.0 (C4), 55.9 (5 OCH3), 54.2 (q, C3), 33.4 (1 CH3). 
 
6.4.13.  Synthesis of compounds 170a e 
 
 
A solution of either compound 169a (1.94 g, 10 mmol) or 169b (2.43 g, 10 
mmol) or 169c (2.73 g , 10 mmol)  bis(triphenylphosphine)palladium (II) 
chloride (0.35 g, 0.5 mmol, 5 mol.%), copper iodide (38 mg, 0.2 mmol, 2 
mol.%), triethlyamine (5.6 mL, 40 mmol) and either arylalkyne 147a (1.12 
g, 11 mmol), 147c (1.50 g, 11 mmol), or 147e (1.28 g, 11 mmol) in THF 
(20 mL) was stirred under an atmosphere of argon at room temperature. 
for 18 h. Water (60 mL) was subsequently added, the phases separated 
and the aqueous phase extracted with ether (3 x 30 mL). The combined 
ethereal  extracts  were  dried  (MgSO4),  concentrated  and  the  residue Page | 201  
 
purified by column chromatography (SiO2; 80:20, petrol: ether). There was 
obtained:  
 
1 Methyl 3 phenylethynyl 1H indole (170a). (1.83 g, 79 %); pale yellow 
crystals; m.p. 106 
°C; FTIR (neat solid) 2925, 2208, 1538, 1487, 1471, 
1381, 1234, 818, 759, 742, 689 cm
 1; 
1H NMR (CDCl3) δ 7.72 (d, J = 7.5, 
1H, H4), 7.47 (dd, J = 8.4, 1.8, 2H, H2''), 7.26 7.14 (m, 7H, H2, H3'', H4'', 
H7, H5, H6), 3.70 (s, 3H, 1 CH3);
 13C NMR (CDCl3) δ 136.3 (q, C9), 132.2 
(C2), 131.3 (C2''), 129.2 (q, C8), 128.3 (C3''), 127.5 (C4''), 124.4 (q, C1''), 
122.7 (C5 or C6), 120.4 (C4 or C5), 120.2 (C4 or C5), 109.6 (C7), 97.2 (q, 
C3), 91.1 (q, C2'), 83.2 (q, C1'), 33.1 (1 CH3).Anal. Calcd for C17H13N: C, 
88.28; H, 5.67; N, 6.06. Found: C, 88.07; H, 5.44; N, 6.36. 
 
1 Methyl 3 (4 methylphenylethynyl) 1H indole  (170b).  (1.99  g,  81  %); 
pale yellow solid; m.p. 117 
°C; FTIR (neat solid)) 3044, 2204, 1504, 1382, 
814, 736 cm
 1; 
1H NMR (CDCl3) δ 7.73 (dd, J = 8.1, 1.8, 1H, H4), 7.36 (d, J 
= 7.8, 2H, H2''), 7.24 (td, J = 8.1, 1.8, 1H, H5), 7.21 (dd, J = 8.1, 1.8, 1H, 
H7), 7.18 (s, 1H, H2), 7.13 (td, J = 8.1, 1.8, 1H, H6), 7.05 (d, J = 7.8, 2H, 
H3''), 3.69 (s, 3H, 1 CH3), 2.28 (s, 3H, 4'' CH3);
 13C NMR (CDCl3) δ 137.6 
(q,  C4''),  136.4  (q,  C9),  132.3  (C2),  131.2  (C2''),  129.3  (q,  C8),  129.2 
(C3''), 122.8 (C6), 121.4 (q, C1''), 120.4 (C5), 120.4 (C4), 109.6 (C7), 97.4 
(q,  C3),  91.2  (q,  C2'),  82.4  (q,  C1'),  33.2  (1 CH3),  21.6  (4'' CH3);  Anal. 
Calcd for C18H15N: C, 88.13; H, 6.16; N, 5.71. Found: C, 88.11; H, 6.20; N, 
5.77. 
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3 (4 Chlorophenylethynyl) 1 methyl 1H indole  (170c).  (1.54  g,  58  %); 
pale yellow solid; m.p. 141 
oC; FTIR (neat solid) 3053, 2212, 1487, 1462, 
1382, 822, 743 cm
 1; 
1H NMR (DMSO d6) δ 7.83 (s, 1H, H2), 7.75 (dd, J = 
7.8, 1.2, 1H, H4), 7.62 (d, J = 8.7, 2H, H2''), 7.58 (dt, J =7.2, 1.2, 1H. H7), 
7.53 (d, J  =8.7, 2H, H3''), 7.33 (td, J = 7.2, 1.2, 1H, H6), 7.24 (td, J = 7.2, 
1.2, 1H, H5), 3.89 (s, 3H, 1 CH3);
  13C NMR (DMSO d6) δ 136.5 (q, C9), 
134.2 (C2), 132.9 (C2''), 132.8 (q, C4''), 129.3 (C3''), 128.9 (q, C8), 123.0 
(q, C1''), 123.0 (C6), 120.9 (C5), 119.7 (C4), 111.1 (C7), 95.3 (q, C3), 90.2 
(q, C2'), 85.7 (q, C1'), 33.3 (1 CH3). 
 
5 Methoxy 1 methyl 3 phenylethynyl 1H indole (170d). (2.12 g, 81 %); 
pale yellow solid; m.p. 126 
°C;
 FTIR (neat solid) 2916, 2214, 1490, 1217, 
1062, 783, 750, 691 cm
 1; 
1H NMR (CDCl3) δ 7.47 (dd, J = 8.4, 1.8, 2H, 
H2''), 7.27 7.23 (m, 3H, H3'', H4''), 7.20 (s, 1H, H2), 7.16 (d, J = 2.4, 1H, 
H4), 7.14 (d, J = 9.0,  1H, H7), 6.85 (dd, J = 9.0, 2.4, 1H, H6), 3.82 (s, 3H, 
5 OCH3),  3.68 (s, 3H, 1 CH3);
  13C NMR (CDCl3) δ 155.0 (q, C5), 132.6 
(C2), 131.6 (q, C9), 131.3 (C2''), 129.7 (q, C8), 128.3 (C3''), 127.4 (C4''), 
124.4 (q, C1''), 113.2 (C6), 110.4 (C7), 101.7 (C4), 96.6 (q, C3), 91.1 (q, 
C2'), 83.3 (q, C1'), 55.9 (5 OCH3), 33.3 (1 CH3); Anal. Calcd for C18H15NO: 
C, 82.73; H, 5.79; N, 5.36. Found: C, 82.79; H, 5.83; N, 5.31. 
 
5 Methoxy 1 methyl 3 (4 methylphenylethynyl) 1H indole (170e). (1.68 
g, 61 %); pale yellow crystals; m.p. 127 
°C; FTIR (neat solid) 2906, 2205, 
1489, 1214, 1060, 816, 797 cm
 1; 
1H NMR (DMSO d6) δ 7.68 (s, 1H, H2), 
7.46 (d, J = 7.8, 2H, H3''), 7.42 (d, J = 8.7, 1H, H7), 7.23 (d, J = 7.8, 2H, Page | 203  
 
H2''), 7.12 (d, J = 2.1, 1H, H4), 6.90 (dd, J = 8.7, 2.1, 1H, H6), 3.84 (s, 3H, 
5 OCH3), 3.80 (1 CH3), 2.35 (s, 3H, 4'' CH3); 
13C NMR (DMSO d6) δ 155.0 
(q,  C5),  137.7  (q,  C4''),  134.0  (C2),  131.7  (q,  C9),  131.2  (C3''),  129.7 
(C2''), 129.5 (q, C8), 121.2 (q, C1''), 113.0 (C6), 111.9 (C7), 101.2 (C4), 
95.4 (q, C3), 91.3 (q, C2'), 83.8 (q, C1'), 56.0 (5 OCH3), 33.4 (1 CH3), 21.5 
(4'' CH3). Anal. Calcd for C19H17NO: C, 82.88; H, 6.22; N, 5.09. Found: C, 
82.84; H, 6.24; N, 5.11. 
 
 
6.4.14.  Synthesis of compounds 171a e 
 
 
Either compound 170a (0.69 g, 3 mmol), 170b (0.74 g, 3 mmol), 170c 
(0.80 g, 3 mmol), 170d (0.78 g, 3 mmol) or 170e (0.83 g, 3 mmol) and 
Hg(OAc)2 (0.095 g, 0.3 mmol, 10 mol.%) were dissolved in 30 % 
w/v H2SO4 
(6  mL) and  acetone  (3  mL). The  resulting  solution  was  stirred  at  room 
temperature for 12 h. The reaction mixture was diluted with water (60 mL), 
neutralised with 10 % aq. NaOH and the aqueous phase extracted with 
EtOAc (3 x 15 mL). The compbined organic extracts were washed with 
brine (20 mL), dried (MgSO4) and the solvent removed under vacuum. The 
crude  product  was  purified  by  column  chromatography  (SiO2;  petrol  : Page | 204  
 
ether, 80 : 20 
v/v) and recrystallised to give the title products. There was 
obtained: 
 
2 (1 Methyl 1H indol 3 yl) 1 phenyl  ethanone  (171a).  (0.46  g,  61  %); 
orange brown solid; m.p. 119 
°C (from EtOAc / petrol); FTIR (neat solid) 
2933, 1631, 1528, 1464, 1371, 1230, 1128, 1090, 747, 722, 693 cm
 1;
 1H 
NMR (DMSO d6) δ 8.55 (s, 1H, H2''), 8.20 (dd, J = 7.8, 1.2, 1H, H4''), 7.55 
(dd, J = 7.8, 1.2, 1H, H7''), 7.37 7.19 (m, 7H, H2', H3', H4', H5'', H6''), 4.13 
(s, 2H, H2), 3.90 (s, 3H, 1'' CH3);
  13C NMR (DMSO d6) δ 192.5 (q, C1), 
138.7 (C2''), 137.9 (q, C9''), 136.9 (q, C1'), 129.9 (C2' or C3'), 128.7 (C2' 
or C3'), 126.7 (C4'), 126.5 (q, C8''), 123.4 (C5''), 122.6 (C6''), 122.0 (C4''), 
115.4  (q,  C3''),  111.1  (C7''),  46.2  (C2),  33.7  (1'' CH3).  Anal.  Calcd  for 
C17H11NO: C, 81.90; H, 6.06; N, 5.70. Found: C, 81.67; H, 6.12; N, 5.71. 
 
2 (1 Methyl 1H indol 3 yl) 1 (4 methylphenyl)  ethanone  (171b).  (0.72 
g, 91%); orange brown solid; m.p. 130 
°C (from EtOAc / petrol); FTIR (neat 
solid) 2905, 1650, 1524, 1383, 1371, 1214, 1077, 932, 784, 742, 569 cm
 1; 
1H NMR (CDCl3) δ 8.34 8.31 (m, 1H, H4''), 7.61 (s, 1H, H2''), 7.23 7.20 (m, 
3H, H5'', H6'', H7''), 7.13 (d, J = 7.8, 2H, H2'), 7.02 (d, J = 7.8, 2H, H3'), 
3.99  (s,  2H,  H2),  3.70  (s,  3H,  1 CH3),  2.22  (s,  3H,  4' CH3); 
13C  NMR 
(CDCl3) δ 192.9 (q, C1), 137.6 (q, C4'), 136.3 (q, C9''), 135.8 (C2''), 133.0 
(q, C1'), 129.4 (C2' or C3'), 129.2 (C2' or C3'), 126.8 (q, C8''), 123.5 (C5'' 
or C6''), 122.9 (C5'' or C6''), 122.7 (C4''), 116.3 (q, C3''), 109.6 (C7), 46.7 
(C2), 33.6 (1'' CH3), 21.2 (4' CH3); Anal. Calcd for C18H17NO: C, 82.10; H, 
6.51; N, 5.32. Found: C, 81.88; H, 6.52; N, 5.42. Page | 205  
 
1 (4 Chlorophenyl) 2 (1 methyl 1H indol 3 yl)  ethanone  (171c).  (0.49 
g, 57 %); orange brown solid; m.p. 110 
°C (from EtOAc / petrol); FTIR 
(neat solid) 2922, 1682, 1648, 1627, 1467, 1376, 2122, 1086, 805, 746, 
569 cm
 1; 
1H NMR (CDCl3) δ 8.32 8.27 (m, 1H, H4''), 7.61 (s, 1H, H2'), 
7.22 7.19 (m, 3H, H5'', H6'', H7''), 7.17 (d, J = 8.7, 2H, H2''), 7.15 (d, J = 
8.7, 2H, H3'), 3.98 (s, 2H, H2), 3.71 (s, 3H, 1 CH3); 
13C NMR (CDCl3) δ 
191.9 (q, C1), 137.6 (q, C4'), 135.7 (C2''), 134.3 (q, C9''), 132.6 (q, C1'), 
130.8 (C2' or C3'), 128.7 (C2' or C3'), 126.6 (q, C8''), 123.6 (C5'' or C6''), 
122.8 (C5''or C6'), 122.7 (C4''), 116.1 (q, C3''), 109.7 (C7''), 46.0 (C2), 33.6 
(1'' CH3); Anal. Calcd for C17H14ClNO: C, 71.96; H, 4.97; N, 4.94; O, 5.64. 
Found: C, 71.74; H, 4.88; N, 4.99. 
 
2 (5 Methoxy 1 methyl 1H indol 3 yl) 1 phenyl ethanone  (171d).  (0.60 
g, 72 %); orange brown solid; m.p. 128 
oC; FTIR (neat solid) 2933, 1631, 
1527, 1464, 1370, 1089, 747, 722 cm
 1;
 1H NMR (DMSO d6) δ 8.47 (s, 1H, 
H2''), 7.71 (d, J = 2.4, 1H, H4''), 7.44 (d, J = 9.0, 1H, H7''), 7.35 (dd, J = 
7.2, 1.5, 2H, H2'), 7.30 (t, J = 7.2, 2H, H3'), 7.21 (tt, J = 7.2, 1.5, 1H, H4'), 
6.90 (dd, J = 9.0, 2.4, 1H, H6''), 4.09 (s, 2H, H2), 3.86 (s, 3H, 1'' CH3), 
3.77 (s, 3H, 5'' OCH3);
  13C NMR (DMSO d6) δ 192.3 (q, C1), 156.3 (q, 
C5''), 138.7 (C2''), 136.9 (q, C1'), 132.9 (q, C9''), 129.8 (C2'), 128.7 (C3'), 
127.3 (q, C8''), 126.7 (C4'), 115.0 (q, C3''), 113.2 (C6''), 111.9 (C7''), 103.7 
(C4''), 55.8 (5'' OCH3), 46.2 (C2), 33.9 (1'' CH3). 
 
2 (5 Methoxy 1 methyl 1H indol 3 yl) 1 (4 methylphenyl) ethanone 
(171e). (0.61 g, 69 %); pale yellow crystals; m.p. 187 188 
°C (from EtOAc / Page | 206  
 
petrol);  FTIR  (neat  solid)  2910,  1646,  1613,  1522,  1482,  1368,  1221, 
1073, 812, 773, 722 cm
 1; 
1H NMR (CDCl3) δ 7.85 (d, J = 2.4, 1H, H4''), 
7.60 (s, 1H, H2''), 7.14 (d, J = 7.8, 2H, H3'), 7.10 (d, J = 9.0, 1H, H7''), 7.04 
(d, J = 7.8, 2H, H2'), 6.85 (dd, J = 9.0, 2.4, 1H, H6''), 3.99 (s, 2H, H2), 3.78 
(s,  3H,  5'' OCH3),  3.70  (s,  3H,  1'' CH3),  2.23  (s,  3H,  4' CH3); 
13C  NMR 
(CDCl3) δ 192.9 (q, C1), 156.6 (q, C5''), 136.2 (q, C4'), 135.6 (C2''), 132.9 
(q, C1' or C9''), 132.6 (q, C1 or C9''), 129.3 (C2' or C3'), 129.2 (C2' or C3'), 
127.5 (q, C8''), 115.9 (q, C3''), 114.1 (C6''), 110.4 (C7''), 103.9 (C4''), 55.8 
(5'' OCH3),  46.4  (C2),  33.7  (1'' CH3),  21.1  (4' CH3);  Anal.  Calcd  for 
C19H19NO2: C, 77.79; H, 6.53; N, 4.77. Found: C, 77.16; H, 6.49; N, 4.70.  
 
 
6.4.15.  2 (1 Methyl 1H indol 3 yl) 1 phenylethanol (177). 
 
 
 
To dry THF (20 mL) at  78 
°C under an atmosphere of argon was added n 
BuLi (4.2 mL, 2.5M, 10.5 mmol). The resulting mixture was stirred for 5 
min at this temperature followed by the addition of 3 bromo 1 methyl 1H 
indole  169a  (2.10  g,  10  mmol)  in  dry  THF  (20  mL)  via  cannula.  The 
reaction  mixture  was  stirred  at   78  C  for  a  further  30  min  followed  by Page | 207  
 
addition over 5 min of aryl epoxide 100a (1.3 mL, 12 mmol) in dry THF (10 
mL). The solution was allowed to warm to room temperature over 1 h and 
stirred for a further 20 min. The reaction mixture was quenched with water 
(60 mL) and extracted with ether (3 x 30 mL). The organic layer was dried 
(MgSO4)  and  concentrated  under  reduced  pressure.  Column 
chromatography of the residue (SiO2; petrol : ether, 80 : 20 
v/v) furnished 
compound 159. (0.55 g, 22 %); tan solid; m.p.110 
°C; FTIR (neat solid) 
3404 (br), 2927, 1682, 1471, 1326, 1246, 1044, 737, 699 cm
 1; 
1H NMR 
(CDCl3) δ 7.72 (d, J = 7.5, 1H, H4''), 7.57 7.23 (m 8H, H2', H5'', H6'', H7'', 
H3', H4'), 6.98 (s, 1H, H2''), 5.08 (dd, J = 8.7, 4.2, 1H, H1), 3.81 (s, 3H, 1 
CH3), 3.33 (dd, J = 9.0, 4.2, 1H, H2A), 3.23 (dd, J = 9.0, 8.7, 1H, H2B), 2.25 
(bs, 1H, OH); 
13C NMR δ 144.5 (q, C1'), 137.3 (q, C9''), 128.7 (q, C8''), 
128.4 (C3'), 128.0 (C2''), 127.5 (C4'), 126.0 (C2'), 121.9 (C6'' and C5''), 
119.1 (C4''), 110.6 (q, C3''), 109.4 (C7''), 74.1 (C1), 36.0 (C2), 32.7 (1 
CH3). 
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6.5.  Synthetic Work, Chapter 4 
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6.5.1.  Synthesis of compounds 195a e, Method A 
 
To  dry  THF  (40  mL)  or  DMF  (25  mL)  under  an  inert  atmosphere  was 
sequentially added: bis(triphenylphosphine) palladium (II) chloride  (0.07 g, 
0.1  mmol,    5  mol  %),  copper  iodide  (0.04  g,  0.2  mmol,  2  mol  %), 
triethylamine (4.2 mL, 30 mmol), either 3 bromo 5 pyridyl acetylene 194a 
(2.58 g, 10 mmol) [for 195a,b or d] or 194b (2.72 g, 10 mmol) [for 195c 
and 195e] followed by arylacetylene 147a (1.12 g, 11 mmol) [for 195a], 
147c (1.50 g, 11 mmol) [for 195d or 195e] or 147e (1.28 g, 11 mmol) [for 
195b or 195c] and the resulting black solution stirred at 80 
oC for 12 18 h. 
After  cooling,  the  mixture  was  poured  into  cold  water  (80  mL)  then 
extracted with ether (4 x 50 mL). The ethereal extracts were combined, 
dried (MgSO4) and concentrated in vacuo to yield brown residues which, 
after  column  chromatography  and  recrystallisation  from  petrol,  yielded Page | 209  
 
195a e as white needles or pale yellow solids.195a (2.26 g, 81 %), 195b 
(2.40 g, 78 %), 195c (2.70 g, 92 %), 195d (1.63 g, 52 %) and 195e (2.36 
g, 72 %).  
 
6.5.2. Synthesis of compounds 195a and 195b, Method B 
 
3,5 Dibromopyridine  120  (1.18  g,  5  mmol),  bis(triphenylphosphine) 
palladium (II) chloride (0.18 g, 0.25 mmol, 5 mol %), copper iodide ( 20 
mg, 0.05 mmol, 2 mol %), triethylamine (2.9 mL, 20 mmol) and acetylene 
147a (1.07 g, 10.5 mmol) [for 195a] or 147e (1.22 g 10.5 mmol) [for 195b] 
were added to dry THF (40 mL) under a blanket of argon and the resulting 
black mixture stirred at 80 
oC for 12 h. After cooling, the reaction mixture 
was poured into water (80 mL), the phases separated and the aqueous 
phase extracted with EtOAc (3 x 20 mL). The combined organic phases 
were  dried  (MgSO4)  and  the  volatiles  removed  in  vacuo.  The  crude 
product was purified by column chromatography (SiO2; petrol: ether, 90 : 
10 
v/v) followed by recrystallisation from petrol. 195a (1.08 g, 77 %), 195b 
(1.35 g, 88 %). 
 
 
6.5.3.  Synthesis of compounds 195c, 195d, 195e, Method C 
 
To  dry  DMF  (10  mL)  under  an  atmosphere  of  argon  was  added  3,5 
dibromopyridine (2.37 g, 10 mmol), bis(triphenylphosphine) palladium (II) 
chloride (0.40 g, 0.6 mmol, 6 mol%), copper iodide (0.20 g, 1.1 mmol, 11 Page | 210  
 
mol%), triethylamine (6 mL) and 147a (1.10 mL, 10 mmol) [for 195c or 
195d] or 147e (1.16 g, 10 mmol) [for 195e]. The resulting black solution 
was stirred at 25 
oC for 3 h after which time the solution became lighter in 
colour. 147e (1.28 g, 11 mmol) [for 195c] or 147c (1.50 g, 11 mmol) [for 
195d or 195e] was added and the mixture heated at 110 
oC overnight. The 
solution was cooled, poured into water (100 mL) and extracted into ether 
(3 x 40 mL). The ethereal extracts were dried (MgSO4) and the solvent 
removed  under  vacuum  to  yield  a  brown  residue.  Subsequent 
chromatography (SiO2; petrol : ether, 90 / 10 
v/v) and recrystallisation from 
petrol afforded the title compounds 195c (2.14 g, 73 %), 195d (1.47 g, 47 
%) and 195e (1.25 g, 38 %). 
 
3,5 Bis(phenylethynyl)pyridine (195a); white needles m.p. 126 
oC (from 
petrol / EtOAc); FTIR (neat solid) 3025, 2209, 1487, 1420, 889, 753, 688 
cm
 1; 
1H NMR (CDCl3) δ 8.60 (d, J = 1.8, 2H, H2, H6), 7.86 (t, J = 1.8, 1H, 
H4),  7.49 7.40  (m,  4H,  H2''),  7.32   7.28  (m,  6H,  H3'',  H4''); 
13C  NMR 
(CDCl3)  δ  150.8  (C2,  C6),  140.6  (C4),  131.8  (C2''),  129.0  (C4''),  128.5 
(C3''), 122.4 (q, C1''), 120.2 (q, C3, C5), 93.3 (q, C2'), 85.2 (q, C1'); Anal. 
Calcd for C21H13N: C, 90.30; H, 4.69; N, 5.01. Found: C, 90.23; H, 4.74; N, 
4.81. 
 
3,5 Bis [(4 methylphenyl)ethynyl]pyridine  (195b);  voluminous  white 
solid; m.p. 182 
oC (from petrol / EtOAc); FTIR (neat solid) 3020, 2210, 
1506, 814, 763 cm
 1; 
1H NMR (CDCl3) δ 8.57 (m, br, 2H, H2, H6), 7.82 (t, J 
= 1.8, 1H, H4), 7.35 (d, J = 8.0, 4H, H2''), 7.10 (d, J = 7.8, 4H, H3''), 2.30 Page | 211  
 
(s, 6H, 4'' CH3); 
13C NMR (CDCl3) δ 150.6 (C2 or C6), 150.5 (C2 or C6), 
140.4 (C4), 139.2 (q, C4''), 131.7 (C2''), 129.3 (C3''), 120.3 (q, C3, C5), 
119.3 (q, C1''), 93.5 (q, C2'), 84.7 (q, C1'), 21.6 (4'' CH3); Anal. Calcd for 
C23H17N: C, 89.87; H, 5.57; N, 4.56. Found: C, 89.65; H, 5.62; N, 4.36.  
 
3 Phenylethynyl 5 [(4 methylphenyl)ethynyl]pyridine  (195c); 
voluminous white solid; m.p. 143 144 
oC; FTIR (neat solid) 3027, 2212, 
1419, 818, 754, 701, 686 cm
 1; 
1H NMR (CDCl3) δ 8.59 (m, br, 2H, H2, 
H6), 7.84 7.82 (m, 1H, H4), 7.48 7.45 (m, 2H, H2''''), 7.35 (d, J = 7.9, 2H, 
H2''), 7.30 7.28 (m, 3H, H3'''', H4''''), 7.10 (d, J = 7.9, 2H, H3''), 2.30 (s, 3H, 
4'' CH3);
  13C NMR (CDCl3) δ 150.6 (C2 or C6), 150.5 (C2 or C6), 140.6 
(C4), 139.3 (q, C4''), 131.8 (C2''''), 131.7 (C2''), 129.3 (C3''), 129.0 (C4''''), 
128.5 (C3''''), 122.4 (q, C1''''), 122.5 (q, C3 or C5), 122.4 (q, C3 or C5), 
119.3 (q, C1''), 93.7 (q, C2'), 93.3 (q, C2'''), 85.3 (q, C1'''), 84.6 (q, C1'), 
21.6 (4'' CH3); Anal. Calcd for C22H15N: C, 90.07; H, 5.15; N, 4.77. Found: 
C, 90.22; H, 5.18; N, 4.78. 
 
3 (4 Chlorophenylethynyl) 5 phenylethynyl pyridine  (195d);  pale 
yellow solid; m.p. 131 132 
oC; FTIR (neat solid) 3027, 2212, 1487, 1090, 
832, 756, 690 cm
 1; 
1H NMR (CDCl3) δ 8.61 8.58 (m, br, 2H, H2, H6), 
7.86 7.82 (m, 1H, H4), 7.48 7.45 (m, 2H, H2''), 7.40 (d, J = 8.7, 2H, H2''''), 
7.32 7.29 (m, 3H, H3'', H4''), 7.27 (d, J = 8.7, 2H, H3''''); 
13C NMR (CDCl3) 
δ 150.9 (C2 or C6), 150.7 (C2 or C6), 140.7 (C4), 135.2 (q, C4''''), 133.0 
(C2''''), 131.8 (C2''), 129.1 (C4''), 128.9 (C3''''), 128.5 (C3''), 122.3 (q, C1''), 
120.8 (q, C1''''), 120.3 (q, C5), 119.9 (q, C3), 93.5 (q, C2'), 92.2 (q, C2'''), Page | 212  
 
86.2 (q, C1'), 85.1 (q, C1'''); Anal. Calcd for C21H12ClN: C, 80.38; H, 3.85; 
N, 4.46. Found: C, 80.35; H, 3.89; N, 4.36. 
 
3 (4 Chlorophenylethynyl) 5 [(4 methylphenyl)ethynyl]pyridine 
(195e); pale yellow solid; m.p.189 
oC; FTIR (neat solid) 3026, 2210, 1578, 
1507, 1487, 1087, 819 cm
 1; 
1H NMR (CDCl3) δ 8.59 (m, br, 1H, H2, H6), 
7.83 (t, J = 1.8, 1H, H4), 7.38 (d, J = 8.7, 2H, H2''''), 7.36 (d, J = 8.1, 2H, 
H2''), 7.27 (d, J = 8.7, 2H, H3''''), 7.10 (d, J = 8.1, 2H, H3''), 2.30 (s, 3H, 4'' 
CH3); 
13C NMR (CDCl3) δ 150.9 (C2 or C6), 150.5 (C2 or C6), 140.5 (C4), 
139.3 (q, C4''), 135.1 (q, C4''''), 133.0 (C2''), 131.7 (C2''''), 129.3 (C3''), 
128.9 (C3''''), 120.9 (q, C1''''), 120.8 (q, C3 and C5), 119.3 (q, C1''), 93.7 
(q, C2'''), 92.0 (q, C2'), 86.3 (q, C1'''), 84.6 (q, C1'), 21.6 (4'' CH3); Anal. 
Calcd for C22H14ClN: C, 80.61; H, 4.30; N, 4.27. Found: C, 80.38; H, 4.39; 
N, 4.18. 
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Synthesis of compounds 197a c 
 
 
 
Compounds 197a c were prepared using GP 3. There was obtained: 
1 Methyl 3,5 bis(phenylethynyl)pyridinium  iodide  (197a),  using  195a 
(1.40 g, 5 mmol). (1.66 g, 79 %); pale yellow solid; m.p. 226 227 
°C (from 
EtOH); FTIR (neat solid) 2996, 2216, 1599, 1585, 1493, 1442, 756, 748, 
687, 662 cm
 1; 
1H NMR (DMSO d6) δ 9.38 (s, 2H, H2, H6), 8.97 (s, 1H, 
H4), 7.68 (dd, J = 6.9, 1.5, 4H, H2''), 7.58 7.55 (m, 6H, H3'', H4''), 4.37 (s, 
3H,  1 CH3); 
13C  NMR  (DMSO d6)  δ  148.0  (C4),  147.3  (C2,  C6),  132.3 
(C2''), 131.0 (C4''), 129.6 (C3''), 123.2 (q, C3), 120.7 (q, C1''), 97.2 (q, 
C2'), 82.7 (q, C1'), 48.9 (1 CH3); Anal. Calcd for C22H16IN: C, 62.72; H, 
3.83; N, 3.32. Found: C, 62.38; H, 3.81; N, 3.22. 
 
1 Methyl 3,5 bis[(4 methylphenyl)ethynyl]pyridinium  iodide  (197b), 
using 195b (1.54 g, 5 mmol). (1.60 g, 71 %); yellow solid; m.p. 218 219 
oC 
(from EtOH); FTIR (neat solid); 2993, 2210, 1584, 1482, 1071, 818 cm
 1; 
1H NMR (DMSO d6) δ 9.34 (s, 2H, H6, H2), 8.91 (s, 1H, H4), 7.56 (d, J = 
8.1, 4H, H2''), 7.35 (d, J = 8.1, 4H, H3''), 4.35 (s, 3H, 1 CH3), 2.40 (s, 6H, 
4'' CH3); 
13C  NMR  (DMSO d6)  δ  147.7  (C4),  146.9  (C2,  C6),  141.2  (q, Page | 214  
 
C4''), 132.3 (C2''), 130.2 (C3''), 123.4 (q, C3), 117.7 (q, C1''), 97.6 (C2'), 
82.3 (C1'), 48.8 (1 CH3), 21.7 (4'' CH3); Anal. Calcd for C24H20IN: C, 64.15; 
H, 4.49; N, 3.12. Found: C, 63.96; H, 4.55; N, 3.23. 
 
1 Methyl 3 phenylethynyl 5 [(4 methylphenyl)ethynylpyridinium] 
iodide (197c), using 195c (1.47 g, 5 mmol). (1.92 g, 88 %); yellow solid; 
m.p. 211 
oC (from EtOH); FTIR (neat solid) 2990, 2211, 1590, 1478, 810, 
748 cm
 1; 1H NMR (DMSO d6) δ 9.36 (s, 2H, H2, H6), 8.94 (s, 1H, H4), 
7.68 (dd, J = 7.2, 1.8, 2H, H2''''), 7.58 7.55 (m, 5H, H2'', H3'''', H4''''), 7.35 
(d, J  = 7.8, 2H, H3''), 4.36 (s, 3H, 1 CH3), 2.40 (s, 3H, 4'' CH3);
 13C NMR 
(DMSO d6) δ 147.9 (C4), 147.1 (C2 or C6), 147.0 (C2 or C6), 141.2 (q, 
C4''), 132.3 (C2'', C2''''), 131.0 (C4''''), 130.2 (C3''), 129.6 (C3''''), 123.5 (q, 
C3 or C5), 123.2 (q, C3 or C5), 120.7 (q, C1''''), 117.7 (q, C1''), 97.6 (q, 
C2'), 97.1 (q, C2'''), 82.7 (q, C1'), 82.3 (q, C1'''), 48.8 (1 CH3), 21.7 (4'' 
CH3);  Anal.  Calcd  for  C23H18IN:  C,  63.46;  H,  4.17;  N,  3.22.  Found:  C, 
63.64; H, 4.21; N, 3.30. 
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Synthesis of compounds 196a c 
 
 
 
Compounds 196a c were prepared using GP 4. There was obtained: 
 
2 [5 (2 Oxo 2 phenylethyl)pyridin 3 yl] 1 phenylethanone  (196a), 
using 195a (2.79 g, 10 mmol). (2.52 g, 80 %); white solid; m.p. 105 106 
°C 
(from EtOAc); FTIR (neat solid) 3026, 2924, 1680, 1208, 1014, 756, 688 
cm
 1; 
1H NMR (CDCl3) δ 8.41 (bs, 2H, H2'', H6''), 8.11 (dd, J = 7.2, 2.1, 4H, 
H2'), 7.71 (tt, J = 7.2, 2.1, 2H, H4'), 7.60 (t, J = 7.2, 4H, H3'), 7.58 (s, 1H, 
H4''), 4.47 (s, 4H, H1); 
13C NMR (CDCl3) δ 196.3 (q, C2), 149.1 (C2'', C6''), 
138.8 (C4''), 136.3 (q, C1'), 133.6 (C4'), 130.1 (q, C3'', C5''), 128.8 (C3'), 
128.4 (C2'), 42.2 (C1); Anal. Calcd for C21H17NO2: C, 79.98; H, 5.43; N, 
4.44. Found: C, 79.80; H, 5.49; N, 4.32. 
 
2 [5 (2 Oxo 2 (4 methylphenyl)ethyl) pyridin 3 yl] 1 (4 methylphenyl) 
ethanone  (196b),  using  195b  (3.07  g,  10  mmol).  (2.99  g,  87  %);  pale 
yellow  solid;  m.p.  134 
°C  (from  EtOAc);  FTIR  (neat  solid)  3026,  2917, Page | 216  
 
1676,  1603,  1409,  1324,  1221,  1204,  1182,  812,  771  cm
 1; 
1H  NMR 
(CDCl3) δ 8.37 (bs, 2H, H2', H6'), 7.83 (d, J = 7.5, 4H, H2''), 7.47 (s, 1H, 
H4'), 7.20 (d, J = 7.5, 4H, H3''), 4.19 (s, 4H, H1), 2.34 (s, 6H, 4'' CH3);
 13C 
NMR (CDCl3) δ 196.0 (q, C2), 149.1 (C2', C6'), 144.4 (q, C4''), 138.5 (C4'), 
133.9 (q, C1''), 129.5 (C3''), 129.4 (q, C3', C5'), 128.6 (C2''), 42.1 (C1), 
21.7  (4'' CH3);  Anal.  Calcd  for  C23H21NO2:  C,  80.44;  H,  6.16;  N,  4.08. 
Found: C, 80.35; H, 6.16; N, 4.05. 
 
2 [5 (2 Oxo 2 (4 methylphenyl)ethyl)pyridin 3 yl] 1 phenylethanone 
(196c), using 195c (2.93 g, 10 mmol). (2.37 g, 72 %); pale yellow solid; 
m.p. 77 
°C (from EtOAc); FTIR (neat solid) 2924, 1680, 1605, 1325, 1209, 
755, 690, 571 cm
 1; 
1H NMR (CDCl3) δ 8.35 (bs, 2H, H2'', H6''), 7.92 (dd, J 
= 7.6, 1.0, 2H, H2'), 7.82 (d, J = 8.1, 2H, H2''''), 7.51 (tt, J = 7.6, 1.0, 1H, 
H4'), 7.46 (bs, 1H, H4''), 7.40 (t, J = 7.6, 2H, H3'), 7.18 (d, J = 8.1, 2H, 
H3''''), 4.21 (s, 2H, H2), 4.18 (s, 2H, H2'''), 2.33 (s, 3H, 4'''' CH3);
 13C NMR 
(CDCl3) δ 196.4 (q, C1 or C1'''), 196.0 (q, C1 or C1'''), 149.2 (C2''), 149.1 
(C6''), 144.5 (q, C4''''), 138.6 (C4''), 136.6 (q, C1'), 133.9 (q, C1''''), 133.5 
(C4'), 130.3 (q, C3'' or C5''), 130.0 (q, C3'' or C5''), 129.5 (C3''''), 128.8 
(C3'),  128.6  (C2''''),  128.5  (C2'),  42.2  (C2),  42.1  (C2'''),  21.7  (4'''' CH3); 
Anal. Calcd for C22H19NO2: C, 80.22; H, 5.81; N, 4.25. Found: C, 80.03; H, 
5.89; N, 4.21. 
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Synthesis of compounds 198a c 
 
 
 
Either compound 196a (1.58 g, 5 mmol), 196b (1.72 g, 5 mmol) or 196c 
(1.65 g, 5 mmol) and methyl trifluoromethanesulfonate (1.23 g, 0.85 mL, 
7.5 mmol) were added to a pressure tube containing dry THF (3 mL) and 
the resultant mixture stirred at 80 
°C for 12 h. The reaction mixture was 
allowed to cool and was then diluted with cold ether (15 mL). The resulting 
precipitate  was  collected  by  filtration  and  recrystallised  to  give  the 
products. There was obtained: 
 
1 methyl 3,5 bis(2 oxo 2 phenylethyl)pyridinium 
trifluoromethanesulfonate (198a); (2.06 g, 83 %); white solid; m.p. 134 
°C (from EtOH); FTIR (neat solid) 3069, 1686, 1598, 1260, 1214, 1149, 
1026, 752, 636, 571 cm
 1; 
1H NMR (DMSO d6) δ 8.90 (s, 2H, H2), 8.42 (s, 
1H, H4), 8.11 (dd, J = 7.5, 2.1, 4H, H2''), 7.75 (tt, J = 7.5, 2.1, 2H, H4''), 
7.63 (t, J = 7.5, 4H, H3''), 4.82 (s, 4H, H2'), 4.41 (s, 3H, 1 CH3);
 13C NMR 
(DMSO d6) δ 196.0 (C1'), 148.8 (C2), 144.8 (C4), 136.3 (q, C3 or C1''), Page | 218  
 
135.9 (q, C3 or C1''), 134.4 (C4''), 129.4 (C3''), 128.8 (C2''), 48.5 (1 CH3), 
41.7  (C2').  Anal.  Calcd  for  C23H20F3NO5S:  C,  57.62;  H,  4.20;  N,  2.92. 
Found: C, 57.44; H, 4.18; N, 2.83. 
 
1 Methyl 3,5 bis[2 oxo 2 (4 methylphenyl)ethyl]pyridinium 
trifluoromethanesulphonate  (198b);  (2.17 g,  83  %);  pale  yellow  solid; 
m.p. 165 
°C (from EtOH); FTIR (neat solid) 3070, 1685, 1598, 1259, 1218, 
1150, 1027, 753, 636, 571 cm
 1; 
1H NMR (DMSO d6) δ 8.90 (s, 2H, H2), 
8.40 (s, 1H, H4), 8.02 (d, J = 8.1, 4H, H3''), 7.43 (d, J = 8.1, 4H, H2''), 4.78 
(s, 4H, H1'), 4.40 (s, 3H, 1 CH3), 2.44 (s, 6H, 4'' CH3); 
13C NMR (DMSO 
d6) δ 195.5 (q, C2'), 148.7 (C4), 144.9 (q, C4''), 144.8 (C2), 135.9 (q, C3), 
133.9 (q, C1''), 129.9 (C2''), 128.9 (C3''), 48.5 (1 CH3), 41.6 (C1'), 21.7 (4'' 
CH3); Anal. Calcd for C25H24F3NO5S: C, 59.16, H, 4.77; N, 2.76. Found: C, 
58.98; H, 4.75; N, 2.76.  
 
1 Methyl 3 (2 oxo 2 phenylethyl) 5 (2 oxo 2 (4 
methylphenyl)ethylpyridinium  trifluoromethanesulphonate  (198c). 
(1.77 g, 69 %); pale yellow solid; m.p. 132 
°C (from EtOH); FTIR (neat 
solid) 3064, 1685, 1607, 1258, 1223, 1212, 1152, 1029, 809, 753, 637, 
570 cm
 1; 
1H NMR (DMSO d6) δ 8.90 (s, 2H, H2 + H6), 8.41 (s, 1H, H4), 
8.12 (d, J = 7.8, 2H, H2''''), 8.02 (d, J = 8.1, 2H, H3''), 7.75 (t, J  = 7.8, 1H, 
H4''''), 7.63 (t, J = 7.8, 2H, H2''''), 7.43 (d, J = 8.1, 2H, H2''), 4.83 (s, 2H, 
H1'''), 4.79 (s, 2H, H1'), 4.40 (s, 3H, 1 CH3), 2.44 (s, 3H, 4'' CH3); 
13C 
NMR (DMSO d6) δ 196.0 (q, C2'''), 195.5 (q, C2'), 148.8 (C4), 144.9 (q, 
C4''), 144.8 (C2 and C6), 136.3 (q, C1''''), 135.9 (q, C5), 135.8 (q, C3), Page | 219  
 
134.4 (C4''''), 133.9 (q, C1''), 129.9 (C2''), 129.4 (C2''''), 128.9 (C2''), 128.8 
(C2''''), 48.5 (1 CH3), 41.7 (C1'''), 41.6 (C1'), 21.7 (4'' CH3); Anal. Calcd for 
C24H22F3NO5S: C, 58.41; H, 4.49; N, 2.83. Found: C, 58.26; H, 4.47; N, 
2.74. 
 
Synthesis of compounds 182a c 
 
 
 
To a stirred solution of either 196a (3.15 g, 10 mmol) 196b (3.43 g, 10 
mmol) or 196c (3.29 g, 10 mmol) in MeOH (15 mL) at room temperature 
was added NaBH4 (1.51 g, 40 mmol) in 3 portions. The reaction mixture 
was stirred at room temperature for 5 h. The solvent was removed under 
reduced  pressure  and  the  residue  re dissolved  in  water  (20  mL).  The 
aqueous phase was extracted with DCM (3 x 15 mL) and the combined 
organic  extracts  washed  with  brine  (15  mL),  dried  (MgSO4)  and 
concentrated  under  reduced  pressure.  The  resultant  residue  was 
recrystallised to afford the products. There was obtained: 
 
2 [5 (2 Hydroxy 2 phenylethyl) 1 pyridin 3 yl] 1 phenylethanol  (196a). 
(2.81  g,  88  %);  white  solid; m.p.  148 149 
°C  (from  EtOAc);  FTIR  (neat 
solid) 3340 (br), 3030, 2854,1586, 1493, 1453, 1433, 1029, 755, 714, 700 
cm
 1; 
1H NMR (DMSO d6) δ 8.09 (bs, 2H, H6'', H2''), 7.36 (bs, 1H, H4''), Page | 220  
 
7.30 7.20 (m, 10H, H2', H3', H4'), 5.33 (d, J = 3.6, 2H, OH), 4.72 (td, J = 
6.6, 3.6, 2H, H1), 2.83 (d, J = 6.6, 4H, H2); 
13C NMR (DMSO d6) δ 148.5 
(C2'', C6''), 145.8 (q, C1'), 138.3 (C4''), 133.9 (q, C3''), 128.4 (C3'), 127.3 
(C4'),  126.4  (C2'),  73.7  (C1),  43.0  (C2);  Anal.  Calcd  for  C21H21NO2:  C, 
78.97; H, 6.63; N, 4.39. Found: C, 78.79; H, 6.67; N, 4.46. 
 
2 [5 (2 Hydroxy 2 4 methyl ethyl) pyridin 3 yl] 1 (4 methylphenyl) 
ethanol (196b). (2.85 g, 82 %); white solid; m.p. 103 
°C (from EtOAc); 
FTIR  (neat  solid)  3332  br,  3029,  2924,  1512,  1053,  814,  783  cm
 1; 
1H 
NMR (CDCl3) δ 8.14 (bs, 2H, H6'', H2''), 7.26 (bs, 1H, H4''), 7.17 (d, J = 
8.4, 4H, H2'), 7.13 (d, J = 8.4, 4H, H3'), 4.73 (td, J = 6.3, 3.6, 2H, H1), 2.90 
(d, J = 6.3, 4H, H2), 2.72 (bs, 2H, OH), 2.34 (s, 6H, 4' CH3); 
13C NMR 
(CDCl3) δ 148.4 (C6'', C2''), 140.7 (q, C4'), 138.6 (C4''), 137.5 (q, C1'), 
133.5 (q, C3''), 129.2 (C3'), 125.8 (C2'), 74.6 (C1), 42.8 (C2), 21.1 (4' 
CH3); Anal. Calcd for C23H25NO2: C, 79.51; H, 7.25; N, 4.03. Found: 79.74; 
H, 7.33; N, 4.11. 
 
2 [5 (2 Hydroxy 2 (4 methylphenyl)ethyl)pyridin 3 yl] 1 phenylethanol 
(196c). (3.13 g, 94 %); white solid; m.p.106 107 
°C (from EtOAc); FTIR 
(neat solid) 3352 (br), 3056, 2924, 1451, 1431, 1039, 818, 753, 700 cm
 1; 
1H NMR (CDCl3) δ 8.04 (bs, 2H, H2'', H6''), 7.25 7.18 (m, 6H, H2', H3', 
H4', H4''), 7.09 (d, J = 8.4, 2H, H2''''), 7.04 (d, J = 8.4, 2H, H3''''), 4.66 (m, 
2H,  H1,  H1'''),  2.92  (s,  br,  2H,  OH),  2.83  (m,  4H,  H2,  H2'''); 
13C  NMR 
(CDCl3) δ 148.3 (C6'', C2''), 143.7 (q, C1'), 140.7 (q, C1''''), 138.8 (C4''), 
137.5 (q, C4''''), 137.4 (q, C1''''), 133.6 (q, C3'' or C5''), 133.5 (q, C3'' or Page | 221  
 
C5''), 129.2 (C3''''), 128.5 (C3'), 127.7 (C4'), 125.9 (C2'), 125.8 (C2''''), 74.7 
(C2 or C2'''), 74.6 (C2 or C2'''), 42.8 (C1 or C1'''), 42.8 (C1 or C1'''), 21.1 
(4'''' CH3); Anal. Calcd for C22H23NO2: C, 79.25; H, 6.95; N, 4.20. Found: 
C, 79.21; H, 7.14; N, 4.12. 
 
Synthesis of compounds 199a c 
 
 
 
Dry THF (2 mL), either compound 196a (0.96 g, 3 mmol), 196b (1.04 g, 3 
mmol) or 196c (1.00 g, 3 mmol) and methyl iodide (0.31 mL, 5 mmol) were 
sequentially placed in an oven dried pressure tube. The reaction mixture 
was stirred at 80 
°C for 12 h. After cooling, the resulting precipitate was 
collected  by  filtration,  washed  with  ether  (10  mL)  and  recrystallised  to 
furnish the products. There was obtained: 
 
3,5 Bis (2 hydroxy 2 phenylethyl) 1 methylpyridinium  iodide  (199a). 
(1.20 g, 87 %); white solid; m.p. 169 170 
°C (from EtOH); FTIR (neat solid) 
3378 (br), 3016, 1451, 1417, 1053, 764, 706, 686 cm
 1; 
1H NMR (DMSO 
d6) δ 8.78 (bs, 2H, H6, H2), 8.27 (t, J = 2.1, 1H, H4), 7.42 7.35 (m, 8H, 
H2'', H3''), 7.32 7.27 (m, 2H, H4''), 5.55 (d, J = 4.2, 2H, OH), 4.89 4.85 (m, 
2H, H2'), 4.32 (s, 3H, 1 CH3), 3.14 2.95 (m, 4H, H1'); 
13C NMR (DMSO d6) 
δ 147.1 (C4), 145.1 (q, C1''), 143.7 (C2, C6), 139.4 (q, C3, C5), 128.7 Page | 222  
 
(C3''), 127.7 (C4''), 126.3 (C2''), 72.5 (C2'), 48.1 (1 CH3), 42.3 (C1'); Anal. 
Calcd for C22H24INO2: C, 57.28; H, 5.24; N, 3.04. Found: C, 57.18; H, 5.20; 
N, 2.93. 
 
3,5 Bis [2 hydroxy 2 (4 methylphenyl)ethyl] 1 methylpyridinium 
iodide (199b). (1.22 g, 83 %); white solid; m.p. 182 183 
°C (from EtOH); 
FTIR (neat solid) 3375, 3026, 1686, 1508, 1210, 1063, 812, 684 cm
 1; 
1H 
NMR (DMSO d6) δ 8.76 (s, 2H, H2, H6), 8.24 (br, 1H, H4), 7.27 (d, J = 7.5, 
4H, H2''), 7.18 (d, J = 7.5, 4H, H3''), 5.48 (d, J = 3.6, 2H, OH), 4.83 4.80 
(m, 2H, H2'), 4.31 (s, 3H, 1 CH3), 3.10 2.91 (m, 4H, H1'), 2.31 (s, 6H, 4'' 
CH3); 
13C NMR (DMSO d6) δ 147.0 (C4), 143.7 (C2, C6), 142.1 (q, C4''), 
139.4 (q, C3, C5), 136.7 (q, C1''), 129.2 (C3''), 126.2 (C2''), 72.4 (C2'), 
48.1  (1 CH3),  42.3  (C1'),  21.2  (4'' CH3);  Anal.  Calcd for  C24H28INO2:  C, 
58.90; H, 5.77; N, 2.86. Found: C, 58.76; H, 5.73; N, 2.76. 
 
3 (2 Hydroxy 2 phenylethyl) 5 [2 hydroxy 2 (4 methylphenyl)ethyl] 1 
methylpyridinium iodide (199c). (0.83 g, 58%); white solid; m.p. 160 161 
°C (from EtOH); FTIR (neat solid) 3382 (br), 3018, 1496, 1056, 818, 761, 
706 cm
 1; 
1H NMR (DMSO d6) δ 8.81 (br, 2H, H2, H6), 8.30 (br, 1H, H4), 
7.44 7.38 (m, 5H, H2'''', H3'''', H4''''), 7.35 (d, J = 8.1, 2H, H2''), 7.23 (d, J = 
8.1, 2H, H3''), 5.60 (d, J = 4.2, 1H, 2''' OH), 5.52 (d, J = 4.2, 1H, 2' OH), 
4.93 4.86 (m, 2H, H2', H2''), 4.36 (s, 3H, 1 CH3), 3.18 2.98 (m, 4H, H1', 
H1'''), 2.36 (s, 3H, 4'' CH3);
 13C NMR (DMSO d6) δ 147.0 (C4), 145.1 (q, 
C1''''), 143.7 (C2, C6), 142.1 (q, C4''), 139.4 (q, C3), 139.3 (q, C5), 136.7 
(q,  C1''),  129.2  (C3''),  128.6  (C3''''),  127.7  (C4''''),  126.3  (C2''''),  126.2 Page | 223  
 
(C2''), 72.5 (C2'), 72.4 (C2'), 72.3 (C2'''), 72.3 (C2'''), 48.1 (1 CH3), 42.3 
(C1, C1''''), 21.2 (4'' CH3); Anal. Calcd for C23H26INO2: C, 58.11; H, 5.51; 
N, 2.95. Found: C, 58.13; H, 5.55; N, 2.90. 
 
Synthesis of compounds 203a d 
 
 
 
A solution of either 194a (1.55 g, 6 mmol) [for 203a or 203c] or 194b (1.63 
g, 6 mmol) [for 203b or 203d, in dry ether (100 mL) was cooled to  78 
°C 
under an atmosphere of argon, followed by the dropwise addition of n BuLi 
(2.6 mL, 2.5 M, 6.6 mmol) in ether (30 mL) over 15 min. The resulting 
bright orange solution was stirred at  78 
°C for 30 min and a solution of 
benzaldehyde  163a  (0.70  g,  6.6  mmol)  [for  203a  or  203b]  or  4 
chlorobenzaldehyde 163c (0.93 g, 6.6 mmol) [for 203c or 203d] in ether 
(30 mL) added dropwise over 10 min. The reaction mixture was allowed to 
warm  to  room  temperature  over  0.5  h  and  stirred  for  a  further  1  h, 
quenched with water (100 mL), the phases separated, and the aqueous 
phase extracted with EtOAc (3 x 15 mL). The combined organic extracts 
were  dried  (MgSO4)  and  the  solvent  removed  under  reduced  pressure. 
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ether : petrol, 90 : 10 
v/v) and recrystallisation as appropriate furnished the 
products. There was obtained: 
 
Phenyl (5 phenylethynylpyridin 3 yl)methanol  (203a).  (0.99  g,  58  %); 
colourless oil; FTIR (neat) 3188 (br), 2215, 1491, 1443, 1024, 754, 698, 
689 cm
 1;
 1H NMR (CDCl3) δ 8.59 (br, 1H, H6''), 8.53 (br, 1H, H2''), 7.91 (t, 
J = 1.8, 1H, H4''), 7.59 –7.55 (m, 2H, H2'''), 7.42 7.35 (m, 8H, H3'''', H4'''', 
H2'''', H3''', H4'''), 5.90 (s, 1H, H1), 3.95 (bs, 1H, OH); 
13C NMR (CDCl3) δ 
150.2 (C6'), 146.3 (C2'), 142.8 (q, C1''''), 139.6 (q, C3'), 137.2 (C4'), 131.8 
(C2'''), 129.0 (C4'''), 128.9 (C3''''), 128.5 (C3'''), 128.2 (C4''''), 126.7 (C2''''), 
122.4 (q, C1'''), 120.6 (q, C5'), 93.2 (q, C2'''), 85.7 (q, C1'''), 73.7 (C1). 
HRMS calcd for C20H15NO (M + H)
+ required 286.1233, found 286.1232. 
  
Phenyl [5 (4 methylphenyl) ethynyl pyridin 3 yl]methanol  (203b). 
(1.29 g, 72 %); pale yellow solid; m.p. 47 48 
°C (EtOAc / petrol); FTIR 
(neat solid) 3193 (br), 2214, 1509, 1044, 1023, 814, 709, 698 cm
 1; 
1H 
NMR (CDCl3) δ 8.43 (br, 1H, H6'), 8.35 (br, 1H, H2'), 7.75 (t, J = 1.8, 1H, 
H4'), 7.32 (d, J = 8.1, 2H, H2'''), 7.27 7.17 (m, 5H, H2'''', H3'''', H4''''), 7.06 
(d, J = 8.1, 2H, H3'''), 5.74 (s, 1H, H1), 3.75 (s, 1H, OH), 2.28 (s, 3H, 4'' 
CH3);
 13C NMR (CDCl3) δ 150.4 (C6'), 146.3 (C2'), 142.9 (q, C1''''), 139.4 
(q,  C3'),  139.2  (q,  C4'''),  136.9  (C4'),  131.7  (C2'''),  129.3  (C3'''),  128.9 
(C3''''), 128.1 (C4''''), 126.7 (C2''''), 120.7 (q, C1'''), 119.4 (q, C5'), 93.3 (q, 
C2''), 85.2 (q, C1''), 73.7 (C1), 21.6 (4'' CH3).  
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(4 Chlorophenyl) (5 phenylethynylpyridin 3 yl)methanol  (203c).  (1.31 
g, 68 %); white solid; m.p. 108 
°C (from EtOAc / petrol); FTIR (neat solid) 
3128 (br), 3052, 1487, 1439, 1086, 1013, 787, 753, 687 cm
 1;
  1H NMR 
(CDCl3) δ 8.50 (br, 1H, H6'), 8.38 (br, 1H, H2'), 7.73 (t, J = 1.5, 1H, H4), 
7.46 7.43 (m, 2H, H2'''), 7.30 7.21 (m, 5H, H3''', H4''', H3''''), 5.76 (s, 1H, 
H1), 3.49 (s, br, 1H, OH); 
13C NMR (CDCl3) δ 150.8 (C6'), 146.5 (C2'), 
141.2 (q, C1''''), 138.9 (q, C3'), 136.8 (C4'), 134.0 (q, C4''''), 131.8 (C2'''), 
129.1  (C3''''),  129.0  (C4'''),  128.5  (C2''''),,  128.0  (C3'''),  122.3  (q,  C1'''), 
118.2  (q,  C5'),  93.3  (q,  C2'),  85.6  (q,  C1'),  73.1  (C1);  Anal.  Calcd  for 
C20H14ClNO: C, 75.12; H, 4.41; N, 4.38. Found: C, 74.91; H, 4.49; N, 4.40. 
 
(4 Chlorophenyl) [5 (4 methylphenyl)ethynylpyridin 3 yl]methanol 
(203d). (1.20 g, 60 %); white solid; m.p. 151 152 
°C (from EtOAc / petrol); 
FTIR  (neat  solid)  3133,  2214,  1508,  1088,  1058,  815  cm
 1;
  1H  NMR 
(CDCl3) δ 8.45 (d, J = 1.5, 1H, H6'), 8.35 (d, J = 1.5, 1H, H2'), 7.71 (t, J = 
1.5, 1H, H4'), 7.33 (d, J = 8.1, 2H, H2'''), 7.25 (d, J = 9.0, 2H, H3''''), 7.21 
(d, J = 9.0, 2H, H2''''), 7.07 (d, J = 8.1, 2H, H3'''), 5.74 (s, 1H, H1), 3.81 (s, 
1H,  OH),  2.29  (s,  3H,  4''' CH3);
  13C  NMR  (CDCl3)  δ  150.5  (C6'),  146.1 
(C2'), 141.2 (q, C1''''), 139.3 (q, C4'''), 139.1 (q, C3'), 137.0 (C4'), 134.0 (q, 
C4''''),  131.7  (C2'''),  129.3  (C3'''),  129.0  (C3''''),  128.0  (C2''''),  120.9  (q, 
C1'''), 119.2 (q, C5'), 93.7 (q, C2''), 85.0 (q, C1''), 73.0 (C1), 21.6 (4''' CH3); 
Anal. Calcd for C21H16ClNO: C, 75.56; H, 4.83; N, 4.20. Found: C, 75.25; 
H, 4.89; N, 4.07.  
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Synthesis of compounds 204a d 
 
 
 
Compounds 204a d were prepared using GP 4. There was obtained: 
 
2 [5 (Hydroxyphenylmethyl)pyridin 3 yl] 1 phenylethanone  (204a), 
using 203a (0.86 g, 3 mmol). (0.50 g, 55 %); white solid; m.p. 102 103 
°C 
(from EtOAc / petrol); FTIR (neat solid) 3143 (br), 1684, 1449, 1327, 1209, 
1052, 743, 716, 702, 686 cm
 1;
 1H NMR (DMSO d6) δ 8.48 (d, J = 1.8, 1H, 
H6''), 8.35 (d, J = 1.8, 1H, H2''), 8.06 (dd, J = 7.8, 1.8, 2H, H2'), 7.70 7.65 
(m, 2H, H4'', H4'), 7.56 (t, J = 7.8, 2H, H3'), 7.39 (dd, J = 7.8, 1.2, 2H, 
H2'''), 7.33 (t, J = 7.8, 2H, H3'''), 7.24 (tt, J = 7.8, 1.8, 1H, H4'''), 6.06 (d, J 
= 3.9, 1H, OH), 5.79 (d, J = 3.9, 1H, H1''''), 4.48 (s, 2H, H2);
  13C NMR 
(DMSO d6)  δ  197.7  (q,  C1),  149.8  (C2''),  146.5  (C6''),  145.4  (q,  C1''''), 
140.8 (q, C5'), 136.8 (q, C1'), 135.6 (C4''), 133.9 (C4'), 130.9 (q, C3''), 
129.2  (C3'),  128.8  (C2'),  128.7  (C3'''),  127.5  (C4'''),  126.7  (C2'''),  72.6 
(C1''''), 42.2 (C2);  Anal. Calcd for C20H17NO2: C, 79.19; H, 5.65; N, 4.62. 
Found: C, 79.05; H, 5.67; N, 4.63. 
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2 [5 (Hydroxyphenylmethyl)pyridin 3 yl] 1 (4 methylphenyl)ethanone 
(204b), using 203b (0.90 g, 3 mmol). (0.78 g, 82 %); white solid; m.p. 139 
140 
°C (from EtOAc / petrol); FTIR (neat solid) 3125, 1683, 1605, 1327, 
1049, 809, 744, 716, 705 cm
 1; 
1H NMR (DMSO d6) δ 8.47 (d, J = 1.8, 1H, 
H6''), 8.34 (d, J = 1.8, 1H, H2''), 7.96 (d, J = 8.1, 2H, H2'), 7.66 (t, J= 1.8, 
1H, H4''), 7.41 7.30 (m, 7H, H3', H2''', H3''', H4'''), 6.07 (d, J = 4.1, 1H, 
OH), 5.79 (d, J = 3.9, 1H, H1''''), 4.43 (s, 2H, H2), 2.40 (s, 3H, 4' CH3);
 13C 
NMR (DMSO d6) δ 197.1 (q, C1), 149.8 (C2''), 146.5 (C6''), 145.4 (q, C4'), 
144.3 (q, C1'), 140.8 (q, C1'''), 135.5 (C4''), 134.3 (q, C5''), 131.1 (q, C3''), 
129.8  (C3'),  128.9  (C2'),  128.7  (C3'''),  127.5  (C4'''),  126.7  (C2'''),  72.7 
(C1''''), 42.1 (C2), 21.6 (4' CH3); Anal.  Calcd for C21H19NO2: C, 79.47; H, 
6.03; N, 4.41. Found: C, 79.04; H, 6.12; N, 4.27. 
 
2 {5 [(4 Chloro phenyl)hydroxymethyl]pyridin 3 yl} 1 phenylethanone 
(204c), using 203c (0.96 g, 3 mmol). (0.65 g, 64 %); white solid; m.p. 107 
°C (EtOAc / petrol); FTIR (neat solid) 3125 (br), 1686, 1488, 1325, 1208, 
1063, 1014, 756, 726, 686 570 cm
 1; 
1H NMR (DMSO d6) δ 8.48 (d, J = 
1.2, 1H, H6''), 8.36 (d, J = 1.2, 1H, H2''), 8.06 (dd, J = 7.8, 1.2, 2H, H2'), 
7.68 (tt, J = 7.8, 1.2, 1H, H4'), 7.64 (t, J = 1.2, 1H, H4''), 7.56 (t, J = 7.8, 
2H, H3'), 7.43 (d, J = 9.0, 2H, H3''''), 7.38 (d, J = 9.0, 2H, H2''''), 6.17 (d, J 
= 4.2, 1H, OH), 5.81 (d, J  = 4.2, 1H, H1), 4.48 (s, 2H, H2); 
13C NMR 
(DMSO d6)  δ  197.6  (q,  C1),  150.0  (C2''),  146.5  (C6''),  144.3  (q,  C1''''), 
140.4 (q, C5''), 136.8 (q, C1'), 135.6 (C4''), 133.9 (C4'), 132.0 (q, C4''''), 
131.0 (q, C3''), 129.2 (C3'), 128.8 (C2'), 128.7 (C3'''' or C2''''), 128.5 (C2'''' Page | 228  
 
or C3''''), 71.9 (C1''''), 42.2 (C2); Anal. Calcd for C20H16ClNO2: C, 71.11; H, 
4.77; N, 4.15. Found: C, 71.12; H, 4.78; N, 4.12. 
 
2 {5 [4 Chlorophenyl)hydroxymethyl]pyridin 3 yl} 1 (4 
methylphenyl)ethanone (204d), using 203d (1.00 g, 3 mmol). (0.79 g, 74 
%); white solid; m.p. 144 145 
°C (from EtOAc / petrol); FTIR (neat solid) 
3108 (br), 1685, 1604, 1487, 1323, 1062, 1013, 807, 793, 766, 725, 566 
cm
 1;
 1H NMR (DMSO d6) δ 8.48 (br, 1H, H6''), 8.35 (br, 1H, H2''), 7.95 (d, 
J = 8.1, 2H, H2'), 7.63 (br, 1H, H4''), 7.35 (m, 6H, H3', H2'''', H3''''), 6.16 (d, 
J = 4.2, 1H, OH), 5.80 (d, J = 4.2, 1H, H1'''), 4.43 (s, 2H, H2), 2.40 (s, 3H, 
4' CH3); 
13C NMR (DMSO d6) δ 197.1 (q, C1), 150.0 (C2''), 146.5 (C6''), 
144.4 (q, C1'''' or q, C4'), 144.3 (q, C1'''' or q, C4'), 140.4 (q, C5'), 135.6 
(C4''), 134.3 (q, C1'), 132.0 (q, C4''''), 131.2 (q, C3''), 129.8 (C3'), 128.9 
(C2'),  128.7  (C3''''),  128.5  (C2''''),  71.9  (C1'''),  42.1  (C2),  21.6  (4' CH3); 
Anal. Calcd for C21H18ClNO2: C, 71.69; H, 5.16; N, 3.98. Found: C, 71.73; 
H, 5.15; N, 3.97. 
 
 
 
 
 
 
 
 
 Page | 229  
 
Synthesis of compounds 194a,c,e 
 
 
 
To dry  THF  (8  mL) was  added  3,5 dibromopyridine  (2.37  g,  10  mmol), 
either terminal acetylene 147a (0.92 g, 9 mmol), 147c (1.23 g, 9 mmol), or 
147e (1.05 g, 9 mmol), bis(triphenylphosphine)palladium (II) chloride (0.4 
g,  0.6  mmol,  5  mol.%),  copper  iodide  (0.2  g,  1.1  mmol,  2  mol.%)  and 
triethylamine (6 mL, 40 mmol). The mixture was stirred for 12 h at 50 
°C 
(110 
°C  for  147c)  under  an  atmosphere  of  argon.  After  cooling,  the 
reaction mixture was washed with water, dried (MgSO4) and the volatiles 
removed under reduced pressure to afford a brown residue. Purification by 
column chromatography (SiO2, 100% petrol) and recrystallisation afforded 
the products. There was obtained: 
 
3 Bromo 5 phenylethynylpyridine  (194a).  (1.39  g,  60  %);  pale  yellow 
solid; m.p. 97 
°C (from petrol / EtOAc); FTIR (neat solid) 3030, 2209, 1580, 
1397, 754, 689 cm
 1; 
1H NMR (CDCl3) δ 8.59 (d, J = 1.8, 1H, H2), 8.54 (d, 
J = 1.8, 1H, H6), 7.89 (t, J = 1.8, 1H, H4), 7.47 (dd, J = 7.5, 2.1, 2H, H2''), 
7.32 7.30 (m, 3H, H3'', H4''); 
13C NMR (CDCl3) δ 150.2 (C2), 149.7 (C6), 
140.7 (C4), 131.8 (C2''), 129.2 (C4''), 128.5 (C3''), 122.1 (q, C1''), 121.9 (q, Page | 230  
 
C3), 120.1 (q, C5), 94.0 (q, C2'), 84.5 (q, C1'); Anal. Calcd for C13H8BrN: 
C, 60.49; H, 3.12; N, 5.43. Found: C, 60.65; H, 3.14; N, 5.32. 
 
3 Bromo 5 (4 methylphenyl)ethynylpyridine  (194b).  (2.06  g,  84  %); 
pale yellow solid; m.p. 121 122 
°C (from petrol / EtOAc); FTIR (neat solid) 
3022, 2210, 1572, 1406, 1109, 828 cm
 1; 
1H NMR (CDCl3) δ 8.58 (d, J = 
1.8, 1H, H2), 8.52 (d, J = 1.8, 1H, H6), 7.87 (t, J = 1.8, 1H, H4), 7.35 (d, J 
= 7.8, 2H, H2''), 7.11 (d, J = 7.8, 2H, H3''), 2.31 (s, 3H, 4'' CH3);
 13C NMR 
(CDCl3) δ 150.1 (C2), 149.5 (C6), 140.6 (C4), 139.5 (q, C4''), 131.7 (C2''), 
129.3 (C3''), 122.2 (q, C1''), 120.1 (q, C5), 119.0 (q, C3), 94.3 (q, C2'), 
83.9 (q, C1'), 21.6 (4'' CH3); Anal. Calcd for C14H10BrN: C, 61.79; H, 3.70; 
N, 5.15. Found: C, 61.79; H, 3.73; N, 5.09. 
 
3 Bromo 5 (4 chlorophenylethynyl)pyridine (194c). (1.29 g, 49 %); pale 
yellow solid 113 114 
°C; FTIR (neat solid) 3017, 1484, 1404, 1091, 880, 
824 cm
 1; 
1H NMR (CDCl3) δ 8.60 (br, 1H, H6), 8.56 (br, 1H, H6), 7.88 (s, 
1H, H4), 7.38 (d, J = 8.7, 2H, H2''), 7.26 (d, J = 8.7, 2H, H3''); 
13C NMR 
(CDCl3) δ 150.0 (C6), 149.8 (C2), 140.7 (C4), 135.4 (q, C4''), 133.0 (C2''), 
128.9 (C3''), 120.5 (q, C3, q, C5, q, C1''), 92.9 (q, C2'), 85.4 (q, C1'); EA 
calc. for C13H17ClBrN: C, 53.37; H, 2.41; N, 4.79. Found: C, 53.29; H, 2.50; 
N, 4.24. 
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Synthesis of compounds 205a and 205b 
 
 
 
Compounds  205a  and  205b  were  synthesised  using  GP  4.  There  was 
obtained: (15 mmol 194a and 194b). 
 
2 (5 Bromopyridin 3 yl) 1 phenylethanone (205a). (3.81 g, 92 %); pale 
yellow solid; m.p. 51 52 
°C (from EtOAc); FTIR (neat solid) 3050, 2970, 
1674, 1423, 1330, 1207, 755, 684 cm
 1; 
1H NMR (CDCl3) δ 8.57 (d, J = 
1.8, 1H, H2''), 8.42 (d, J = 1.8, 1H, H6''), 8.00 (dd, J = 8.1, 1.2, 2H, H2'), 
7.77 (t, J = 1.8, 1H, H4''), 7.60 (tt, J = 8.1, 1.8, 1H, H4'), 7.49 (t, J = 8.1, 
2H, H3'), 4.28 (s, 2H, H2); 
13C NMR (CDCl3) δ 195.6 (q, C1), 149.4 (C2''), 
148.8 (C6''), 140.0 (C4''), 136.1 (q, C1'), 133.8 (C4'), 131.9 (q, C3''), 128.9 
(C2'), 128.4 (C3'), 120.6 (q, C5''), 41.6 (C2); Anal. Calcd for C13H10BrNO: 
C, 56.55; H, 3.65; N, 5.07. Found: C, 56.39; H, 3.64; N, 4.88. 
 
2 (5 Bromopyridin 3 yl) 1 (4 methylphenyl)ethanone  (205b).  (4.05  g, 
93 %); white solid; m.p. 102 103 
°C (from EtOAc); FTIR (neat solid) 3020, 
2919, 1681, 1603, 1338, 1203, 1182, 809, 697, 568 cm
 1; 
1H NMR (CDCl3) 
δ 8.60 (br, 1H, H2''), 8.44 (br, 1H, H6''), 7.92 (d, J = 8.1, 2H, H2'), 7.79 (t, J 
= 1.8, 1H, H4''), 7.31 (d, J = 8.1, 2H, H3'), 4.27 (s, 2H, H2), 2.45 (s, 3H, 4' 
CH3);
 13C NMR (CDCl3) δ 195.2 (q, C1), 149.4 (C2''), 148.8 (C6''), 148.8 Page | 232  
 
(q, C4'), 139.8 (C4''), 133.6 (q, C1'), 131.2 (q, C3''), 129.6 (C2'), 128.5 
(C3'),  120.1  (q,  C5''),  41.6  (C2),  21.7  (4' CH3);  Anal.  Calcd  for 
C14H12BrNO: C, 57.95; H, 4.17; N, 4.83. Found: C, 57.79; H, 4.18; N, 4.74. 
 
Synthesis of compounds 181a and 181b 
 
Compounds  181a  and  181b  were  synthesised  using  GP  1.  There  was 
obtained: (10 mmol 205a,b) 
 
2 (5 Bromopyridin 3 yl) 1 phenylethanol (181a). (2.64 g, 95 %); white 
solid; m.p. 77 78 
oC (from EtOAc); FTIR (neat solid) 3263 (br), 3029, 1581, 
1423, 1050, 698 cm
 1; 
1H NMR (CDCl3) δ 8.33 (d, J = 1.8, 1H, H6''), 8.13 
(d, J = 1.8, 1H, H2''), 7.57 (t, J = 1.8, 1H, H4''), 7.20 7.18 (m, 5H, H2', H3', 
H4'), 4.78 (dd, J = 7.2, 5.4, 1H, H1), 2.91 (dd, J = 13.2, 7.2, 1H, H2A), 2.85 
(dd, J = 13.2, 5.4, 1H, H2B), 2.84 (s, 1H, OH); 
13C NMR (CDCl3) δ 148.7 
(C2''), 148.6 (C6''), 143.4 (q, C1'), 140.0 (C4''), 135.8 (q, C3''), 128.6 (C3'), 
128.1 (C4'), 125.8 (C2'), 120.4 (q, C5''), 74.5 (C1), 42.3 (C2); Anal. Calcd 
for C13H12BrNO: C, 56.14; H, 4.35; N, 5.04. Found: C, 56.23; H, 4.55; N, 
4.78. 
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2 (5 Bromo pyridin 3 yl) 1 (4 methylphenyl) ethanol (181b). (2.51 g, 86 
%); white solid; m.p. 100 101 
°C (from EtOAc); FTIR (neat solid) 3402, 
3031, 1598, 1507, 1420, 1041 cm
 1; 
1H NMR (CDCl3) δ 8.38 ( br, 1H, H6''), 
8.18 (br, 1H, H2''), 7.59 (t, J = 2.1, 1H, H4''), 7.08 (d, J = 8.4, 2H, H2'), 
7.05 (d, J = 8.4, 2H, H3'), 4.76 (dd, J = 7.5, 5.4, 1H, H1), 2.92 (dd, J = 
13.8, 7.5, 1H, H2A), 2.84 (dd, J = 13.8, 5.4, 1H, H2B), 2.27 (s, 3H, 4' CH3);
 
13C NMR (CDCl3) δ 148.6 (C2''), 148.4 (C6''), 140.3 (C4''), 140.1 (q, C1'), 
137.8 (q, C4'), 136.0 (q, C3''), 129.3 (C3'), 125.8 (C2'), 120.4 (q, C5''), 74.4 
(C1), 42.3 (C2), 21.1 (4' CH3); Anal. Calcd for C14H14BrNO: C, 57.55; H, 
4.83; N, 4.79. Found: C, 57.55; H, 4.85; N, 4.68. 
 
Synthesis of compounds 201a c 
 
 
 
To dry DMF (20 mL) under a steady stream of argon was added either 
181a (2.78 g, 10 mmol) [for 202a or 202c] or 181b (2.92 g, 10 mmol) [for 
202b], bis(triphenylphosphine) palladium (II) chloride (0.35 g, 0.5 mmol, 5 
mol.%), copper iodide (0.19 g, 0.1 mmol, 2 mol.%), triethylamine (6 mL, 40 
mmol) and either arylacetylene 147a (1.12 g, 11 mmol) [for 202a or 202b]  
or 147e (1.28 g, 11 mmol) [for 202c]. After 2 h at 110 
°C, the reaction 
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(4 x 30 mL). The combined ethereal extracts were washed with water (2 x 
50 mL), brine (30 mL), dried (MgSO4), the solvent removed under reduced 
pressure  and  the  resultant  residue  purified  by  column  chromatography 
(SiO2; EtOAc : petrol, 60 : 40 
v/v) to afford the products 202a c. There was 
obtained: 
 
1 Phenyl 2 (5 phenylethynylpyridin 3 yl)ethanol (201a). (1.80 g, 60 %); 
white solid; m.p. 125 126 
°C (from EtOAc / petrol); FTIR (neat solid) 3167 
br, 2850, 1489, 1441, 1065, 754, 702, 698 cm
 1; 
1H NMR (DMSO d6) δ 
8.57 (br, 1H, H6'), 8.36 (br, 1H, H2'), 7.81 (br, 1H, H4'), 7.61 7.56 (m, 2H, 
H2'''), 7.46 7.44 (m, 3H, H3''', H4'''), 7.38 7.32 (m, 4H, H2'''', H3''''), 7.26 
7.21 (m, 1H, H4''''), 5.43 (d, J = 4.5, 1H, OH), 4.83 (ddd, J = 8.1,4.8, 4.5, 
1H, H1), 2.97 (dd, J = 13.5, 4.8, 1H, H2A), 2.89 (dd, J = 13.5, 8.7, 1H, 
H2B); 
13C  NMR  (DMSO d6)  δ  150.6  (C2'),  149.6  (C6'),  145.6  (q,  C1''''), 
139.8 (C4'), 135.0 (q, C3'), 131.9 (C2'''), 129.6 (C4'''), 129.3 (C3'''), 128.4 
(C3''''), 127.4 (C4''''), 126.4 (C2''''), 122.3 (q, C1'''), 119.0 (q, C5'), 92.4 (q, 
C2''), 86.8 (q, C1''), 73.2 (C1), 42.5 (C2); Anal. Calcd for C21H17NO: C, 
84.25; H, 5.72; N, 4.68. Found: C, 83.97; H, 5.80; N, 4.68. 
 
2 (5 Phenylethynylpyridin 3 yl) 1 (4 methylphenyl)ethanol  (201b). 
(1.57 g, 50 %); cream solid; m.p. 126 
°C (from EtOAc / petrol); FTIR (neat 
solid) 3285 (br), 2212, 1490, 1443, 1419, 1071, 840, 758, 705, 693, 577 
cm
 1; 
1H NMR (DMSO d6) δ  8.56 (s, br, 1H, H6''), 8.34 (s, br, 1H, H2''), 
7.80 (t, J = 1.8, 1H, H4''), 7.60 7.57 (m, 2H, H2''''), 7.46 (t, J = 3.0, 3H, 
H3'''', H4''''), 7.23 (d, J = 7.8, 2H, H2'), 7.17 (d, J = 7.8, 2H, H3'), 5.32 (d, J Page | 235  
 
= 4.5, 1H, OH), 4.78 (ddd, J = 7.8, 5.1, 4.5, 1H, H1), 2.93 (dd, J = 12.9, 
5.1, 1H, H2A), 2.86 (dd, J = 12.9, 7.8, 1H, H2B), 2.28 (s, 3H, 4' CH3);
 13C 
NMR  (DMSO d6)  δ  150.6  (C2),  149.6  (C6),  142.7  (q,  C4'),  139.7  (C4), 
136.3 (q, C1'), 135.0 (q, C3''), 131.9 (C2''''), 129.6 (C4''''), 129.3 (C3''''), 
129.0 (C3'), 126.3 (C2'), 122.3 (q, C1''''), 119.0 (q, C5''), 92.4 (q, C2'''), 
86.9  (q,  C1'''),  73.0  (C1),  42.5  (C2),  21.2  (4' CH3);  HRMS  calcd  for 
C22H19NO (M + H)
+ required 314.1546, found 314.1541. 
 
1 Phenyl 2 [5 (4 methylphenyl)ethynylpyridin 3 yl]ethanol  (201c). 
(1.94 g, 62 %); pale yellow or white solid; m.p. 132 133 
°C (from EtOAc); 
FTIR (neat solid) 3174 (br), 2210, 1507, 1450, 1415, 1066, 816, 747, 701 
cm
 1; 
1H NMR (DMSO d6) δ 8.70 8.30 (br, 2H, H6'', H2''),  7.79 (s, 1H, 
H4''), 7.49 (d, J = 8.1, 2H, H2'''), 7.38 7.23 (m, 7H, H2', H3', H4', H3''''), 
5.40 (d, J = 4.5, 1H, OH), 4.83 (ddd, J = 7.8, 4.8, 4.5 1H, H1), 2.96 (dd, J = 
13.8, 4.8, 1H ,H2A), 2.88 (dd, J = 13.8, 8.1, 1H, H2B), 2.35 (s, 3H, 4'''' 
CH3); 
13C  NMR  (DMSO d6)  δ  150.4  (C6''),  149.5  (C2''),  145.7  (q,  C1'), 
139.6 (C4), 139.5 (q, C3''), 139.5 (q, C4''''), 131.8 (C2''''), 129.9 (C3''''), 
128.4 (C3'), 127.3 (C4'), 126.4 (C2'), 119.3 (2C; C5'', q, C1''''), 92.6 (q, 
C2'''), 86.3 (q, C1'''), 73.2 (C1), 42.5 (C2), 21.6 (4'''' CH3); Anal. Calcd for 
C22H19NO: C, 84.31; H, 6.11; N, 4.47. Found: C, 84.09; H, 6.16; N, 4.38. 
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Synthesis of compounds 202a c 
 
 
 
Hg(OAc)2 (0.16 g, 0.5 mmol, 10 mol.%) and either 201a (1.50 g, 5 mmol) 
201b (1.57 g, 5 mmol) 201c (1.57 g, 5 mmol) were dissolved in 10 % 
w/v 
aq. H2SO4 (40 mL) and acetone (15 mL) and the mixture heated to reflux. 
After 12 h the reaction mixture was allowed to cool, poured into water (50 
mL), neutralised with 10 % NaOH and extracted with EtOAc (3 x 30 mL). 
The  combined  organic  layers  were  dried  (MgSO4),  and  the  solvent 
removed  in  vacuo.  The  crude  material  was  purified  by  column 
chromatography (SiO2; EtOAc : petrol, 80 : 20 
v/v) There was obtained: 
 
2 [5 (2 Hydroxy 2 phenyl ethyl) pyridin 3 yl] 1 phenylethanone 
(202a). (1.24 g, 75 %); white solid; m.p. 89 
oC (from EtOAc); FTIR (neat 
solid) 3212, 2919, 1684, 1595, 1447, 1210, 1048, 752, 699, 689 cm
 1; 
1H 
NMR (DMSO d6) δ 8.29 (bd, J = 1.5, 1H, H6''), 8.21 (bd, J = 1.5, 1H, H2''), 
8.08 8.05 (m, 2H, H2'), 7.67 (tt, J = 7.3, 1.2, 1H, H4'), 7.56 (t, J = 7.3, 2H, 
H3'), 7.50 (dt, J = 1.5, 1H, H4''), 7.32 7.25 (m, 4H, H2'''', H3''''), 7.23 7.20 
(m, 1H, H4''''), 5.37 (d, J = 4.5, 1H, OH), 4.76 (td, J = 7.2, 5.7, 4.5, 1H, 
H2'''), 4.42 (s, 2H, H2), 2.90 (dd, J = 13.2, 5.7, 1H, H1'''A), 2.84 (dd, J = 
13.2, 7.2, 1H, H1'''B);
13C NMR (DMSO d6) δ 197.6 (q, C1), 149.1 (C2''), 
148.8 (C6''), 145.8 (q, C1''''), 138.7 (C4''), 136.8 (q, C1'), 134.5 (q, C5''), Page | 237  
 
133.9 (C4'), 130.5 (q, C3''), 129.3 (C3'), 128.8 (C2'), 128.4 (C3''''), 127.3 
(C4''''), 126.4 (C2''''), 73.6 (C1'''), 42.9 (C2'''), 42.2 (C2). HRMS calcd for 
C21H19NO2 (M + H)
+ required 318.1495, found 318.1491. 
 
2 [5 (2 Hydroxy 2 phenylethyl)pyridin 3 yl] 1 (4 
methylphenyl)ethanone  (202c).  (1.22  g,  77  %);  colourless  oil;  FTIR 
(neat) 3223, 2919, 1680, 1605, 1436, 1180, 1052, 754, 700 cm
 1; 
1H NMR 
(DMSO d6) δ 8.34 (br, 1H, H6''), 8.33 (br, 1H, H2''), 8.01 (d, J = 8.1, 2H, 
H2'), 7.54 (br, 1H, H4''), 7.41 (d, J = 8.1, 2H, H3'), 7.37 7.30 (m, 4H, H2'''', 
H3''''), 7.28 7.23 (m, 1H, H4''''), 5.39 (d, J = 4.5, 1H, OH), 4.80 (td, J = 7.2, 
4.5, 1H, H2'''), 4.41 (s, 2H, H2), 2.90 (d, J = 7.2, 2H, H1'''), 2.44 (s, 3H, 4' 
CH3);  
13C NMR (DMSO d6) δ 197.1 (q, C1), 149.1 (C2''), 148.7 (C6''), 
145.8 (q, C1''''), 144.3 (q, C4'), 138.6 (2C; C4'', q, C5''), 134.3 (q, C1'), 
130.8 (q, C3''), 129.8 (C3'), 128.9 (C2'), 128.3 (C3''''), 127.3 (C4''''), 126.3 
(C2''''), 73.6 (C2'''), 42.9 (C2), 42.1 (C1'''), 21.6 (4' CH3). HRMS calcd for 
C22H21NO2 (M + H)
+ required 332.1651, found 332.1653. Page | 238  
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